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Abstract 
A fast and efficient synthetic route was developed for the synthesis of a novel class of enone-
containing α-amino acid. An amino acid-derived β-ketophosphonate ester was subjected to 
Horner-Wadsworth-Emmons conditions using a variety of aldehydes to produce a diverse library 
of α,β-unsaturated amino acids. E-Configured enone-containing amino acids were also 
deprotected using a two-stage approach to give the parent α-amino acids. A minor modification 
to the route enabled the synthesis of Z-configured enones via the Still-Gennari reaction. A small 
library of Z-enones was produced using various aldehydes.  
 
 
Enone-functionalised α-amino acids were employed as substrates for an intramolecular 
cyclisation reaction to generate 6-substituted-4-oxopipecolic acids. A diastereoselective one-pot 
reductive amination/cyclisation strategy was developed to gain access to the anti-diastereomer of 
the chiral N-heterocycles. A small selection of 6-substituted-4-oxopipecolic acids was synthesised. 
6-Substituted-4-oxopipecolic acids were also reduced diastereoselectively to generate 4-
hydroxypipecolic acid analogues. 
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1 Saturated 6-Membered N-Heterocycles 
1.1 Introduction 
Within the structurally diverse field of organic chemistry, heterocyclic chemistry represents a vast 
and complex discipline of significant importance. A heterocycle can be defined as a ring system 
containing at least one heteroatom and can be subcategorised as either aromatic or non-
aromatic. Six-membered non-aromatic N-heterocycles have warranted a great deal of attention 
due to their abundance in nature and synthetic utility in the pharmaceutical industry.  
Representatives of the saturated six-membered N-heterocycle family include piperidine 1, 
piperazine 2, morpholine 3 and thiomorpholine 4 (Figure 1.1). An enormous array of 
permutations to the heterocyclic core exists with incorporation of different functional groups, 
various substitution patterns and stereogenic centres are also frequently observed. Structural 
variation of the heterocyclic scaffold can substantially alter the properties of the molecule. 
 
Figure 1.1 Saturated 6-membered N-heterocycles  
Heterocycles are attractive targets for synthetic chemists because they possess broad and 
important biological properties. Many heterocyclic compounds are naturally occurring and their 
functions are fundamentally important to living systems. Alkaloid natural products contain 
nitrogen heterocycles as molecular scaffolds.  Heterocycles have also been deemed privileged 
structures in the pharmaceutical industry as they often account for potent medicinal properties.1 
Within this group of saturated six-membered heterocyclic compounds, the piperidine core 
attracts considerable attention.  
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1.2 Piperidine 
Piperidine is one of the most important members within the class of saturated six-membered N-
heterocycles. The molecular fragment is widely distributed in nature within numerous plants, 
insects and amphibians. The chemical properties of the heterocyclic core have been extensively 
studied throughout the years. 
Saturated heterocycles possess slightly different properties from their analogous open-chain 
derivatives. The most important factors that cause the distinction between cyclic and acyclic 
molecules are the size of the ring and the overall shape. Flexible molecules can adopt 
conformations to maximise bonding interactions and minimise repulsive interactions. In contrast, 
a ring system will impose certain constraints on these favourable interactions. Preferred features 
such as natural bond angles, intrinsic bond lengths and staggered hydrogen arrangements are 
often compromised and therefore ring systems can be strained. A cyclic molecule will still 
endeavour to adopt the lowest energy conformation possible.    
Piperidine preferentially adopts a six-membered chair conformation equivalent to cyclohexane. 
The difference between the two arises as a result of the heteroatom. Unlike cyclohexane, two 
different types of conformational change can occur. Piperidine can undergo tetrahedral inversion 
of the nitrogen substituent (processes a and b) and also ring inversion (processes c and d) (Figure 
1.2).2 Equatorial positioning of the hydrogen atom with the lone pair axial (6 and 7) is more stable 
as 1,3-diaxial interactions are minimised. The barrier to tetrahedral inversion however is a low 
energy process and therefore piperidine can rapidly equilibrate, which means that nitrogen, 
unlike sulfur and phosphorus, cannot be chiral. 
 
Figure 1.2 Tetrahedral inversion and ring inversion of piperidine 
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Another important feature of saturated heterocyclic compounds is the anomeric effect. This 
stereoelectronic effect was first recognised in carbohydrate chemistry, however is also observed 
in nitrogen and sulfur containing heterocycles. Saturated heterocycles bearing an electronegative 
substituent in the 2-position will prefer the substituent in an axial conformation (Figure 1.3). An 
antiperiplanar arrangement of the lone pair and exocyclic substituent is thermodynamically 
favoured as the lone pair can overlap with the parallel, low-lying anti-bonding orbital of the C–X 
bond to stabilise the molecule.  Displacement of electron density from the nitrogen towards the 
electronegative substituent results in a stronger, shorter C–N bond and a longer, weaker C–X 
bond. 
 
Figure 1.3 Anomeric effect in piperidine  
Aside from the varied and interesting chemical properties that piperidine exhibits, the structurally 
diverse natural products containing piperidine also have an array of important biological 
properties. Alkaloid natural products are basic compounds derived from secondary metabolism of 
amino acids. A vast selection of alkaloids containing a piperidine ring have been isolated from 
plants (Figure 1.4). (−)-Coniine 10 is a member of the poisonous hemlock alkaloid family and was 
the first alkaloid to be chemically synthesised.3 The neurotoxin disrupts the peripheral nervous 
system and is fatal to humans and livestock as respiratory paralysis causes death.4 Atropine 11 
and solanine 12 belong to the Solanaceae family and are also toxins. Atropine is found in deadly 
nightshade, Atropa belladonna, and the steroidal alkaloid, solanine, is present in unripe potatoes.5 
Several piperidine containing secondary metabolites have beneficial medicinal properties such as 
morphine 13. Morphine is the major component of opium from the poppy, Papaver somniferum, 
and is known for its potent analgesic properties. Morphine acts on the central nervous system 
(CNS) to relieve pain. The disadvantages of this powerful opiate analgesic are the propensity for 
addiction, tolerance and psychological dependence. The macrolactone, carpaine 14, contains two 
piperidine motifs. The pharmacology of carpaine includes use as a cardiac stimulant, an anti-
hypertensive agent and a diuretic.6 Piperine 15, isolated from Piper nigrum (black pepper), has 
been found to possess antimicrobial activity. 
P a g e  | 4 
 
 
Figure 1.4 Secondary metabolites from plants containing piperidine 
Many secondary metabolites derived from piperidine have also been identified in animal species 
(Figure 1.5). (+)-Stenusine 16 has been isolated as a diastereomeric mixture from the rove beetle 
genus, Stenus.7 The compound displays a repellent activity against predators and also functions as 
a surface-active fluid to propel the beetle over water, as the beetle cannot swim.8 Cryptophorine 
17 is another animal natural product containing the saturated N-heterocycle.9 Solenopsin A 18 is a 
constituent of fire ant venom, used as a defence mechanism against predators and possesses 
haemolytic, insecticidal and antibiotic properties.10 Histrionicotoxin 19 is a spiropiperidine found 
in the skin of the Columbian frog, Dendrobate histrionicus.11 The chemical functions as a defence 
mechanism and acts as a non-competitive inhibitor of the neuromuscular ganglionic and central 
neuronal nicotinic acetylcholine receptors.12 
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Figure 1.5 Secondary metabolites from animals containing piperidine 
The piperidine scaffold is an essential pharmacophore in medicinal research with thousands of 
clinical and pre-clinical therapeutic agents containing the privileged structure.13 Selected 
examples of drugs include paroxetine 20 produced by GlaxoSmithKline to treat depression and 
anxiety (Figure 1.6). Morphine analogues such as codeine 21, heroin 22 and oxycodone 23, used 
to relieve severe pain, contain the saturated N-heterocycle. Non-selective 5-HT/D2 receptor 
antagonist, risperidone 24, has proven effective to alleviate symptoms of schizophrenia.14 2,6-
Disubstituted piperidine 25, is a β2-adrenoreceptor agonist which induces bronchodilation.
15 
Many other pharmaceutically active compounds contain the piperidine nucleus with various 
substitution patterns.16 
 
Figure 1.6 Therapeutic agents containing piperidine 
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The biological importance of piperidine derivatives has invoked substantial attention. Extensive 
research has been conducted into general approaches for the synthesis of the piperidine core. 
With increasing potential for applications in biological systems, the goal has been to develop 
enantioselective strategies to produce chiral piperidine derivatives. Another aspect for chemical 
syntheses is the ability to attain varied substitution patterns. These factors govern the direction of 
novel preparations and continue the drive for new methodologies. Many substitution patterns 
remain difficult to access and therefore new short, versatile, stereocontrolled routes are of great 
potential value.  
1.2.1 Piperidine Synthesis 
A great deal of research has been carried out in the field of piperidine synthesis.17 Many different 
approaches to the N-heterocycle have been explored, however this is a demanding challenge and 
still has scope for improvement. 
1.2.1.1 Reduction of Pyridine 
Reduction of pyridine to synthesise piperidine derivatives has been extensively investigated. The 
strategy is efficient as the N-heterocyclic ring is already present, however it can be difficult to 
generate chirality in the molecule and therefore the approach is rarely employed in modern 
organic chemistry. 
An example of pyridine reduction was presented by Comins and co-workers who devised an 
approach using an N-acylpyridinium salt containing a chiral auxiliary to induce asymmetry.18 The 
objective of the work was to carry out a total synthesis of (+)-deoxoprosopinine 35. Compound 35 
is an analogue of the naturally occurring piperidine alkaloid, (+)-prosopinine, which exhibits 
antibiotic and anaesthetic properties.  
Enantiopure pyridinium salt 26 was treated with cyanocuprate reagent 27 to introduce selectively 
the C-2 stereocentre and then acid-promoted tautomerism generated dihydropyridone 28 as a 
single diastereomer (Scheme 1.1).  Hydrolysis of the chiral auxiliary was carried out using sodium 
methoxide, followed by acidic removal of the resultant carboxylic acid and the tri-iso-propylsilyl 
group to yield cyclic enone 29. Protection of the amine with phenyl chloroformate and then 
diastereoselective acetoxylation using lead(IV) acetate gave intermediate 31. Excellent 
diastereoselectivity to introduce the acetoxy group is achieved because the C-2 substituent exists 
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in an axial position as a result of allylic strain. A one-pot procedure to form bicyclic compound 32 
involves cleavage of the benzyl ether, subsequent formation of a formate ester and then 
ammonia-induced ring closure. Generation of the oxazolidinone ring system is crucial for control 
of the final stereocentre. Chemoselective 1,2-reduction of the carbonyl followed by acetylation 
yields allylic acetate 33. Treatment of 33 with a Lewis acid induces formation of an N-acyliminium 
ion in situ and then addition of the allylsilane occurs from the Re face. The stereoselectivity arises 
because the bicyclic system forces the C-2 stereogenic centre into a pseudo-equatorial position 
and therefore attack on the iminium species occurs in an axial manner to give 34. Finally, basic 
hydrolysis of the acetate and opening of the oxazolidinone ring along with decarboxylation yields 
(2R,3S,6R)-(+)-deoxoprosopinine 35. 
 
Scheme 1.1 Total synthesis of (+)-deoxoprosopinine 35 
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Comins and co-workers were able to synthesise the desired 2,3,6-trisubstituted piperidine natural 
product in 10 steps with 16% overall yield. The pyridinium reduction step is high yielding and 
generates a densely functionlised dihydropyridone 28 as a single stereoisomer. The group have 
shown that allylic acetate 33 can be readily further functionalised diastereoselectively and 
therefore, this approach is efficient and amenable for the generation of other analogues. 
1.2.1.2 Heterocycle Construction 
A variety of cyclisation reactions are frequently encountered for the synthesis of piperidine 
derivatives. Well-established transformations are employed in ring-closing reactions to generate 
the saturated N-heterocyclic core. 
Kim and co-workers developed an elegant approach for the synthesis of conformationally 
constrained sphingoid base analogues containing a piperidine scaffold.19 Naturally occurring 
sphingoid bases have several biological functions and can induce apoptotic cell death.20 
Conformationally restricted analogues of these bases exhibit potent cytotoxic activity and inhibit 
cancer cell growth. An efficient approach to synthesise the desired piperidine framework was 
investigated using a tandem enyne/diene-ene metathesis reaction.  
The synthesis employed a Sonogashira cross-coupling reaction using 3-bromopropargyl alcohol 36 
and silyl-protected acetylene to give diyne 37 (Scheme 1.2). Lithium aluminium hydride selectively 
reduced the alkyne with the pendant hydroxyl group to yield the E-isomer 38 in excellent yield. 
Allylic alcohol 38 was subjected to Sharpless asymmetric epoxidation conditions with (−)-diethyl 
tartrate to produce epoxy alcohol 39 in good yield with good enantiomeric excess. Epoxy alcohol 
39 was reacted with allyl isocyanate to generate allyl carbamate 40. Regioselective intramolecular 
ring-opening of the epoxide produced oxazolidinone 41 in excellent yield. Removal of the silyl 
protecting group, followed by acetylation of the free hydroxyl generated the substrate for the 
tandem ring-closing metathesis and subsequent cross-metathesis reaction. Enyne 43 was 
subjected to the metathesis conditions using Grubbs second-generation catalyst in the presence 
of 1-tetradecene to afford diene 44 in good yield and with complete E-selectivity of the external 
alkene. Completion of the synthesis involved hydrogenation of diene 44 using Raney nickel, which 
proceeded with complete facial selectivity. Finally, hydrolysis of the oxazolidinone ring and 
acetate group produced (2S,3R,4S)-trisubsituted piperidine 46 in 10 linear steps in 30% overall 
yield.  
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Scheme 1.2 Tandem ring-closing/cross-metathesis approach for the synthesis of trisubstituted 
piperidine 46 
This tandem metathesis approach provides the piperidine core highly efficiently. The chirality is 
achieved using asymmetric catalysis and therefore it would be feasible to use the opposite 
enantiomer of diethyl tartrate to obtain ent-46. The highly functionalised diene intermediate 44 
may also allow variations to the piperidine template making this a versatile synthetic route. 
Another recent synthetic strategy employing metathesis was developed by Davis and co-workers 
to allow entry to a potent neurokinin substance P receptor antagonist.21 
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A fast and efficient route was published by González-Gómez et al for the synthesis of highly 
desirable 2,6-cis-disubstituted piperidines.22 2-Methyl-6-alkylpiperidines are an important class of 
natural products. Dihydropinidine 5923 is produced by the Mexican bean beetle as a defense 
mechanism against predators and isosolenopsins 60 and 6124 are found in the venom of fire ants. 
The piperidine-containing alkaloid natural products were produced using a reductive amination 
strategy to form the N-heterocyclic core. 
Indium-mediated allylation of (S)-tert-butylsulfinimines 47-50 with allyl bromide gave N-tert-
sulfinylamines 51-54 in moderate to good diastereoselectivity (Scheme 1.3). Subsequent cross-
metathesis of sulfinylamines 51-54 with methyl vinyl ketone using Hoveyda-Grubbs catalyst 
yielded enones 55-58. Hydrogenation of the alkene was carried out with Wilkinson’s catalyst. 
Acidic cleavage of the chiral auxiliary resulted in concurrent intramolecular imine formation, then 
subsequent reduction with sodium cyanoborohydride, followed by hydrochloride salt formation 
generated the N-heterocyclic core of piperidine derivatives 59-62 in excellent diastereomeric 
excess. The diastereoselective outcome is rationalised by the conformation adopted by the cyclic 
imine (Figure 1.7). Stereoelectronically favoured axial attack of the hydride on the most stable 
half-chair conformation 63, where both substituents are pseudo-equatorial, results in the cis-
configuration of piperidines. 2-Phenyl-6-methylpiperidine 62 has also been further transformed 
into 6-methylpipecolic acid in 41% yield over 3 steps.  
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Scheme 1.3 Reductive amination strategy to piperidine-containing alkaloid natural products 
 
Figure 1.7 Axial attack on lowest energy conformation of cyclic imine  
This reductive amination strategy is appealing because the piperidine ring is produced in 6 steps 
in 62% overall yield, on average. A range of substituents can be introduced at the 2-position as 
exemplified by the synthesis. Also, various 6-substituents could be incorporated by varying the 
enone employed for the cross-metathesis reaction and therefore the scope of this methodology is 
wide-ranging.  
Using an intramolecular reductive amination reaction to form the piperidine core is a popular 
approach as illustrated by several recent syntheses.25 Intramolecular nucleophilic substitution 
reactions also feature heavily in many modern piperidine syntheses.26 
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1.2.1.3 Cycloaddition 
Cycloaddition reactions are often used as an efficient method to synthesise piperidine 
derivatives.27 Nelson and co-workers published an expeditious route using a hetero Diels-Alder 
cyclisation to generate a highly functionalised piperidine skeleton.28 Allylic sulfonamide 64 was 
subjected to an alkene isomerisation using an iridium-based catalyst to give enamine 65 with high 
E-selectivity (Scheme 1.4). In a one-pot process, cationic aza-diene 66 was formed by Lewis acid-
mediated N,O-acetal ionisation of precursor 65. Subsequent hetero Diels-Alder cycloaddition with 
allyltrimethylsilane produced syn-iminium cycloadduct 67 via an endo transition state. In the 
presence of excess allyltrimethylsilane, allylation of the iminium ion gave piperidine 68 with 2:1 
diastereofacial control. 
 
Scheme 1.4 Hetero Diels-Alder cycloaddition to generate trisubstituted piperidine 68 
Nelson and co-worker’s route provides a fast and efficient method to generate structurally 
diverse piperidines as various nucleophiles could be introduced at the 2-position. The 
disadvantage is that only relative stereochemistry is established in this case, however a chiral 
auxiliary in place of the N-tosyl group may induce asymmetry during the [4+2] cycloaddition. 
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1.2.1.4 Ring Expansion / Rearrangement 
Rearrangement and ring expansion strategies are scarcely used for the synthesis of piperidines. 
They are usually employed in specific cases rather than as a general method. 
Honda and co-workers devised a synthetic scheme for the synthesis of a potential antimalarial 
piperidine alkaloid, (+)-febrifugine 79.29 The sequence involved a samarium diiodide-promoted 
carbon–nitrogen bond cleavage of a five-membered ring, followed by ring-closure to produce a 
six-membered piperidine ring. 
Starting from protected (4S)-4-hydroxy-L-proline 69, ruthenium(IV) oxide oxidation produced 
lactam 70 (Scheme 1.5). Reduction of the lactam gave aminal 71, which is in equilibrium with the 
corresponding aminoaldehyde. A one-pot Horner-Wadsworth-Emmons (HWE) reaction generated 
α,β-unsaturated amide 72 and then an intramolecular conjugate addition reaction yielded amide 
73 in good yield. The stereochemistry arises from selective attack of the amine on the less 
hindered face to produce 73 as a single diastereomer. Methyl ketone 74 was generated by 
treatment of Weinreb amide 73 with methylmagnesium bromide. Methylenation of the ketone 
with Tebbe’s reagent, followed by Boc deprotection yielded amine 75. Reductive deamination 
using samarium diiodide as a one-electron reducing agent cleaved the C–N bond of the proline 
derivative to give intermediate 76, which spontaneously cyclised in situ with expansion of the ring 
to produce piperidone 77 in excellent yield. Reduction of piperidone 77 with lithium aluminium 
hydride and simultaneous removal of the hydroxy-protecting group followed by protection of the 
secondary amine yielded 3-hydroxypiperidine 78. Several transformations were required to 
convert piperidine 78 into the desired product, (+)-febrifugine 79.  
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Scheme 1.5 Rearrangement reaction for the synthesis of (+)-febrifugine 79 
This approach is effective as the stereochemistry derived from the one-pot HWE/conjugate 
addition reaction proceeds with complete diastereoselectively. Also, the key reductive 
deamination step to rearrange the proline to the piperidine scaffold occurs in high yield. This 
method could enable the synthesis of a variety of analogues because piperidone 77 is suitably 
functionalised to allow subsequent transformations.  
A review of recent literature demonstrates the wide selection of strategies available to synthetic 
chemists for the preparation of substituted piperidine scaffolds. The approaches illustrated 
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generally allow the target heterocycle to be synthesised in reasonable yields, however certain 
routes are long and inefficient. The drive towards short, enantiocontrolled strategies continues to 
be a priority within the field. Many variations to the piperidine core exist and therefore 
incorporation of diversity is another vital feature to enable the synthesis of important piperidine 
derivatives.  
1.3 Pipecolic Acid 
Pipecolic acid 80 is a naturally occurring non-proteinogenic α-amino acid that is widely distributed 
in plants, animals and microorganisms (Figure 1.8). The molecular scaffold consists of a saturated 
N-heterocycle substituted at the C-2 position with a carboxylic acid. Pipecolic acid has a wealth of 
different functions as it can be observed underivatised in biological systems or used as a natural 
or synthetic derivative.  
 
Figure 1.8 (2S)-Pipecolic acid 
Isotopic labelling studies have demonstrated that pipecolic acid is biosynthesised from lysine in 
mammals, higher plants and microbes.30 Multiple putative pathways exist for lysine catabolism 
depending on the species.31 Microbial biosynthesis occurs via a gene which codes for lysine 
cyclodeaminase. This enzyme is responsible for the NAD+–dependant synthesis of the non-
proteinogenic amino acid. The α-amino group of lysine 81 is oxidised to imine 82 using cofactor 
NAD+, followed by cyclisation of the ε-amine onto the imine to generate the quaternary 
substituted N-heterocycle 83 (Scheme 1.6).32 Subsequent loss of ammonia produces unsaturated 
piperidine 84. Stereospecific reduction with NADH yields L-pipecolic acid 80 and recycles the 
coenzyme.  
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Scheme 1.6 Microbial biosynthesis of pipecolic acid 80 from lysine 81 
A similar metabolic pathway is currently accepted for pipecolic acid biosynthesis in mammals, 
however, 2-keto-6-amino caproic acid is thought to be the direct precursor of 84.33 
Metabolism of lysine into pipecolic acid has been observed in various human physiological fluids 
and in particular, in the brain. It has been suggested that pipecolic acid has a functional role in the 
mammalian central nervous system related to the GABAergic system, however much debate 
surrounds this hypothesis.34,35 γ-Aminobutyric acid (GABA) is a fundamental neurotransmitter in 
the CNS, responsible for neuronal excitation and inhibition and therefore understanding the role 
of pipecolic acid in this critical pathway may lead to potential therapies for neurological 
disorders.36  
(2S)-Pipecolic acid has also been incorporated into many elaborate structures which have a wide 
range of interesting biological properties. Several microbial secondary metabolites contain the 
pipecolic acid motif and these compounds possess significant pharmacological activity.  
Rapamycin 85, FK506 86 and FK520 87 are macrolactone natural products that are primarily 
polyketide structures with the exception of a single pipecolic acid residue (Figure 1.9). Macrolides 
85-87 exhibit potent anti-fungal and immunosuppressant activity and are currently used in 
transplant medicine, dermatology and cardiology.37 The pipecolic acid moiety within the 
structures serves as a substrate mimic and is critical for affinity with the target FK506-binding 
proteins (FKBP12).38,39,40 
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Figure 1.9 Immunosuppressant secondary metabolites containing the pipecolic acid motif 
Two novel polyketides containing pipecolic acid; nocardiopsin A and B, have recently been 
identified from marine-derived microorganisms.41 These are closely related structurally and 
biosynthetically to the immunosuppressants 85-87, however as yet, no biological activity has been 
determined despite micromolar binding to FKBP12 proteins.  The structures have been elucidated, 
although determination of the relative and absolute configurations of the stereogenic centres 
remains to be carried out. 
Sandramycin 88, a potent anti-tumor antibiotic, is a cyclic decadepsipeptide with two pipecolic 
acid residues incorporated (Figure 1.10). The structure is C2-symmetric and contains two 
heteroaromatic groups responsible for sequence-specific bis-intercalation with DNA.42  This 
disrupts DNA replication within rapidly dividing cancerous cells. Pipecolic acid is also a precursor 
of other important naturally occurring secondary metabolites including the indolizidine alkaloid, 
swainsonine 89, which exhibits potent antimetastatic, antiproliferative and immunomodulatory 
properties.43 The anthelmintic agent marcfortine A 90, used to expel parasitic worms, also uses 
pipecolic acid as a precursor. 
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Figure 1.10 Secondary metabolites derived from pipecolic acid 
Pipecolic acid has also been used as a scaffold for synthetic therapeutic agents such as the local 
anaesthetic analogues; bupivacaine 91, ropivacaine 92 and levobupivacaine 93 administered via 
epidural or intrathecal injection (Figure 1.11). Bupivacaine was marketed as the racemic mixture, 
however, certain patients experienced cardiac arrest as a result of the anaesthetic. Employing the 
(S)-enantiomer of pipecolic acid in derivatives 92 and 93 prolonged the duration of action and 
reduced cardiotoxicity.44 This illustrates the need for enantioselective syntheses of pipecolic acid 
for medicinal use.  
A potent angiotensin converting enzyme (ACE) inhibitor 94 was developed that contained a 
pipecolic acid motif to mimic binding of the endogenous ligand, angiotensin, to the positive C-
terminus of the active site.45 Synthetic ACE inhibitors have been widely employed to treat 
hypertension. 
 
Figure 1.11 Synthetic therapeutic derivatives containing the pipecolic acid motif 
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In modern organic synthesis, pyrrolidine-based organocatalysts have been extensively studied for 
use in asymmetric reactions.46 (S)-Proline has been successfully employed as an organocatalyst, 
however, the six-membered analogue, pipecolic acid, has received limited attention.47,48 Recent 
work published by Barbas and co-workers, revealed the potential to use (S)-pipecolic acid to 
catalyse a highly enantioselective Mannich reaction.49 Reaction of aldehyde 95 with protected α-
imino ethyl glyoxylate 96, catalysed by pipecolic acid, gave a 2:1 mixture of syn:anti products in 
greater than 99% enantiomeric excess (Scheme 1.7). In light of this development, the full 
synthetic potential of pipecolic acid in organic chemistry is perhaps yet to be fully investigated. 
 
Scheme 1.7 Pipecolic acid-catalysed asymmetric Mannich reaction 
Pipecolic acid is a common structural element in peptide chemistry. Several conformationally 
constrained amino acids 99-102 have been devised to mimic turn motifs of biologically relevant 
peptides (Figure 1.12).50 Pipecolic acid is often utilised within bicyclic structures as the 
heterocyclic amino acid is ideally positioned to mimic a peptidic β-turn. This expanding area of 
research will allow an enhanced understanding of interactions of small molecules with biological 
targets such as enzymes or receptors.  
 
Figure 1.12 Pipecolic acid-derived peptidomimetics 
The examples illustrated above demonstrate the significance of unfunctionalised pipecolic acid in 
the free form or as a structural element within natural or synthetic molecules for a wide range of 
roles. However, one of the largest classes of pipecolic acid derivatives studied is 4-substituted 
pipecolic acid, in particular, 4-oxygenated species 103-105 (Figure 1.13). These naturally occurring 
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pipecolic acid motifs have been extensively examined as they have interesting and potent 
biological activities. 
 
Figure 1.13 4-Oxopipecolic acid and 4-hydroxypipecolic acids 
The 4-oxopipecolic acid moiety has been identified in the cyclic hexadepsipeptide antibiotic, 
virginiamycin S2 106 (Figure 1.14). Virginiamycin is a microbial secondary metabolite produced by 
Streptomyces virginiae, which has potent bactericidal properties against a wide spectrum of drug-
resistant strains of gram-positive bacteria such as Staphylococcus aureus.51 Other complex 
biologically active antibiotics containing the 4-oxopipecolic acid motif include virginiamycin S1, 
pristinamycin 1A, vernamycin B and ostreogrycin B3.52 
 
Figure 1.14 Antibiotic virginiamycin S2 
A secondary metabolite was identified from a marine sponge which contains a (2R,4R)-
hydroxypipecolic acid  residue. Damipipecolin 107 is a bromopyrrole alkaloid that exhibits a 
modulating effect on a serotonin receptor in vitro (Figure 1.15).53 
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Figure 1.15 Marine alkaloid secondary metabolite with 4-hydroxpipecolic acid nucleus 
Synthetic therapeutic agents have been devised that possess 4-oxygenated pipecolic acid 
derivatives. Natural excitatory amino acids; aspartate and glutamate are important mediators of 
neuronal function in the mammalian CNS. They are agonists of the N-methyl-D-aspartic acid 
(NMDA) receptor that gates a calcium ion channel. Excessive stimulation by neurotransmitters is 
known to cause cell death in cerebral ischemia and is implicated in neurological disorders such as 
Alzheimer’s disease and Huntington’s chorea.54 Antagonism of the NMDA receptor to block the 
over-excitation could potentially be a useful therapeutic tool to treat a range of 
neurodegenerative diseases. A potent and selective competitive NMDA receptor antagonist 108 
has been developed that consists of a (4R)-hydroxypipecolic acid element (Figure 1.16).55  
Alternative analogues of NMDA antagonists have also been produced using 4-hydroxypipecolic 
acid as a synthetic intermediate.54,56 
 
Figure 1.16 Competitive NMDA receptor antagonist  
(4R)-Hydroxypipecolic acid is also present in the synthetic human immunodeficiency virus (HIV) 
protease inhibitor, palinavir 109 (Figure 1.17). HIV protease enzyme is responsible for producing 
mature protein components for the retrovirus and therefore is essential for the viral life cycle. 
Inhibition of HIV protease results in immature, non-infectious virions and suppresses viral 
replication.57 Targeted inhibition of HIV protease has emerged as an effective strategy in HIV 
therapy.58 
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Figure 1.17 HIV protease inhibitor, palinavir 
As exemplified, the 4-oxygenated pipecolic acid moiety is an important element in a variety of 
medicinally relevant compounds. In general, the development of therapeutic agents requires 
asymmetric syntheses, as the unwanted enantiomer is regarded as a medicinal pollutant. 
Significant synthetic efforts have therefore been devoted to synthesise 4-oxo- and 4-
hydroxypipecolic acids in high yield and with high enantioselectively.  
1.3.1 4-Oxopipecolic Acid Synthesis 
Pipecolic acid is a desirable target in organic synthesis as it is associated with three important 
families of natural products; α-amino acids, aza-sugars and alkaloids. Also, the biological 
significance of 4-oxygenated pipecolic acids makes them attractive synthetic targets.  An efficient, 
stereocontrolled strategy to construct the N-heterocyclic product is crucial, however, 
enantioselective preparations of the 4-oxopipecolic acid skeleton remain a contemporary 
challenge. 
1.3.1.1 Heterocycle Construction 
The most common method in the literature for the construction of the 4-oxopipecolic acid motif is 
to use an intramolecular cyclisation to synthesise the saturated N-heterocyclic core. Well-
established, classical reactions are often employed for the ring-closing step, however, the 
difficultly remains to incorporate high levels of asymmetry. 
An asymmetric synthesis of 4-oxopipecolic acid bearing a trifluoromethyl group was developed by 
Canet and co-workers.59 Selective incorporation of fluorine atoms into small, therapeutic 
molecules can often lead to enhanced efficacy and therefore, the synthesis of saturated N-
heterocycles containing fluorine is a topical field. Construction of the heterocyclic core of the 4-
oxopipecolic acid derivative was carried out using an intramolecular Mannich reaction of an 
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enantiomerically pure α-trifluoromethyl-β-amino ketal. A β-amino alcohol was employed as the 
enantiopure starting material to enable asymmetric induction. 
The synthetic route involved formation of oxazolidine 111 from trifluoroacetaldehyde methyl 
hemiacetal 110 and (R)-phenylglycinol (Scheme 1.8). This produced a 2:1 mixture of 
diastereomers in 98% yield. Subsequently, the diastereomeric mixture was treated with a silyl 
enol ether to give rise to β-amino ketone 112 with high diastereoselectivity. The high level of 
diastereoselectivity is accounted for by formation of a chiral imine which results from ring 
opening of the oxazolidine. This produces a rigid, ordered intermediate with the phenyl group 
blocking one face and therefore, selective attack occurs from the opposing face.60 Protection of 
the carbonyl as ketal 113, followed by hydrogenolysis generated substrate 114 for the 
intramolecular Mannich reaction. Formation of the pipecolic acid core was achieved using ethyl 
glyoxylate to give an imine. Under acidic conditions, the ketal ring-opened to give the 
corresponding enol ether, which cyclised onto the imine to produce the desired N-heterocycle 
and regeneration of the ketal protecting group occurred in situ. Cis-trifluoromethyl pipecolic acid 
115 was the major diastereomer obtained as a result of the intramolecular Mannich reaction in an 
85:15 cis:trans ratio. 
 
Scheme 1.8 Synthetic route to trifluoromethyl-4-oxopipecolic acid derivative 115 
Canet and co-workers proceeded to demonstrate that the ketal-protected pipecolic acid scaffold 
115 could be efficiently converted to desirable pipecolic acid congeners (Scheme 1.9). Oxidative 
cleavage of the ketal moiety with cerium ammonium nitrate (CAN) generated 4-oxopipecolic acid 
116 and then reduction with sodium borohydride gave the (4R)-hydroxypipecolic acid analogue 
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117. Alternatively, conversion of the ketal to dithiane 119 and subsequent reduction with Raney 
nickel produced pipecolic acid 120 in excellent yield. Finally, deprotection of the esters with 
sodium hydroxide in methanol gave the parent pipecolic acid derivatives 118 and 121.  
 
Scheme 1.9 Modification of trifluoromethyl-4-oxopipecolic acid derivative 115 to give pipecolic 
acid analogues 
The synthetic route devised by Canet and co-workers enabled the synthesis of 4-oxopipecolic acid 
in 6 steps from a commercial fluoro-acetal in 27% overall yield. The strategy benefits from high 
stereoselectivity for the enol ether addition to the oxazolidine to produce the enantiopure β-
amino ketone 112. This reaction dictates the stereochemistry of the 6-substituent of the pipecolic 
acid derivative. High diastereoselective discrimination is also observed for the intramolecular 
Mannich reaction to give the syn-6-substituted configuration on the heterocyclic core. This 
approach for the synthesis of substituted pipecolic acids is a versatile route because variation is 
possible to an extent when other hemiacetals are employed as the starting material.61  
An intramolecular Mannich-type reaction was also investigated by Aitken and co-workers for the 
synthesis of 4-oxopipecolic acid.62 Enantiomerically pure oxazolidine 122 was deprotonated with 
lithium diisopropylamide (LDA) and subsequent nucleophilic attack on MOM-protected allyl 
chloride 123 gave intermediate 124 as the major diastereomer (Scheme 1.10). The key cyclisation 
step took place under Lewis acid catalysed conditions to form the N-heterocyclic core with two 
possible products 125 and 126.  
P a g e  | 25 
 
 
Scheme 1.10 Intramolecular Mannich-type reaction for the synthesis of 4-oxopipecolic acid 
The mechanism for the cyclisation involved boron trifluoride etherate-induced ring opening of the 
oxazolidine to generate an iminium 129, followed by spontaneous cyclisation through the enol 
ether to provide the piperidine nucleus containing an electrophilic centre (Scheme 1.11).  The 
oxyanion 130 can attack the carbonyl from either face to produce the major bicyclic product 125 
as a 1:1 mixture of diastereomers at the bridgehead carbon. With excess Lewis acid, coordination 
to the MOM group takes place and allows abstraction of the protecting group by the oxyanion 
with concomitant cyclisation to yield piperidone derivative 126. The yields and ratios of products 
were dependent on the quantity of boron trifluoride etherate employed (Table 1.1).  
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Scheme 1.11 Mechanism for the intramolecular Mannich-type addition 
Entry BF3.Et2O (equiv.) Solvent Yield 125 (%) Yield 126 (%) 
1 0.5 THF 36 12 
2 1.5 THF 72 26 
3 2.5 THF 38 62 
4 1.5 Et2O 84 10 
Table 1.1 Intramolecular Mannich-type cyclisation conditions 
Completion of the synthesis entailed formation of amide 127, which was hydrolysed to the 
corresponding carboxylic acid under basic conditions (Scheme 1.10). Acid-promoted cleavage of 
the semi-cyclic acetal produced an alcohol which cyclised to form a lactone and simultaneous 
deprotection of the MOM group yielded intermediate 128. Finally, hydrogenolysis gave rise to the 
desired 4-oxopipecolic acid 103. 
This approach produces 4-oxopipecolic acid in seven steps in a respectable 29% overall yield. One 
limitation of this method is that it would be difficult to place substituents around the heterocyclic 
core as this may complicate the cyclisation step. This method therefore lacks the versatility to 
synthesise pipecolic acid derivatives. 
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An alternative route where the piperidine core is constructed via an intramolecular cyclisation is 
Bousquet and co-worker’s synthesis of 4-oxopipecolic acid.58 They embarked on a programme to 
target inhibition of HIV protease, where the lead compound, palinavir 109, contained a cis-
configured 4-hydroxypipecolic acid motif (Figure 1.17). The aim of the research was to develop an 
efficient approach to the pipecolic acid core that was amenable on a large scale to produce 
sufficient quantities for clinical trials. 
A Dieckmann condensation was employed as the key step to produce the heterocyclic core using 
an enantiopure α-amino acid as the starting material. The initial step involved a conjugate 
addition of L-aspartic acid derivative 132 to methyl acrylate, then Boc-protection of the amine in a 
one-pot procedure generated diester 133 (Scheme 1.12). Formation of the pipecolic acid core was 
achieved when intermediate 133 was subjected to standard Dieckmann condensation conditions 
to produce regioisomers 134 and 135. Decarboxylation in situ under thermal conditions followed 
by acidification enabled extraction of the crude product. 4-Oxopipecolic acid 136 was isolated as 
the tert-butyl amine salt. Finally, addition of dilute hydrochloric acid yielded the desired 4-
oxopipecolic acid 137. 
 
Scheme 1.12 Dieckmann cyclisation to produce Boc-protected 4-oxopipecolic acid 
The Dieckmann strategy used by Bousquet and co-workers requires few steps and the yields are 
reasonable. Also, the stereochemistry of the carboxylic acid is defined by the starting material 
from the chiral pool and therefore, the enantiopurity of the product is high. The difficulty with 
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implementing this approach for access to a wider range of pipecolic acid derivatives is that 
installing substituents in the 5- or 6-position may be problematic. Permutations of methyl acrylate 
would be necessary for this approach and therefore the aza-conjugate addition reaction may be 
less efficient with substituted alkenes. Mixtures of diastereomers could also be obtained from the 
intermolecular conjugate addition of substituted olefins. 
Access to 4-oxo-, cis-4-hydroxy- and trans-4-hydroxypipecolic acid is possible using Burger and co-
worker’s route which employs an intramolecular aza-conjugate addition as the key step to 
construct the heterocycle.63 L-Aspartic acid was the enantiopure synthetic precursor for the 
approach, which was reacted with hexafluoroacetone to give protected oxazolidinone 138 
(Scheme 1.13). Intermediate 138 was converted to acid chloride 139 and then subjected to 
standard Stille coupling conditions with vinyltrimethyltin as the corresponding partner to produce 
unsaturated amino acid derivative 140. Subsequent Lewis acid-induced 6-endo-trig conjugate 
addition generated saturated N-heterocycle 141 in 60% yield. Finally deprotection yielded 4-
oxopipecolic acid 103 quantitatively.  
 
Scheme 1.13 Conjugate addition reaction for the synthesis of 4-oxopipecolic acid 
4-Oxopipecolic acid derivative 141 could also be reduced diastereoselectively using sodium 
borohydride in the presence of pentafluorophenol to produce alcohol 142 (Scheme 1.14).63 The 
fluorine-mediated boron reduction has been shown to reduce cyclohexanones via axial attack 
under the given conditions.64 The equatorial hydroxyl of 142 can be inverted using a Mitsunobu 
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reaction with formic acid to give trans-4-hydroxy derivative 143. Both derivatives were fully 
deprotected to yield cis- and trans-4-hydroxypipecolic acids 104 and 105. 
 
Scheme 1.14 Synthesis of cis- and trans-configured 4-hydroxypipecolic acids 
The scope and limitations of this strategy were explored in an attempt to obtain 6-substituted-4-
oxygenated pipecolic acid analogues. Employing a variety of substituted vinylic tributyltin 
derivatives for the Stille coupling enabled the synthesis of methyl, methyl ester, phenyl and gem-
dimethyl substituted enones. The intramolecular aza-conjugate addition was attempted on the 
enone derivatives, however, only the methyl analogue cyclised slowly in 30% yield and therefore, 
analogous to previous approaches, the method doesn’t appear to be flexible enough to synthesise 
alternative pipecolic acid scaffolds.  
A one-pot, three component intermolecular reaction was investigated by Pätzel and co-workers 
to form 6-substituted-(2R)-4-oxopipecolic acids.65 Employing a chiral α,β-unsaturated ketone, an 
aliphatic aldehyde and an amine gave rise to cis-2,6-disubstituted piperidones in moderate yields. 
Enantiomerically pure E-enone 144 reacted via conjugate addition with the imine of ammonia and 
iso-butyraldehyde formed in situ (Scheme 1.15). Concomitant intramolecular Mannich reaction 
closed the heterocyclic ring to give piperidone 145 with moderate diastereoselectivity. Boc 
protection of the amine, followed by ketal hydrolysis generated diol 147. Finally, oxidation of the 
alcohol to the carboxylic acid produced novel cis-(2R,6S)-6-substituted-4-oxopipecolic acid 148 in 
13% overall yield.   
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Scheme 1.15 Multicomponent method to synthesise 6-substituted-4-oxopipecolic acid 
This multicomponent reaction is appealing because in theory, diversity could be easily attained by 
varying the aldehyde or amine source, of which there are plenty available. The disadvantage is 
that the yields and diastereoselectivities are modest as a result of competing reactions.  
Leighton and co-workers reported a method to synthesise 3-substituted-4-oxopipecolic acid 
derivatives using a tandem asymmetric aza-Darzens reaction with nucleophilic ring opening in 
situ.66 A chiral silane-containing Lewis acid was employed to activate both the imine for the aza-
Darzens reaction and facilitate subsequent nucleophilic opening of the aziridine. In a one-pot 
process, a sulfonium ylide was generated from ethyl diazoacetate 150 and diphenylsulfide 
catalysed by rhodium acetate (Scheme 1.16). The ylide attacks the acylhydrazone 149, which is 
complexed with enantiomerically pure silane 151, followed by elimination of diphenylsulfide to 
form chiral aziridine 152. The silane remains complexed to the aziridine. This activates it towards 
nucleophilic attack by the chloride liberated from the silane and gives rise to a single regioisomer 
of aminohalide 153 in good yield with excellent enantiomeric excess. To produce the N-
heterocyclic core, intermediate 153 was reacted with acrolein to give aldehyde 154. 
Deprotonation of thiazolium salt 155 forms an N-heterocyclic carbene which reacts with the 
aldehyde moiety to give an enol.67 Subsequent cyclisation of the enol via a nucleophilic 
substitution reaction with inversion of the stereogenic centre generates 4-oxopipecolic acid 
analogue 156 in good yield with retention of enantiopurity.  
P a g e  | 31 
 
 
Scheme 1.16 Tandem asymmetric aza-Darzens/ring-opening reaction for the synthesis of 4-
oxopipecolic acid derivative 156 
The appeal of this route is the ability to telescope the aza-Darzens reaction and nucleophilic 
addition to carry out an aminohalogenation reaction, as well as using a one-pot procedure to 
generate the pipecolic acid. This methodology is fast and efficient and an excellent overall yield of 
64% is obtained with high levels of enantioselectivity. This approach is interesting as it also allows 
entry to unusual linear α-amino acid derivatives. Alternative 3-substituted analogues could be 
formed by varying the hydrazone. 
To summarise, a range of intramolecular cyclisation strategies can be applied for the synthesis of 
4-oxopipecolic acid derivatives. In most cases, commercially available or naturally occurring chiral 
starting materials are employed, however, the use of a chiral ligand also proved to be extremely 
effective. The disadvantage of the approach is that a number of steps are required to obtain a 
suitably functionalised precursor for the cyclisation. In contrast, pericyclic chemistry can offer 
faster access to the desired pipecolic acid core. 
1.3.1.2 Cycloaddition 
Pericyclic chemistry is an under-exploited method to produce 4-oxopipecolic acid, however 
advances within the field reveal that there is significant potential. Utilising cycloaddition reactions 
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to form the heterocyclic core can be difficult because controlling the relative and absolute 
stereochemistry is challenging. There are however a limited number of examples that obtain 
asymmetric induction. 
Weinreb and co-workers reported the use of a Diels-Alder reaction for the preparation of a 
piperidine-containing precursor to the alkaloid natural product, cylindrospermopsin.68 The 
tetracyclic molecule is a heptatoxin produced in the cyanobacterium, Cylindrospermopsin 
raciborskii, thought to inhibit cell-reduced glutathione synthesis which leads to hepatoenteritis in 
humans.69 
The synthetic strategy to produce the 4-oxopipecolic acid scaffold involved an aza Diels-Alder 
cycloaddition as the first step. Oxygenated diene 158 was prepared as a 4:1 mixture of Z:E 
isomers. Diene 158 was reacted with ethyl glyoxylate-derived N-tosyl imine 157 to generate the 
heterocyclic core. Acidic hydrolysis of the trimethylsilyl (TMS) group in situ with concomitant 
elimination produced unsaturated cycloadducts 159 and 160 (Scheme 1.17). 
 
Scheme 1.17 Diels-Alder cycloaddition to form unsaturated pipecolic acid derivatives 
Weinreb observed significant variation in the ratios of cycloaddition products obtained depending 
on the reaction conditions employed (Table 1.2). The optimal conditions utilised zinc chloride as a 
catalyst to facilitate the reaction to give excellent diastereoselectivity in favour of the syn-
analogue 159 in 60% yield. Preference for the syn diastereomer is rationalised as the Diels-Alder 
cycloaddition will occur via an endo transition state with the major Z-diene. The variation in the 
ratios observed is postulated to be the result of E/Z isomerisation under the reaction conditions.  
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Entry Catalyst Temp. (°C) Ratio (syn:anti) Yield (%) 
1 AlCl3 −78  7:1 53 
2 ZnCl2 −78 22:1 60 
3 - r.t. 5:1 51 
  Table 1.2 Diels-Alder conditions 
In order to synthesise the saturated N-heterocycle, a copper-mediated conjugate addition was 
investigated. According to 1H NMR spectroscopic analysis of 159, the heterocycle exists as a half-
chair conformation 161 with the ethyl ester axial to avoid steric clash and minimise allylic strain 
with the N-tosyl group (Scheme 1.18). It is well documented that C-2 substituents of N-
acylpiperidines reside axial for this reason.70,71 Copper-catalysed conjugation addition of vinyl 
magnesium bromide occurs with an equatorial trajectory to avoid 1,3-diaxial interactions with the 
ester to produce 3,6-disubstituted-4-oxopipecolic acid derivative 162. Subsequent reduction of 
the ketone with L-Selectride® led to formation of 4-hydroxypipecolic acid analogue 163. This 
product however did not have the desired stereochemistry for the target molecule. 
 
Scheme 1.18 Further functionalisation of syn-derivative 159 
Similarly, the trans-cycloaddition product 160 adopts a half-chair conformation 164, however 
attack of the vinyl magnesium bromide occurs via an axial direction to give 4-oxopipecolic acid 
165 (Scheme 1.19). Reduction of the ketone to 4-hydroxy derivative 166 provided the 
stereochemistry necessary for the synthesis of the natural product. Subsequent modifications 
allowed the pipecolic acid analogue to be converted to a useful cylindrospermopsin intermediate. 
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Scheme 1.19 Further functionalisation of anti-derivative 160 
Hetero Diels-Alder chemistry is an efficient method to form the piperidine nucleus in one step. A 
variety of substituents can also be introduced around the heterocyclic core which makes this 
route attractive. The limitation of this approach is that only relative stereochemistry is established 
and ideally the route would be asymmetric. The problem could be rectified by using a chiral 
component for the Diels-Alder reaction as exemplified by the following methods. 
Lau and co-workers have presented a large-scale, asymmetric synthesis of 4-oxopipecolic acid 
using an aza Diels-Alder cycloaddition with an enantiomerically pure dienophile.72 During work on 
a programme to synthesise 2-aminomethyl-4-oxopiperidine for use as a protein tyrosine 
phosphatase inhibitor, pericyclic chemistry was explored to incorporate the desired functionality 
of the piperidine ring. Enantiopure S-(−)-α-methylbenzylamine 167 was reacted with ethyl 
glyoxylate to give imine 168 (Scheme 1.20). Addition of diene 169 to the prepared imine 168 
along with trifluoroacetic acid (TFA) and boron trifluoride etherate gave 4-oxopipecolic acid 170 
as the major diastereomer in a 7:5 ratio. The major stereoisomer produced is the unnatural (2R)-
pipecolic acid, however, using the opposite enantiomer of the starting material, (R)-(+)-α-
methylbenzylamine, can give rise to the (2S)-configuration. Several steps were required to convert 
170 to Lau’s desired protected 2-aminomethyl-4-ketalpiperidine 172. 
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Scheme 1.20 Asymmetric hetero Diels-Alder cycloaddition for the synthesis of 2-aminomethyl-4-
ketalpiperidine 172 
The aza Diels-Alder process is elegant and efficient because the desired heterocycle is produced in 
two steps via a one-pot process. Devising synthetic strategies where multiple reactions are carried 
out in the one vessel enables less solvent to be used for the reactions and fewer work-ups. Also, 
fewer purification steps are required which makes tandem reactions environmentally friendly and 
economically viable for industrial purposes. The limitation of this approach is that the Diels-Alder 
reaction offers only a 16% diastereomeric excess. 
An asymmetric hetero Diels-Alder approach to synthesise 4-oxopipecolic acid was published by 
Gálvez and co-workers using an enantiomerically pure imine.73 Danishefsky’s diene 173 was 
reacted with a chiral imine 174 derived from 2,3-dibenzyl-D-glyceraldehyde and benzylamine, 
catalysed by zinc chloride to produce the piperidone core in moderate yield with excellent 
diastereoselectivity (Scheme 1.21). To generate the desired product, L-Selectride® was employed 
to reduce the alkene and then protection of the ketone as a ketal gave intermediate 176. 
Hydrogenolysis of the benzyl protecting groups then Boc protection of the nitrogen, followed by 
oxidation of diol 177 gave carboxylic acid 178. Finally, removal of the protecting groups under 
acidic conditions yielded the unnatural enantiomer of 4-oxopipecolic acid 179.  
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Scheme 1.21 Asymmetric hetero Diels-Alder cycloaddition for the synthesis of 4-oxopipecolic acid 
Gálvez and co-worker’s synthetic methodology gives rise to improved yields and excellent 
stereoselectivity in comparison to Lau’s results. The imino Diels-Alder reaction allows rapid access 
to the desired pipecolic acid motif and has the potential for subsequent modifications to be 
undertaken. A later paper published by Gálvez suggested the mechanism may occur via a tandem 
Mannich-Michael reaction as opposed to the concerted [4+2]-Diels-Alder approach suggested.74 
In comparison to the previous syntheses that employ chiral dienophiles to induce facial 
diastereoselectivity, Barluenga and co-workers have developed an approach using a chiral diene 
for an asymmetric cycloaddition to produce highly functionalised 4-oxopipecolic acid 
derivatives.75 A Lewis acid-catalysed Diels-Alder reaction of chiral diene 181 with an N-
silylaldimine 180 was carried out (Scheme 1.22). Basic hydrolysis cleaved the nitrogen-silicon 
bond and the resultant enamine of the chiral auxiliary to form piperidone 182 in excellent 
enantiomeric excess. Several transformations were carried out to protect selectively the amine 
with 2,2,2-trichloroethyloxycarbonyl chloride (TrocCl). The protecting group reactions were 
followed by oxidation of the alcohol to the corresponding carboxylic acid and subsequent 
esterification gave rise to the pipecolic acid motif 184. Finally, deprotection of the Troc-protecting 
group yielded (2R,3S,6S)-4-oxopipecolic acid analogue 185 in 99% yield.  
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Scheme 1.22 Hetero Diels-Alder cycloaddition using a chiral diene for the synthesis of 3,6-
disubstituted-4-oxopipecolic acid 185 
This alternative imino Diels-Alder methodology benefits from simple cleavage of the chiral 
auxiliary with a mild base. Whereas, previous examples using imines derived from 
enantiomerically pure α-methylbenzylamine require hydrogenation to remove the benzyl moiety 
from the amine. This expeditious route also generates the diversely functionalised 4-oxopipecolic 
acids with high levels of enantiopurity and enables simple variation of the 6-substitutent by 
employing different aldehyde starting materials. 
As illustrated, pericyclic chemistry has emerged as a powerful method to rapidly synthesise 4-
oxopipecolic acid derivatives. High levels of enantioselectivity can be achieved when chiral imines 
or chiral dienes are employed. An opportunity for diversity can also be readily introduced 
depending on the starting materials used. The asymmetric hetero Diels-Alder strategy may 
become even more prevalent in the future.  
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1.3.2 4-Hydroxypipecolic Acid Synthesis 
The review of 4-oxopipecolic acid synthesis revealed various methods can be employed to 
construct the saturated N-heterocyclic core.  The 4-hydroxy permutation of pipecolic acid has 
received significant attention because of the biological importance of the motif and its use as a 
synthetic scaffold and therefore numerous strategies have been devised. There are several 
examples where the carbonyl of 4-oxopipecolic acid is diastereoselectively reduced to give both 
(4R)- and (4S)-hydroxypipecolic acids depending on the reagent used. There are however many 
syntheses developed that provide the hydroxylated N-heterocycle directly. 
1.3.2.1 Heterocycle Construction 
Analogous to the approaches used to synthesise 4-oxopipecolic acid, intramolecular ring-closing 
reactions are prevalent to yield 4-hydroxypipecolic acids. More variation of reaction types exists 
with the hydroxylated analogues. 
Riera and co-workers published a route that included ring-closing metathesis (RCM) to generate 
the N-heterocyclic core of 4-hydroxypipecolic acid.76 This synthesis is one of the few examples 
where all the stereogenic centres have been constructed via asymmetric methods. A Sharpless 
asymmetric epoxidation of 2,5-hexadien-1-ol was employed to give rise to allylic epoxide 186 in 
93% enantiomeric excess. The epoxide was subjected to a regioselective ring-opening with 
allylamine to give the 3-amino-1,2-diol in a ratio of 10:1, followed by Boc protection to produce 
187 (Scheme 1.23). Ring-closing metathesis of diene 187 with Grubbs first generation catalyst 
gave unsaturated piperidine derivative 188 in good yield. Subsequent two step oxidative cleavage 
yielded N-Boc-(S)-baikiain 189, in 99% enantiomeric excess after recrystallisation. To introduce 
the hydroxyl substituent, an iodolactonisation, then reduction of the iodide with tributyltin 
hydride gave bicyclic lactone 191. Finally, basic hydrolysis produced Boc-protected (2S,4R)-4-
hydroxypipecolic acid 192.  
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Scheme 1.23 Ring-closing metathesis to form N-protected cis-4-hydroxypipecolic acid 
The route devised by Riera enables the synthesis of cis-4-hydroxypipecolic acid 192 in 8 steps 
from epoxide 186 in 17% overall yield. Using the Sharpless asymmetric epoxidation to dictate the 
stereochemistry of the starting material would allow both enantiomers of 4-hydroxypipecolic acid 
to be synthesised. However, only the cis-products can be obtained by this method as the 
iodolactonisation can only occur on the same face as the carboxylic acid substituent. 
Alternative methods to synthesise 4-hydroxypipecolic acid using ring-closing metathesis as the 
key step have also been demonstrated. Hou and co-workers used a chiral auxiliary to establish the 
stereochemistry of the carboxylate, then Grubbs second generation catalyst to affect the RCM in 
excellent yield.77 Whereas, Johnson and co-workers used commercially available vinylglycinol as 
the starting material, Grubbs (I) for the metathesis and a Prevost reaction to install the hydroxyl 
substituent.78 
An alternative method described by Jurczak and co-workers involved an intramolecular ene-
iminium cyclisation to close the heterocyclic ring.79 Asymmetric induction was achieved by using a 
menthol-derived chiral auxiliary. Enantiomerically pure glyoxylic acid derivative 193 was reacted 
with para-toluenesulfonyl isocyanate to generate imine 194, which was used in situ (Scheme 
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1.24). An asymmetric 1,2-addition of allyltrimethylsilane to the imine was carried out in the 
presence of a Lewis acid. α-Aminoketone 195 was obtained in good yield with excellent 
diastereoselectivity. The high level of diastereoselectivity is postulated to be a result of face-to-
face π stacking interactions of the phenyl group of the auxiliary and the imine (Figure 1.18). The 
allyltrimethylsilane therefore preferentially adds to the Si-face.  
 
Scheme 1.24 Ene-iminium cyclisation using a chiral auxiliary to produce 4-hydroxypipecolic acid 
derivatives 
 
Figure 1.18 Facial discrimination due to face-to-face π stacking interaction 
Generation of the 4-hydroxypipecolic acid core entails formation of an iminium ion from 
homoallylic amine 195 and paraformaldehyde (Scheme 1.24). Subsequent cyclisation of the 
terminal alkene onto the imine occurs to close the ring and the resultant carbocation can be 
trapped by a water molecule at the 4-position. A moderate yield for the 4-oxygenated pipecolic 
acid derivative 197 was obtained, however, the diastereoselectivity was poor. Anti-product 197 
was obtained as the major stereoisomer in a 2:1 anti:syn ratio. The chiral auxiliary does not exert 
long distance steric effects and therefore, fails to influence asymmetric induction.  
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The ene-iminium cyclisation route to 4-hydroxypipecolic acid presented by Jurczak has several 
disadvantages. The addition of allyltrimethylsilane occurs highly stereoselectively to create the 
first stereogenic centre, however incorporation of the hydroxyl substituent occurs with poor 
diastereoselectivity. The use of a chiral auxiliary is not ideal as additional steps for synthesis and 
cleavage are necessary, despite Jurczak not demonstrating the removal. 
A much improved variation of the ene-iminium cyclisation was published by Kadouri-Puchot and 
co-workers using a chiral pool starting material.80 Enantiomerically pure (S)-phenylglycinol 200 
was converted into oxazolidine 201 by reaction with butyraldehyde (Scheme 1.25). Oxazolidine 
201 was reacted with organolithium species 202 to yield β-aminoalcohol 203 with high 
diastereoselectivity. Oxazolidine 201 exists in equilibrium with the ring-opened imine tautomer 
with E-geometry. In the presence of the organolithium reagent, a highly ordered, chelated 
transition state results (Figure 1.19). The facial discrimination is rationalised as internal delivery of 
the nucleophile occurs from the less-hindered Si face of the imine.  
 
Scheme 1.25 Ene-iminium cyclisaton to produce 6-substituted-4-hydroxypipecolic acid 
P a g e  | 42 
 
 
Figure 1.19 Chelated transition state 
Reaction of β-aminoalcohol 203 with glyoxal forms an imine which cyclises to give hemi-acetal 
204 (Scheme 1.25). The ene-iminium cyclisation then occurs with complete facial discrimination 
as the phenyl substituent hinders the Re face and therefore the concerted process occurs to 
produce bicyclic intermediate 205. Completion of the synthesis involves oxidative cleavage of the 
terminal alkene, followed by Swern oxidation of the hemi-acetal to produce lactone 207. 
Diastereoselective reduction of ketone 207 with K-Selectride® installs the 4-hydroxy substituent. 
Finally, hydrogenolysis yields trans-6-substituted-4-hydroxypipecolic acid 208 in almost 
quantitative yield. A 27% overall yield is achieved in seven steps. 
The diastereoselectivity of Kadouri-Puchot’s approach for the ene-iminium cyclisation and prior 
steps are significantly improved in comparison to Jurczak’s attempt. The presence of the phenyl 
stereogenic centre on the rigid cyclic iminium intermediate 204 facilitates the smooth conversion 
of the tethered alkene during the cyclisation. Using a highly selective, bulky reducing agent to 
provide the 4-hydroxyl centre also led to good facial selectivity. 
Several other approaches have been published which involve an ene-iminium cyclisation,54,57,81,82 
however they suffer from similar difficulties as Jurczak’s synthesis and generally provide a 1:1 
ratio of (4R)- to (4S)-hydroxypipecolic acid diastereomers.  
An unusual strategy for heterocycle synthesis was developed by Funk and co-workers.83 The 
synthesis centres around a bromomethyl vinyl ketone equivalent 213 that possesses two sites of 
electrophilic character, however the sensitive enone functional group is conveniently masked 
until required. Once the enone is revealed, an intramolecular conjugate addition reaction closes 
the N-heterocyclic ring.  
The bromomethyl vinyl ketone equivalent 213 was synthesised in three steps from allyl iodide 210 
(Scheme 1.26). A Prins reaction with allyl iodide 210 and paraformaldehyde followed by 
elimination under reduced pressure produced methylene-1,3-dioxane 212. Bromination of 212 in 
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the presence of base generated bromomethyl vinyl ketone equivalent 213 in 57% yield over the 
three steps. Williams’ lactone 21484 was alkylated stereoselectively with allylic bromide 213 to 
produce enol ether 215. The enone moiety was then unveiled under thermal conditions via 
fragmentation and the Boc protecting group was removed to yield intermediate 216. A 
concomitant 6-endo-trig conjugate addition reaction occurred to generate the pipecolic acid core 
217. Stereoselective reduction of the ketone installed the 4-hydroxy substituent as a single 
diastereomer and then hydrogenolysis liberated the carboxylic acid side-chain to give the natural 
stereoisomer, (2S,4R)-4-hydroxypipecolic acid 104 in excellent yield. 
 
Scheme 1.26 Intramolecular conjugate addition reaction for the synthesis of 4-hydroxypipecolic 
acid 
Funk’s approach enables the synthesis of 4-hydroxypipecolic acid in eight steps with good to 
excellent yields. The communication does not present the diastereoselectivity of the alkylation 
step and therefore cannot be compared to other approaches. Assuming the alkylation step is 
highly selective as a result of the chiral lactone, the opposite enantiomer of 4-hydroxypipecolic 
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acid could, in theory be formed with use of the opposite configuration of the William’s lactone. 
Funk’s method however lacks the ability to incorporate variation to the heterocyclic template. 
An alternative approach using an intramolecular lactamisation devised by Occhiato and co-
workers enabled the synthesis of both (2S,4R)- and (2R,4R)-4-hydroxypipecolic acids.85 
Commercially available ethyl (R)-4-cyano-3-hydroxybutanoate 219 was employed as the starting 
material. The hydroxyl substituent was protected as tert-butyl ether 220, which served as a 
protecting group and due to the steric bulk allowed facial discrimination during a later reduction 
step (Scheme 1.27). The cyano group was reduced to an amine, which underwent an 
intramolecular lactamisation to generate piperidone 221. Protection of the nitrogen with methyl 
chloroformate gave intermediate 222. Treatment of piperidone 222 with potassium 
hexamethyldisilazide produced an enolate that was trapped with diphenylchlorophosphate to 
yield stable vinyl phosphonate 223. Vinyl phosphonate 223 is employed as a more stable 
alternative to the vinyl triflate used in Occhiato’s preliminary communication.86 The enolate 
equivalent 223 was subjected to palladium-catalysed carbonylation conditions in the presence of 
methanol to yield vinyl methyl ester 224. Stereoselective reduction of the alkene occurs from the 
Re face, as a result of the bulky tert-butyl ether hindering the top face of the heterocycle. Syn-4-
hydroxypipecolic acid 225 is formed in excellent yield and with a high diastereomeric ratio of 19:1  
syn:anti. Acid-mediated deprotection generated the free amino acid 226. 
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Scheme 1.27 Lactamisation approach to generate 4-hydroxypipecolic acid 
Occhiato’s route is stereodivergent at the reduction stage of the vinyl methyl ester 224. To 
synthesise the opposite configuration of the carboxylic acid, a conjugate reduction with Super 
hydride® was carried out to give the trans-isomer as the major product in 80:20 d.r. (Scheme 
1.28).  To overcome problems with separation of the diastereomers, the mixture of pipecolic acids 
227 was treated with para-toluenesulfonic acid. This induced deprotection of the hydroxyl 
substituents and initiated formation of bicyclic lactone 229 from only the syn-diastereomer. The 
desired trans-product 228 was readily isolated and deprotected to yield (2R,4R)-4-
hydroxypipecolic acid 230 quantitatively.  
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Scheme 1.28 Conjugate reduction to yield unnatural (2R,4R)-4-hydroxypipecolic acid 
The lactamisation route enables access to (2S,4R)-4-hydroxypipecolic acid in 7 steps in a high 66% 
overall yield. The stereodivergent route could potentially allow synthesis of all four stereoisomers 
of 4-hydroxpipecolic acid if ethyl (S)-cyano-3-hydroxybutanoate was employed as the starting 
material. It may also be feasible to functionalise the vinylic methyl ester 224 with nucleophiles to 
create a new stereocentre in the C-3 position making this approach highly versatile. 
The lactamisation approach has also proved successful for Davis and co-workers with an 
expeditious entry to 4-hydroxypipecolic acids.87 A chiral sulfoxide auxiliary was employed for 
asymmetric induction to synthesise the lactam precursor. Guichard and co-workers also published 
a similar route via lactamisation of an L-aspartic acid derivative for formation of the N-
heterocycle.88 
Other techniques used to close the heterocyclic ring of 4-hydroxypipecolic acid include a 
reductive amination approach used by Haddad and co-workers.89 Low yields were obtained for 
the heterocycle construction as a result of chemoselectivity issues. Nucleophilic substitution 
reactions are also commonly employed for the ring closing reaction as exemplified by the 
research groups of Lesma90 and Varela.91,92 
A wide range of reactions have been utilised to close the heterocyclic ring of 4-hydroxypipecolic 
acid. Using enantiomerically pure starting materials or a chiral auxiliary appears to be the most 
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common method to obtain asymmetry, however asymmetric catalysis has also been successfully 
employed.  
1.3.2.2 Cycloaddition 
A variety of pericyclic reactions have been explored for the synthesis of 4-hydroxypipecolic acid. 
Analogous to the cycloaddition chemistry utilised to form 4-oxopipecolic acids, the significant 
challenge is to exert control over the regio- and stereochemistry during the reaction. 
A minor adaption to Gálvez and co-worker’s previously published route to 4-oxopipecolic acid74 
has proved successful for direct access to 4-hydroxypipecolic acid using a hetero Diels-Alder 
strategy.93 The aim of the synthesis was to use the previously established methodology to 
synthesise palinavir 109 from (2S,4R)-4-hydroxypipecolic acid. In the earlier route, protected (R)-
glyceraldehyde yielded (2R)-pipecolic acid (Scheme 1.21). In this incidence, protected (S)-
glyceraldehyde was employed as the chiral imine and was anticipated to give the opposite 
enantiomer.  
(S)-2,3-Di-O-benzylglyceraldehyde was synthesised in six steps from L-mannonic γ-lactone in 44% 
overall yield and reacted with (R)-α-methylbenzylamine to produce chiral imine 231 (Scheme 
1.29). A Lewis acid catalysed hetero Diels-Alder reaction of imine 231 with Danishefsky’s diene 
173 produced unsaturated (2S)-piperidone 232 with complete diastereoselectivity. Concurrent 
reduction of the enamine and the ketone moiety with sodium borohydride gave a single 
diastereomer with the desired (4R)-4-hydroxy stereochemistry. Acetylation of the hydroxyl and 
selective hydrogenation of the N-benzyl group in the presence of Boc anhydride yielded 
intermediate 234. Hydrogenation of both O-benzyl protecting groups followed by oxidative 
cleavage gave (2S,4R)-4-hydroxypipecolic acid 236. Further steps were required to convert 
pipecolic acid 236 into a suitably functionalised key intermediate for the synthesis of palinavir. 
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Scheme 1.29 Hetero Diels-Alder cycloaddition to generate (2S,4R)-4-hydroxypipecolic acid 
derivative 236 
This method demonstrated by Gálvez and co-workers is highly efficient. The key hetero Diels-
Alder reaction and subsequent reduction are completely stereoselective and high yielding. Access 
to both (2S)- and (2R)-carboxylic acid substituents is possible using either (S)- or (R)-configurations 
of starting material respectively. Gálvez has also shown that the opposite sterochemistry of the 
hydroxyl group can be obtained with L-Selectride®. The negative point of this approach is the 
seven linear steps required to make the starting imine 231. 
1,3-Dipolar cycloaddition reactions have also been effective for the synthesis of 4-
hydroxypipecolic acid. Cordero and co-workers published a route to both cis- and trans-4-
hydroxypipecolic acid using a nitrone-containing chiral auxiliary as the 1,3-dipole.94 Thermally 
stable Z-C-aminocarbonyl nitrone 237 possessing a chiral auxiliary was reacted with butenol to 
produce an equimolar mixture of diastereomeric isoxazolidines 238 and 239 (Scheme 1.30). An 
exo-type transition state gives rise to the relative syn-configuration, however the 
conformationally labile N-chiral auxiliary of the acyclic nitrone does not induce diastereofacial 
discrimination. The diastereomeric mixture was separated, then isoxazolidine 239 was mesylated 
and subsequent nucleophilic substitution yielded the bicyclic N-heterocycle 240. Catalytic 
hydrogenation opened the isoxazolidinium ring to reveal the 4-hydroxy substituent of 
intermediate 241. Removal of the chiral auxiliary attached to nitrogen by hydrogenation followed 
by amide hydrolysis generated (2R,4R)-4-hydroxpipecolic acid 230 in five steps in an overall 52% 
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yield from 239. The same synthetic route was employed using isoxazolidine 238 to produce the 
opposite enantiomer, (2S,4S)-4-hydroxypipecolic acid in 54% overall yield from 238. 
 
Scheme 1.30 1,3-Dipolar cycloaddition to produce trans-4-hydroxypipecolic acid 230 
The use of a cyclic E-C-carboxy nitrone 243 enabled the synthesis of cis-4-hydroxypipecolic acid 
246.94 In this example, the rigid nitrone produces only one cycloadduct from the 1,3-dipolar 
cycloaddition. Nitrone 243 was reacted with butenol to give bicyclic intermediate 244 as a single 
diastereomer (Scheme 1.31). An exo-type addition to the less hindered Re face, opposite to the 
phenyl substituent, allows excellent diastereofacial discrimination. Mesylation followed by 
hydrogenolysis as before generated (2R,4S)-4-hydroxypipecolic acid 246 in four steps in 4% overall 
yield. The poor yield during the mesylation and subsequent intramolecular cyclisation is 
attributed to the high degree of ring strain of tricyclic intermediate 245. 
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Scheme 1.31 1,3-Dipolar cycloaddition to generate cis-4-hydroxypipecolic acid derivative 246 
The efficacy of Cordero and co-worker’s strategy is compromised by the lack of facial control 
during the 1,3-dipolar cycloaddition of acyclic nitrones to alkenes. This problem was overcome 
with the use of rigid cyclic nitrones, however the cyclic nature of the auxiliary hindered 
subsequent synthetic steps. 
A 1,3-dipolar cycloaddition strategy was also published by Merino and co-workers, however they 
employed an intramolecular cyclisation.95 This approach provides significantly enhanced facial 
selectivity in comparison to the previous route. Access to highly desirable syn-6-substituted 4-
hydroxypipecolic acid analogues was feasible using this method.  
Enantiopure nitrone 247, derived from protected D-glyceraldehyde, was subjected to allylation 
conditions to yield either the anti- 248 or syn-product 249 depending on the Lewis acid employed 
(Scheme 1.32, Table 1.3). The selectivity was efficiently tuned to give the syn-diastereomer with 
zinc bromide and the anti-diastereomer using boron trifluoride in excellent yields. The syn-
product 249 was oxidised with manganese dioxide to produce Z-nitrone 250 quantitatively. The 
nitrone containing the tethered alkene was subjected to thermal cycloaddition conditions to 
produce cycloadduct 251 as the major diastereomer via an endo-type transition state. The 
dioxolane of bicyclic intermediate 251 was oxidatively cleaved to give an aldehyde, then oxidised 
to a carboxylic acid and then esterified to produce fused 2,6-disubstituted piperidine 252. Zinc-
promoted reduction of the N–O bond generated the 4-hydroxypipecolic acid skeleton 253 in good 
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yield. Conversion of substituted pipecolic acid into orthogonally protected product 254 in 2 steps 
yielded the N-heterocycle in nine steps in 23% overall yield. 
 
Scheme 1.32 1,3-Dipolar cycloaddition to generate 6-substituted-4-hydroxypipecolic acid 
derivative 254 
Entry Metal 
[M] 
Lewis Acid Solvent Temp. (°C) Time (h) Ratio (anti:syn) Yield (%) 
1 Li ZnBr2 Et2O −80  1 10:90 75 
2 MgBr ZnBr2 Et2O −50 8 5:>95 100 
3 SnBu3 BF3.Et2O CH2Cl2 25 72 95:≤5 90 
4 MgBr BF3.Et2O THF −50 10 5:95 90 
Table 1.3 Conditions for the allylation of nitrone 247 
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Using the anti-product 248, Merino and co-workers demonstrated that the opposite enantiomer 
(2S,4R,6R)-4-hydroxypipecolic acid could also be synthesised.95 They also showed that other 
substituents could potentially be introduced into the 6-position by transhydroximation. Nitrone 
255 was converted into hydroxylamine 256, which was reacted with propionaldehyde to yield 
nitrone 257 (Scheme 1.33). Cyclisation of nitrone 257 would allow the incorporation of an ethyl 
substituent into the 6-position of pipecolic acid. In theory, a wide range of aldehydes could be 
condensed in the same way to allow access to various 6-substituted-4-hydroxypipecolic acid 
analogues.  
 
Scheme 1.33 Transhydroximation to yield C-ethyl-N-alkenyl nitrone 257 
The use of pericyclic chemistry is less popular because of issues with establishing relative and 
absolute stereochemistry of substituents. However, several elegant and highly diastereoselective 
approaches have been developed. Undoubtedly, further advances in this expanding field will 
increase the importance in the future. 
1.3.2.3 Ring Expansion / Rearrangement  
Rearrangement and ring expansion reactions are much less common for the synthesis of N-
heterocycles, however they can provide a novel entry to desirable structures with high levels of 
asymmetric induction. 
A cascade involving a rearrangement reaction was employed by Haufe and co-workers to 
synthesise a 6-substituted-4-hydroxypipecolic acid derivative following observation of a reaction 
by-product.96 Seebach’s chiral Boc-protected imidazolidinone 258 was alkylated asymmetrically 
with 2-fluoroallyltosylate in good yield with excellent diastereoselectivity to produce vinylfluoro 
intermediate 259 (Scheme 1.34). Functionalised imidazolidinone 259 was heated under reflux in 
hydrochloric acid, which induced a reaction cascade. Acid-promoted cleavage of the Boc 
protecting group with concomitant opening of the imidazolidinone ring produces iminium 261. 
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Rotation of the vinylfluoro group enables an ene-iminium cyclisation to occur followed by 
hydration and elimination of hydrogen fluoride to generate the N-heterocyclic ring 263. Syn-6-
substituted-4-oxopipecolic acid derivative 263 was produced as a single diastereomer due to the 
tert-butyl group which adopts an energetically favourable equatorial position during the 
cyclisation. Reduction of the ketone occurred with an axial trajectory to yield the (4R)-4-hydroxy 
diastereomer 264 with excellent stereocontrol. Finally, acidic hydrolysis of the amide yielded 6-
substituted-4-hydroxypipecolic acid 265 in 30% overall yield in 4 steps. 
 
Scheme 1.34 Rearrangement of a vinylfluoro imidazolidinone to yield 6-substituted-4-
hydroxypipecolic acid 265 
Interestingly, only vinylfluoro imidazolidinone 259 will undergo the rearrangement reaction. 
Equivalent vinylbromo and vinylchloro compounds fail to yield the desired pipecolic acid product. 
This is rationalised by the unique resonance and inductive effects caused by fluorine.  
The rearrangement reaction illustrated by Haufe and co-workers provides excellent asymmetric 
induction throughout the synthetic scheme. The tert-butyl group serves as a highly efficient 
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equatorial locking-group to provide high levels of diastereoselectivity. An attempt was made to 
simulate the ene-iminium cyclisation by reacting a selection of aldehydes with an open-chain 
analogue of vinylfluoro intermediate 259. Reaction with pivaldehyde gave 4-oxopipecolic acid 
derivative 263 in 73% yield, however enolisable aldehydes or benzaldehydes did not produce the 
desired product. This may indicate a limitation of this approach as incorporation of different 
substituents into the 6-position might not be possible. 
1.4 Summary 
The importance of the piperidine motif has been illustrated by the numerous synthetic, biological 
and medicinal applications. A survey of recent literature for the synthesis of piperidine derivatives 
revealed multiple methods to yield chiral N-heterocycles.  
Chiral substituted piperidines are most commonly synthesised via intramolecular ring-closing 
reactions such as metathesis, reductive amination and nucleophilic substitution reactions. 
Construction of the saturated N-heterocycle by cycloaddition has been demonstrated and can be 
highly efficient. Rearrangement reactions to generate six-membered rings are present in the 
literature, however are usually employed in specific cases rather than applicable for general 
syntheses. Extensive research has been carried out in the field of pyridine reduction, however 
stereochemistry can be difficult to control and therefore the synthetic utility is limited. Numerous 
other synthetic methodologies also exist which haven’t been mentioned. Many of the general 
methods to synthesise piperidines have been used to construct the heterocycle of pipecolic acid 
analogues. 
The synthesis of 4-oxopipecolic acid derivatives is commonly carried out using classical chemistry 
such as the Dieckmann reaction and conjugate additions. In most cases examined, asymmetry is 
established using the chiral pool as a source of starting materials. Several examples using 
pericyclic chemistry have been demonstrated and this appears to provide rapid entry to the 
desired 4-oxopipecolic acid scaffold. The on-going challenge is to control regio- and 
stereochemistry efficiently. 
4-Hydroxypipecolic acid is one of the most studied members of the pipecolic acid family. A range 
of transformations have been utilised to synthesise this important motif including ring-closing 
metathesis, intramolecular lactonisation and nucleophilic substitution. Synthetic strategies 
devised containing intramolecular conjugate addition reactions are frequent. Pericyclic chemistry 
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such as hetero Diels-Alder reactions and 1,3-dipolar cycloadditions have also successfully yielded 
the desired framework. 
Despite the numerous synthetic strategies developed to date, a great deal of interest in these 
molecules remains and therefore the challenge to provide a fast, efficient and varied route to 
these important compounds is still active. 
1.5 Proposed Methodology to Synthesise 4-Oxygenated Pipecolic 
Acid Derivatives 
There were two primary aims of this Ph.D. research programme to be investigated. The first 
objective was to develop a fast and efficient method to synthesise a novel class of unnatural, 
linear α-amino acids containing an enone 268. The second endeavour was to employ the enone-
containing α-amino acids 268 as precursors for an intramolecular cyclisation to produce highly 
desirable 4-oxygenated pipecolic acid derivatives 270.  
The strategy devised takes advantage of the chiral pool by employing L-aspartic acid 266 as the 
enantiomerically pure starting material. The proposed approach was to transform L-aspartic acid 
266 into β-ketophosphonate ester 267 capable of undergoing a stereoselective olefination 
reaction to install the enone alkene with defined E- or Z-geometry (Scheme 1.35). Deprotection of 
enone 268 to the corresponding parent α-amino acid 269 was also desirable. This unusual class of 
amino acid derivative may have several important uses as a result of the highly conjugated, 
electrophilic acceptor functionality coupled with the amino acid moiety. 
Following the development of an expeditious route to the unnatural α-amino acids, the intention 
was to use a protected version of the enone 268 and investigate a diastereoselective 6-endo-trig 
cyclisation to yield 6-substituted-4-oxopipecolic acid analogues 270. As mentioned previously, 4-
oxygenated pipecolic acid congeners possess many interesting biological properties which make 
them attractive targets in organic synthesis. They can also serve as valuable synthetic scaffolds. 
The 2,6-substitution pattern around the heterocyclic core is significant because of the many 
natural products and synthetic derivatives of pipecolic acid that contain this motif.69,97,98  
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Scheme 1.35 Proposed route to unnatural α-amino acids and 4-oxopipecolic acid derivatives 
The research programme strives to provide an alternative route to these important molecular 
building blocks. The proposed strategy to substituted pipecolic acid will enable diversity to be 
readily achieved by varying the R group of the enone. These highly functionalised saturated N-
heterocyclic structures contain several functional groups that can easily be transformed via a 
variety of chemical interconversions to provide a versatile synthetic scaffold. 
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2 Novel Enone-Containing α-Amino Acids 
2.1 Introduction 
The synthesis of unnatural α-amino acids is a well-established field that continues to gain 
popularity and relevance with recent developments in the biosciences and fine-chemical industry. 
Advances in genetic technologies99 and proteomics have led to innovation with regard to 
producing novel α-amino acids and corresponding congeners.  
 Non-proteinogenic α-amino acids play an integral role in numerous aspects of chemistry, biology 
and medicine. In modern organic synthesis, they have found applications as organocatalysts and 
as ligands for asymmetric induction.100 They can also serve as optically active synthetic scaffolds. 
Pioneering research in the field of peptidomimetics requires the incorporation of unnatural amino 
acid analogues. Peptide surrogates with enhanced metabolic stability have been designed to have 
analogous therapeutic effects as the endogenous peptide101 and therefore, this technology could 
potentially lead to the identification of biological enzyme or receptor targets for drug molecules. 
Modified α-amino acids have also been shown to act directly as therapeutic agents.102 
Although an array of unnatural amino acid analogues exists for a variety of different functions, 
novel α-amino acids that comprise an enone motif are relatively scarce in the literature. There are 
however a limited number of examples that possess the intriguing α,β-unsaturated ketone 
moiety.63,103,104 
2.2 Previous Syntheses of Enone-Containing α-Amino Acids 
A range of unsaturated α-amino acids were synthesised by Lubell and Gosselin with the intention 
to use the enones as substrates to produce azabicyclo[X.Y.0]alkane amino acids.103 These bicyclic 
structures have been shown to act as conformationally restricted dipeptide surrogates that 
restrain the backbone and side-chain geometry of native proteins.101 
The synthetic strategy devised by Lubell made use of naturally occurring α-aminodicarboxylates; 
aspartate, glutamate and α-aminoadipate, as chiral starting materials. These were converted to 
suitable substrates for a Horner-Wadsworth-Emmons (HWE) reaction in order to incorporate the 
enone portion of the α-amino acids.  
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Protection of the carboxylic acid moieties as esters and amine protection with a 9-(9-
phenylfluorenyl) group generated intermediates 271-273. The protected amino acids were 
converted to β-ketophosphonate esters using the anion of dimethyl methylphosphonate to 
produce the HWE precursors 274-276 in 40–84% yield (Scheme 2.1). Installation of the α,β-
unsaturated ketone using a HWE olefination with an amino acid-derived aldehyde produced the 
enone-containing diamino acids 277-279 in moderate to good yield. Completion of the synthesis 
involved a further 5 steps to generate the azabicyclo[X.Y.0]alkane amino acid 282 for use as a 
conformationally restricted dipeptide surrogate.  
 
Scheme 2.1 Lubell’s synthesis of peptiodomimetic 282 
Lubell’s eloquent synthesis provides a versatile route to access a range of β-ketophosphonate 
esters by varying the α-amino acid starting material. This enables the synthesis of enone-
containing α-amino acids that differ by the number of carbon atoms connecting the enone 
carbonyl to the amino acid moiety. Choice of a connective double bond forming methodology, 
such as the HWE reaction, provides further scope for variation because there is a wealth of 
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aldehydes available for use as the corresponding HWE partner and therefore, highly diverse 
structures can be designed. 
Enone-containing α-amino acids have also been used as synthetic intermediates in carbohydrate 
chemistry as exemplified by Davis and co-worker’s synthesis of a C-linked glycoamino acid.105 
Replacement of the naturally occurring carbon–nitrogen or carbon–oxygen glycosidic bond of 
glycoproteins with a carbon–carbon bond enables C-glycoside analogues to be resistant to 
chemical and enzymatic cleavage and therefore, these analogues may function as potential 
enzyme inhibitors.106 
Davis’ synthesis involved a tandem HWE olefination/oxo-conjugate addition to produce the 
unsaturated amino acid as an intermediate that was not isolated. The route involved generation 
of a β-ketophosphonate ester 283 from L-aspartic acid.107 HWE reaction of phosphonate ester 283 
with hemi-acetal 284 gave the C-glycoside analogue 286 (Scheme 2.2). The reaction proceeded 
through an enone-functionalised α-amino acid intermediate 285, which underwent subsequent 
intramolecular oxo-conjugate addition to give the target molecule in moderate yield.  
 
Scheme 2.2 C-linked glycoamino acid synthesis via a tandem HWE/conjugate addition reaction 
Although the synthesis of enone-containing amino acids was not the objective of Davis’ work, this 
scheme illustrates the potential to use unsaturated amino acids as scaffolds for further 
modification to generate synthetically useful molecules. The limitations of this strategy are the 
moderate yield and the lack of significant variation to the template.  
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Jackson and co-workers published a short route to synthesise enantiomerically pure 4-
oxopipecolic acid by means of an intramolecular cyclisation of an α-amino acid containing a 
terminal enone.104 In contrast to the previous approaches that used a connective double bond 
forming strategy, Jackson employed a palladium-catalysed coupling reaction to install the alkene.  
The stereogenic centre of the product arises from the L-serine-derived organozinc reagent 287.108 
Palladium-mediated coupling of organozincate 287 with acryloyl chloride generated the terminal 
enone 288 directly (Scheme 2.3). Exposing the enone-containing α-amino acid to anhydrous, 
acidic conditions promoted the 6-endo-trig cyclisation to give rise to 4-oxopipecolic acid benzyl 
ester 289 in quantitative yield. 
 
Scheme 2.3 4-Oxopipecolic acid derivative synthesis via a terminal enone α-amino acid 
Jackson’s expeditious route is beneficial as it produces enone-containing α-amino acids in one 
step from the organozincate, however the drawback of this coupling method is the limited 
sources of vinylic acid chlorides to produce useful variation. Jackson indicates that 3-
bromopropionyl chloride can be employed in the coupling process to yield the terminal alkene 
288, however is less efficient than acryloyl chloride. Also the use of a metal catalyst may be 
undesirable if the targets are to be used for biological purposes due to trace metal residues. 
A brief synopsis of previously synthesised enone-functionalised α-amino acids has been 
presented. In all cases illustrated, naturally occurring α-amino acids have been selected as the 
synthetic start point because they are readily available and have the advantage that the α-
stereogenic centre is already present and therefore the process offers high atom economy. It is 
also evident that the most versatile strategies employ a connective alkene bond forming approach 
to allow maximum structural diversity. The previously synthesised enones have predominantly 
served as synthetic intermediates, however there are several potential uses that could be 
explored with enone-containing α-amino acids. 
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2.3 Potential of Novel Enone-Containing α-Amino Acids 
A novel class of α-amino acid-derived enones of the form 290 (Figure 2.1) may have numerous 
potential functions. The possible uses of previously synthesised enone-containing α-amino acids 
of this type have yet to be fully explored, as they have primarily been employed as synthetic 
intermediates. A crucial factor that has also hindered the application of these structures is that 
the enones have not been deprotected and liberated as the parent α-amino acids.  
 
Figure 2.1 Generic enone-containing α-amino acid structure  
It is feasible that α-amino acids of the type 290 may function as irreversible enzyme inhibitors in 
certain eukaryotic or prokaryotic cells. The amino acid portion will act as the recognition motif to 
allow the substrate to be transported across cell membranes via embedded amino acid 
transporter proteins.109 It is proposed that once transported into a cell, the presence of the highly 
reactive enone functionality of the α-amino acid could react with nucleophilic residues of amino 
acid side-chains within active or allosteric sites of enzymes. This would result in covalent bonding 
to the enzyme, and therefore irreversibly decrease enzymatic activity. 
Another area of interest for exploration is the synthesis of short biologically active peptides. The 
field of small bioactive peptides is expansive due to the multiple functions these molecules 
exhibit. They have found applications as antibiotics, anti-fungal and anti-cancer agents, as well as 
other biological applications.110 Development of orthogonally protected enone-containing α-
amino acids would enable efficient amide coupling to produce novel short peptides which may 
possess biological activity. 
Incorporation of an unsaturated R group to the amino acid would generate an extensively 
conjugated system. Highly conjugated molecules are significant because they can have 
photoluminescent properties. Consequently, it is possible that novel conjugated enone-containing 
α-amino acids may behave as fluorophores, and therefore could be employed as fluorescent 
biological probes. 
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A fast and efficient route is required to enable exploration of these interesting, novel structures 
with ample potential. To employ the enone-containing α-amino acids in biological systems, they 
must be synthesised with high levels of enantiopurity. Ideally, the synthetic strategy will allow 
diverse structures to be produced from a common intermediate. 
2.4 Synthesis of Novel Enone-Containing α-Amino Acids 
The strategy devised for the synthesis of novel enone-functionalised α-amino acids was to employ 
naturally occurring L-aspartic acid as the enantiomerically pure starting material. This allows for 
excellent atom economy, as the amino acid moiety is already present and the correct 
configuration of the α-stereogenic centre is set.  Amino acids are also readily available and 
inexpensive, which makes them attractive starting materials. A connective double bond approach 
was preferential to incorporate variation into the structures from an advanced intermediate, 
which would enable libraries of compounds to be easily synthesised. 
2.4.1 E-Configured Enone-Functionalised α-Amino Acids 
A rapid and highly efficient four-step synthesis was developed utilising the Horner-Wadsworth-
Emmons reaction as the crucial double bond forming step to yield the novel enone-containing α-
amino acid derivatives (Scheme 2.4). The strategy devised was to synthesise amino acid-derived 
β-ketophosphonate ester 293 as the key intermediate.   
L-Aspartic acid 266 was converted to the dimethyl ester hydrochloride salt 291 in quantitative 
yield.111 Subsequent protection of the amino group with the bulky trityl protecting group gave 292 
quantitatively. Formation of the β-ketophosphonate ester 293 was achieved by reacting the 
lithium anion of dimethyl methylphosphonate with the less-hindered β-methyl ester of 
intermediate 292.107 The steric bulk of the trityl protecting group enabled regioselective 
discrimination and therefore, led to a highly selective and high yielding reaction to generate the 
Horner-Wadsworth-Emmons substrate in 84% yield.  
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Scheme 2.4 Synthetic route to amino acid-derived β-ketophosphonate ester 293 
Following the synthesis of intermediate 293, formation of the alkene was investigated using a 
Horner-Wadsworth-Emmons reaction to generate the enone.  The HWE reaction is a well-
established and reliable method for the formation of alkenes. It was developed in 1958 by 
Horner112 and popularised by Wadsworth and Emmons113 in 1961. Analogous to the Wittig 
reaction, the HWE reaction can generate both E- and Z-alkenes, however the advantage of the 
HWE reaction in comparison to the Wittig reaction is the formation of water-soluble by-products 
that enable simpler purification. 
The HWE reaction of β-ketophosphonate ester 293 with benzaldehyde was initially attempted 
using Masamune-Roush conditions to give enone 294.114 Lithium chloride was employed as an 
additive to lower the pKa of the protons between the carbonyl and the phosphonate ester, and 
therefore the neutral organic base, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), could carry out the 
deprotonation at room temperature. Reaction of β-ketophosphonate 293 with benzaldehyde 
under the mild conditions gave a moderate 42% yield with complete E-selectivity (Scheme 2.5).  
In an attempt to optimise the HWE reaction, alternative conditions developed by Lubell using the 
inorganic base, potassium carbonate, in acetonitrile at 50 °C were explored (Scheme 2.5).115 
Under these conditions, the desired enone-functionalised α-amino acid 294 was produced in an 
excellent 95% yield with complete E-selectivity. 
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Scheme 2.5 Horner-Wadsworth-Emmons reaction 
The geometry of the alkene was confirmed as the E-isomer by 1H NMR spectroscopy, as a vicinal 
coupling constant of 16.2 Hz was observed. The selectivity of the HWE reaction arises from the 
initial carbon-carbon bond forming step and the reversibility of intermediates. Stepwise attack of 
phosphoryl-stabilised carbanion 296 on aldehyde 295 generates interchangeable oxyanions 297 
and 300 (Scheme 2.6).116 The more stable trans-intermediate 300 can then decompose via a 
transient four-centred oxaphosphonate 301 to allow the thermodynamic product 302 to be 
generated.  
  
Scheme 2.6 Horner-Wadsworth-Emmons mechanism 
With the optimised route to synthesise novel enone-containing α-amino acids in place, the scope 
of the HWE reaction was explored. A variety of aldehydes were employed to generate a diverse 
library of analogues (Figure 2.2). 
A wide range of side-chains could be incorporated to give a selection of enone-containing α-
amino acids. α,β-Unsaturated ketones with para-substituted aryl halide motifs 303-305 were 
synthesised in good to excellent yield. An enone with an ortho-substituted aryl bromide side-
chain 306 was also produced in good yield. The electron-withdrawing effect of the halide enabled 
P a g e  | 65 
 
a rapid reaction rate and high yield. These substrates were of interest as they have the potential 
to be further modified via cross-coupling reactions. 
Alternative substitution patterns around the aromatic ring were also possible. Meta-substituted 
vinylic analogue 307 was synthesised in moderate yield. Elaboration using a Heck cross-coupling 
reaction could be envisaged to further functionalise the unsaturated α-amino acid. A surprisingly 
moderate yield was obtained for meta-nitrophenyl derivative 308. A fast rate of reaction had 
been anticipated due to the electron-withdrawing capability of the nitro group, however this was 
not observed. It should be noted that the reaction was not optimised and therefore, 
recrystallisation of the aldehyde would possibly give an improved yield. 
Electron rich aldehydes were suitable for the HWE reaction to give para-methoxyphenyl 309 and 
3,4-dimethoxyphenyl 310 analogues. Despite the low yield when veratraldehyde was employed, 
there doesn’t appear to be a correlation with the decrease in reactivity with electron rich 
aldehydes, as a moderate 66% yield was obtained for the 4-methoxyphenyl derivative. Instead, 
the quality and stability of the aldehyde employed appears to be the determining factor for the 
yield.  
The HWE reaction is not limited to aromatic aldehydes, as several non-conjugated alkyl variants 
have been synthesised including methyl 311, iso-butyl 312, tert-butyl 313 and phenethyl 314 
derivatives. The tert-butyl analogue 313 demonstrated the limitation of the reaction, as the 
sterically demanding pivalaldehyde required a significantly higher reaction temperature (82 °C) 
and longer reaction time. However, even under the harsh conditions, a poor yield of 11% was the 
maximum obtained. 
Heteroaromatic groups can be attached to the enone-containing α-amino acids. For example 
furan 315, 5-bromofuran 316, thiophene 317 and pyridine 318 moieties were incorporated in 
moderate to good yield. Addition of privileged structures such as heteroaryl groups is significant 
as these motifs commonly feature in pharmaceutical products because of recognition within the 
human body. Inclusion of these side-chains may therefore increase the potential to use the 
enone-containing α-amino acids as therapeutic agents. 
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Synthesis of highly conjugated structures was also possible using this approach to produce 
naphthalene 319 and diene 320 derivatives. The extensive conjugation of these analogues may 
give rise to luminescent properties and therefore they may be useful as biological probes. 
 
Figure 2.2 Enone-functionalised α-amino acid analogues 
Overall, nineteen examples of novel enone-functionalised α-amino acids were produced. The 
small library illustrates that both electron rich and deficient aldehydes are applicable for the HWE 
reaction, as well as, aromatic and non-aromatic substrates. The four step synthetic route 
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developed allows rapid access to a range of enones using robust chemistry to give reliably high 
yields and complete E-selectivity.  
2.4.2 Z-Configured Enone-Functionalised α-Amino Acids 
Following the success of the HWE route to produce E-alkenes, it was desirable to gain access to 
the corresponding Z-configured enone-derived α-amino acids. We anticipated that a minor 
modification to the existing route would enable Z-enones to be prepared, whilst retaining the 
benefits of the original synthetic scheme. Application of the Still-Gennari modification of the HWE 
reaction was explored to permit a connective double bond forming approach to be used. This 
would enable diverse analogues to be synthesised from a common intermediate. 
Enantiomerically pure L-aspartic acid 266 was converted to the dimethyl ester and the amine was 
subsequently protected with a trityl group as previously described. N-Trityl protected 
intermediate 292 was then converted to bis(2,2,2-trifluoroethyl) phosphonate ester 321 using 
commercially available bis(2,2,2-trifluoroethyl) methylphosphonate in 81% yield (Scheme 2.7).117 
Synthesis of phosphonate ester 321 required a lower reaction temperature  of −100 °C in 
comparison with the −78 °C reaction temperature required to produce phosphonate ester 293. 
The anion of bis(2,2,2-trifluoroethyl) methylphosphonate is destabilised due to the inductive 
effect of the two trifluoroethyl groups and therefore is short-lived. A lower temperature 
lengthened the lifespan of the anion and therefore enabled the reaction to occur. Previous 
syntheses of bis(2,2,2-trifluoroethyl) phosphonate esters117 generally employ acid chlorides as the 
coupling partner, however we have demonstrated that less reactive methyl esters can be 
successfully employed to gain access in high yields. The dual-purpose, bulky trityl protecting group 
proved equally as efficient to shield the hindered ester from attack of the bis(2,2,2-trifluoroethyl) 
methylphosphonate anion to give a clean, high yielding reaction. 
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Scheme 2.7 Synthesis of bis(2,2,2-trifluoroethyl) phosphonate ester 321 
The Still-Gennari olefination with bis(2,2,2-trifluoroethyl) phosphonate ester 321 and 
benzaldehyde was then investigated (Scheme 2.8). Strongly dissociating conditions to favour rapid 
elimination are required for the Still-Gennari modification to limit equilibration of intermediates 
and therefore facilitate Z-alkene formation.118 The two trifluoroethyl groups disfavour resonance 
stabilisation of the carbanion and therefore the initial addition reaction is irreverisible and rapid 
elimination occurs to give the Z-alkene. Low temperatures were employed to ensure the reaction 
was under kinetic control. However, a rapid rate of reaction was still possible at reduced 
temperatures because the bis(2,2,2-trifluoroethyl) phosphonate ester anion is a very powerful 
nucleophile.  
 
Scheme 2.8 Still-Gennari reaction 
Initial exploration using sodium hydride, with and without 15-crown-5, proved unsuccessful (Table 
2.1).117 Using potassium hexamethyldisilazide (KHMDS) and 18-crown-6 at −78 °C gave a good 
yield of 76% with 10:3 Z/E-selectivity.118 When potassium carbonate and 18-crown-6 were 
utilised, Z-enone 322 was produced in an excellent 91% yield with 8:1 Z/E-selectivity.118 Changing 
the base and solvent employed led to a more selective reaction and an increase in temperature 
accounts for the improved yield.  
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Entry Base Ionophore Solvent Temperature E/Z ratioa Yield (%)b 
1 NaH none THF 0 °C - - 
2 NaH 15-crown-5 THF 0 °C - - 
3 KHMDS 18-crown-6 THF −78 °C 3:10 76 
4 K2CO3 18-crown-6 toluene −20 °C 1:8 91 
aDetermined by 1H NMR spectroscopy bOverall isolated yield of both E- and Z-isomers 
Table 2.1 Still-Gennari reaction conditions 
The Z-geometric isomer was confirmed by 1H NMR spectroscopy with a vicinal alkene coupling 
constant of 12.8 Hz detected. According to Karplus, the coupling constant of cis-configured 
alkenes can range from approximately 6–12 Hz.119 The observed coupling constant resides at the 
top end of this scale and therefore we concluded that the desired Z-enone had been formed. 
With conditions in place for reliable Z-selective alkene formation, a small library of Z-configured 
enone-containing α-amino acids were synthesised. Analogous to the E-enones, it was possible to 
produce a diverse selection of Z-enones (Figure 2.3). 
In addition to phenyl derivative 322, both electron-deficient para-bromophenyl 323 and electron-
rich para-methoxyphenyl 324 analogues could be generated in 78% and 70% yield, respectively. 
Non-conjugated aliphatic examples were also feasible, however lower selectivities were observed. 
This is possibly due to the reduced electrophilicity of the alkyl aldehydes, which retards the rate of 
condensation and therefore elimination. 
 
Figure 2.3 Z-configured enone-containing α-amino acids aRepresents the overall isolated yield of 
both E- and Z-enone bRepresents the isolated yield of Z-enone 
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For the Z-configured enone-containing α-amino acids, a small selection of five examples were 
generated in moderate to good yield. The E/Z-isomers could be separated readily by column 
chromatography on silica to give pure samples of the Z-configured enones. The Still-Gennari 
method proved fairly reliable for the formation of Z-alkenes with high levels of geometric 
selectivity for the aromatic analogues, although to a lesser extent with non-conjugated 
derivatives. A minor modification to the original route allowed the novel amino acids to be 
produced in only four synthetic steps, all of which gave excellent yields. The efficient route to 
generate bis(2,2,2-trifluoroethyl) phosphonate ester 321 enabled a divergent synthesis from a 
common intermediate.  
2.5 Further Elaboration of Novel Enone-Functionalised α-Amino 
Acids 
The possibility to further functionalise the halide-containing HWE products was alluded to 
previously, and therefore elaboration via a Suzuki-Miyaura cross-coupling was investigated to 
produce a biaryl system. The presence of a biaryl side-chain is a desirable feature for certain 
therapeutic small molecules, as favourable interactions can occur within a hydrophobic pocket of 
a biological receptor. 
Initially, the trityl-protected para-bromophenyl analogue 305 was employed as the model 
substrate for the aryl halide coupling partner. The α-amino acid was subjected to standard Suzuki-
Miyaura cross-coupling conditions using phenylboronic acid as the corresponding coupling 
partner, tetrakis(triphenylphosphine)palladium to catalyse the reaction and potassium phosphate 
tribasic as the base.120 A base is required to activate the boronic acid as a quaternised boronate 
complex to facilitate the transmetallation step of the catalytic cycle.121 First attempts under 
thermal conditions in DMF at 80 °C after 24 hours did not afford any product. Changing to a co-
solvent system of toluene and methanol gave an isolated yield of 14% of the biaryl product 328 
(Scheme 2.9). Switching the bulky trityl protecting group to a Boc-protecting group did not affect 
the reaction outcome and gave an equally poor yield of 18% (see Scheme 2.15 for details of the 
synthesis of 327). 
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Scheme 2.9 Suzuki-Miyaura cross-coupling with 4-bromophenyl derivatives 
One possible explanation for the poor yield may be the presence of the enone system. 
Coordination of palladium to the α,β-unsaturated moiety could cause degradation of the 
substrate and therefore result in complex reaction mixtures. Removal of palladium from the 
catalytic cycle may also attribute to the low yields of the cross-coupled product. There are limited 
examples of Suzuki-Miyaura cross-coupling reactions in the presence of enone-systems, however 
one case has proven successful utilising nickel as the catalyst.122 Attempts were made to carry out 
the cross-coupling using the nickel-catalysed reaction conditions with trityl protected 4-
bromophenyl enone 305, however no biaryl product was obtained (Scheme 2.10). 
 
Scheme 2.10 Attempted nickel-catalysed Suzuki-Miyaura cross-coupling reaction 
Direct functionalisation of the para-bromophenyl enone-containing α-amino acid analogues via a 
Suzuki-Miyaura cross-coupling reaction proved to be capricious and therefore an alternative 
approach was sought.  
The proposed methodology was to reverse the coupling order, whereby the Suzuki-Miyaura 
reaction was carried out using a bromo-substituted aryl aldehyde prior to the HWE reaction with 
β-ketophosphonate ester 293. Para-bromobenzaldehyde was coupled to 3-nitrophenylboronic 
acid 330 and 4-(benzyloxycarbonylamino)phenylboronic acid 333 to give biaryl products 331 and 
334, respectively (Scheme 2.11). 2-Bromofuraldehyde was coupled to 4-fluorophenylboronic acid 
336 to generate the hetero-biaryl system 337. Following synthesis of the three biaryl aldehydes, 
the HWE reaction using conditions previously described with β-ketophosphonate ester 293 
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enabled access to novel enone-containing α-amino acid derivatives 332, 335 and 338 in moderate 
to good yields. 
 
Scheme 2.11 Suzuki-Miyaura cross-coupling prior to HWE reaction aRepresents crude yield of 
product bRepresents isolated yield of product 
The ability to gain access to interesting biaryl derivatives has been exemplified using Suzuki-
Miyaura cross-coupling of a boronic acid to a halo-substituted aryl aldehyde, followed by HWE 
reaction with the β-ketophosphonate ester 293.  With the methodology in place, a variety of 
novel enone-containing α-amino acids with biaryl side-chains could be readily synthesised. 
2.6 Deprotection to Parent α-Amino Acids 
A crucial component of the research programme was to deprotect the novel enone-functionalised 
amino acids to generate the parent amino acid structures. In general, an unprotected amino acid 
motif would be required to employ the enone substrates for potential biological purposes as this 
would enable recognition. Although, there are a few examples of protected enone-containing α-
amino acids in the literature, the amino acid motif has not previously been liberated. 
Consequently, an efficient approach was sought to fully deprotect the novel enone-derived α-
amino acids. 
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2.6.1 Deprotection of E-Configured Enones 
The initial strategy to obtain the parent α-amino acids was to firstly hydrolyse the methyl ester, 
then remove the trityl protecting group with trifluoroacetic acid to give the amino acids as TFA 
salts. Generation of the TFA salt of the amine was critical because the presence of the nucleophilic 
amine and electrophilic conjugate acceptor may lead to unwanted reactions such as cyclisation or 
polymerisation. Masking the amine as a salt was anticipated to circumvent side reactions at this 
stage. Phenyl derivative 294 was employed as the model substrate to explore the deprotection 
(Scheme 2.12). 
 
Scheme 2.12 Proposed deprotection of enone-containing α-amino acid 294 
Initial investigations to cleave the ester employed conventional, basic hydrolytic conditions. 
Sodium and lithium hydroxide were used at both room and elevated temperatures, however 
these conditions gave rise to complex reaction mixtures and no carboxylic acid product could be 
identified or isolated (Table 2.2). The strongly basic conditions degraded the enone-substrates. 
Whereas, using milder cesium carbonate conditions only returned starting material, presumably 
due to the bulky trityl protecting group which is known to hinder α-ester hydrolysis.123 
Entry Base Conditions Outcome 
1 NaOH 65 °C, 24 h complex mixture 
2 LiOH r.t., 48 h complex mixture 
3 Cs2CO3 60 °C, 48 h complex mixture 
4 Cs2CO3 r.t., 48 h S.M. 
Table 2.2 Basic conditions for attempted hydrolytic ester cleavage 
Failure to obtain the carboxylic acid under basic conditions promoted investigation using acid to 
cleave the protecting groups. An attempt to simultaneously hydrolyse the ester and remove the 
trityl protecting group was explored using hydrochloric acid under reflux (Scheme 2.13).  The 
hydrochloride salt of the parent amino acid could be obtained, however isolation of the product 
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proved challenging and a maximum yield of 32% was obtained. The extremely polar nature of the 
amino acid salt made purification difficult, resulting in a low isolated yield. Harsh reaction 
conditions may cause decomposition or promote unwanted side-reactions which would also lead 
to a diminished yield.  
 
Scheme 2.13 Acid-promoted deprotection to yield parent α-amino acid 340 
An alternative approach was investigated where the order of deprotection was reversed (Scheme 
2.14). The bulky trityl protecting group that had previously hindered ester hydrolysis was firstly 
removed using TFA to give the TFA salt of the amine in quantitative yield. A range of mild 
hydrolytic conditions were then explored to generate the carboxylic acid. 
 
Scheme 2.14 Attempted reversal of the order of deprotection 
Inorganic bases such as lithium hydroxide and cesium carbonate gave complex reaction mixtures 
when reacted with the TFA salt (Table 2.3, entries 1 and 2). Under acidic conditions, a low 28% 
yield of the hydrochloride salt 340 was isolated (entry 3). Hydrolysis of the ester with 
trimethylsilyl iodide (TMSI) was also attempted, however starting material was returned at 
ambient temperature and complex mixtures were observed at higher temperatures (entries 4 and 
5).124 The final endeavour via this approach was to explore enzymatic cleavage of the ester using 
both lipase and α-chymotrypsin125 under buffered conditions (entries 6 and 7). Both enzymes 
yielded complex reaction mixtures and no product could be identified. 
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Entry Reagents Conditions Outcome 
1 LiOH r.t., 24 h complex mixture 
2 Cs2CO3 r.t., 24 h complex mixture 
3 HCl reflux, 24 h 28% 
4 TMSI r.t., 48 h S.M. 
5 TMSI reflux, 7 h complex mixture 
6 lipase r.t., 24 h complex mixture 
7 α-chymotrypsin r.t., 24 h complex mixture 
Table 2.3 Conditions for attempted ester hydrolysis 
In order to overcome the problems previously described, a mild two-stage approach was 
investigated to generate the parent enone-functionalised α-amino acids. The previous research 
suggested that the bulky trityl protecting group was too sterically encumbered to allow 
nucleophilic hydrolysis, whereas, in the absence of amine protection, the enone substrate 
appeared to be overly sensitive to various hydrolytic conditions. 
The successful approach adopted was firstly to remove the bulky trityl protecting group of phenyl 
derivative 294 with TFA to give the TFA salt in quantitative yield (Scheme 2.15). Subsequent 
protection of the amine with a less-sterically demanding Boc-protecting group enabled access to a 
stable, orthogonally protected intermediate 342 in good yield. The Boc-protected intermediate 
could then be readily hydrolysed under mild basic conditions, employing cesium carbonate to 
quantitatively synthesise the carboxylic acid. Finally, removal of the Boc-group with TFA produced 
the target parent α-amino acid 339 in high isolated yield and high purity. 
Development of the general two-stage deprotection strategy, where the amine protecting groups 
are exchanged, allowed access to a selection of unsaturated parent α-amino acid derivatives. The 
4-bromophenyl 305 and phenethyl 314 analogues were subjected to the conditions as previously 
described to give the orthogonally protected Boc-intermediates 327 and 343 in excellent yields. 
Hydrolysis under basic conditions, followed by TFA-facilitated removal of the Boc-group 
generated the parent α-amino acids 344 and 345 in excellent yields.  
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Scheme 2.15 Two-stage deprotection of enone-functionalised α-amino acids 
2.6.2 Deprotection of Z-Configured Enones 
The deprotection of Z-configured enone-containing α-amino acids was also desirable for 
subsequent modifications to the structures. It was anticipated that deprotection of Z-enones 
would occur in the same manner as the E-enones. Initial exploration sought to employ the two-
stage synthetic strategy as previously described. 
Phenyl derivative 322 and 4-bromophenyl derivative 323 were utilised as model substrates for 
initial removal of the trityl protecting group using TFA (Scheme 2.16, Table 2.4). However, in the 
presence of the strong acid, the deprotected compound isomerised to give a 1:1 ratio of E/Z 
isomers. It is feasible that protonation of the enone carbonyl induces enol formation and 
therefore allows free rotation around the double bond which results in the geometric scrambling. 
The reaction was also attempted on para-bromophenyl derivative 323 with mild citric acid, 
however a crude mixture of unknown products was attained. Stoichiometric quantities of Lewis 
acids; magnesium and zinc bromide were employed with a view to circumvent isomerisation.126,127 
Unfortunately, a mixture of 1:1 E/Z-isomers of deprotected product was produced as before. 
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Scheme 2.16 Trityl deprotection of Z-enones 322 and 323  
Entry R Reagents Conditions E/Z Ratio Yield (%) 
1 H TFA, CH2Cl2 r.t., 2 h 1:1 78 
2 Br citric acid, MeCN/H2O r.t., 24 h - - 
3 Br MgBr2, CH2Cl2 r.t., 3 h 1:1 quant. 
4 Br ZnBr2, CH2Cl2 r.t., 3 h 1:1 quant. 
Table 2.4 Deprotection conditions for Z-enones 322 and 323 
Preliminary investigations for trityl removal with the Z-enones proved unsuccessful. General 
methods utilise either acidic or Lewis acid conditions, under which enol formation is promoted. To 
overcome this problem, further investigation would be required into an alternative protecting 
group that could be removed under milder or non-acidic conditions.  One possible protecting 
group that could be employed is the relatively stable triphenylsilyl group. This should offer 
comparable selectivity as the trityl group for the synthesis of the phosphonate esters and be 
stable under basic conditions, whilst enabling removal with a fluoride source. 
For the first time, E-configured enone-containing α-amino acids have been formed as the parent 
amino acid structures 339, 344 and 345. The ability to deprotect the novel α-amino acids under 
mild reaction conditions to yield an orthogonally protected intermediate increases the number of 
potential applications of this methodology. For example, Boc-protected carboxylic acid 
intermediates could be employed for the synthesis of short peptides. Obtaining the desired amino 
acid products in high yields and high chemical purity is synthetically beneficial, however high 
optical purity is also required if the compounds are to be employed for biological purposes. 
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2.7 Stereochemical Evaluation 
An important aspect of the synthetic route devised to gain access to the novel enones requires 
that the conditions employed do not cause epimerisation of the α-stereogenic centre. High 
enantiomeric excess is necessary to use the novel enones within biological systems.  
Determination of the enantiopurity of the enone-containing α-amino acids was carried out by 
analytical chiral high performance liquid chromatography (HPLC). Boc-protected phenyl derivative 
342 was selected as the substrate for HPLC analysis. The L-aspartic acid starting material 
employed in the asymmetric synthesis was purchased from Sigma-Aldrich and specifies an 
enantiomeric excess of greater than 96%. The corresponding racemic Boc-protected phenyl 
derivative 348 was synthesised from D/L-aspartic acid in order to identify the two enantiomers for 
comparison with the enantiomerically pure form.  
Both racemic and enantiomerically pure analogues were analysed by chiral HPLC using an OD-H 
column with hexane/iso-propanol (90:10) as the solvent system at a flow rate of 1 mL min-1. Chiral 
HPLC of the racemic substrate shows a clear separation of enantiomers (Figure 2.4a). Under the 
given conditions, the D-enantiomer has a retention time of 18.3 minutes and the L-enantiomer 
peaks at 21.6 minutes. When compared to the chiral material, the L-enantiomer is evident at 21.4 
minutes (Figure 2.4b), however the D-enantiomer is not observed and therefore, the enantiomeric 
excess is calculated at greater than 99%. 
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Figure 2.4 a. Chiral HPLC of racemic Boc-protected phenyl derivative 348 b. Chiral HPLC of 
enantiopure Boc-protected phenyl derivative 342 
Confirmation that the stereochemical integrity of the α-centre has been retained throughout the 
synthetic route has been proven using chiral HPLC. Successful optimisation of the synthetic 
strategy and stereochemical evaluation of the approach to generate chiral enone-containing α-
amino acids has been carried out and therefore the utility of the synthetic methodology was then 
explored with a potential application. 
2.8 Application of Enone-Functionalised α-Amino Acids 
With an established route for the fast and efficient synthesis of novel enone-containing α-amino 
acids in place, an application was sought to highlight the potential use of these interesting 
structures. During the research, it was apparent that certain analogues of the enones emitted 
light in the visible region of the electromagnetic spectrum. We hypothesised that a highly 
conjugated enone-containing α-amino acid derivative may possess photoluminescent properties 
and therefore, could be employed as a fluorescent biological probe. 
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2.8.1 Fluorescent Labelling  
Imaging living cells is an important, yet challenging area of cellular biology. The ability to visualise 
intracellular components such as nucleic acids, peptides and metabolites is crucial to further our 
understanding of the nature and dynamics of cellular events.128 Labelling is one of the most 
common bioanalytical techniques to evaluate biological processes, in particular using radioactive 
and fluorescent approaches.  
The use of fluorescent tags has increased in recent years due to the technical improvements in 
fluorescent instrumentation and the synthesis of novel fluorophores.129 Fluorescent markers can 
be produced by using semi-conductor nanocrystals,130 green fluorescent protein131 or organic 
molecules.129 Historically, using the former two methods has been challenging and therefore, 
using fluorescent organic compounds can be more straight-forward. 
2.8.2 Synthesis of a Novel α-Amino Acid Fluorophore 
 
Synthesis of a potential α-amino acid fluorophore was carried out using the previously developed 
route. This entailed a HWE reaction with β-ketophosphonate 293 and commercially available 4-
N,N-dimethylamino-1-naphthaldehyde to generate enone 349 in 72% yield (Scheme 2.17). The 
novel highly conjugated analogue was subsequently deprotected using the mild two-stage 
deprotection procedure to give parent α-amino acid 351 as the TFA salt. 
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Scheme 2.17 Synthesis of novel α-amino acid fluorophore 351 
The highly conjugated N,N-dimethylaminonaphthyl side-chain was selected because it is 
analogous to the commonly employed dansyl fluorescent tag. Incorporation of the substituted 
naphthyl group adjacent to the enone generated an extensively conjugated system of overlapping 
p-orbitals. Highly conjugated molecules have a smaller energy gap between the HOMO and LUMO 
than their non-conjugated counterpart and therefore can absorb longer wavelengths of light. 
Depending on the maximum absorbance, relaxation to the electronic ground state can occur with 
emission of photons of lower energy leading to photoluminescence. It is therefore possible that 
highly conjugated enone-containing α-amino acids may function as fluorophores. 
To test the hypothesis, the fluorescent output of the compound was measured in a variety of 
common solvents using a fluorescent spectrometer. Initially, the ultra-violet (UV) absorption of α-
amino acid 351 was determined. The compound was then irradiated at the absorption 
wavelength and the fluorescent emission was measured qualitatively. Strong fluorescent emission 
was detected in organic solvents such as dimethyl sulfoxide (DMSO), methanol, ethyl acetate and 
toluene, however, lower fluorescence was observed in aqueous solution (Figure 2.5). A shift in 
emission maxima was observed depending on the polarity of the solvent. The wavelength of 
fluorescent emission ranged from 506 nm to 552 nm depending on the solvent employed (Table 
2.5). 
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Figure 2.5 Fluorescent emission spectra for N,N-dimethylaminonaphthyl analogue 351 
Entry Solvent Concentration (mol L−1) λabs (nm) λEm. (nm) 
1 DMSO 9 × 10−6 390 525 
2 Methanol 9 × 10−6 390 540 
3 EtOAc 9 × 10−6 390 509 
4 Toluene 9 × 10−6 390 506 
5 Water 9 × 10−6 390 552 
Table 2.5 Absorption and emission measurements of novel α-amino acid fluorophore 351 
The excitation and emission properties of this unnatural analogue differ significantly from 
fluorescent proteinogenic amino acids. Naturally occurring fluorescent amino acid residues; 
tryptophan and tyrosine, absorb UV light at 278 and 274 nm and fluoresce at 352 and 303 nm 
respectively, in ethanol.132 If the novel α-amino acid analogue were to be incorporated into a 
peptide as a fluorescent biomarker, detection of fluorescence could be distinguished from native 
amino acids because of the significant difference in spectroscopic properties.  
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2.9 Summary 
A rapid and efficient synthetic route has been devised to synthesise novel enone-containing α-
amino acids from a common, advanced intermediate. Using the methodology, a library of E-
configured enones was produced to demonstrate the versatility of the HWE reaction. A smaller 
selection of Z-enones showed the possibility to synthesise efficiently Z-enones containing an 
aromatic side-chain using the Still-Gennari reaction. The non-aromatic Z-analogues exhibited 
comparable yields, but inferior Z-selectivity. 
Initial attempts to modify para-halide substituted enone-containing α-amino acids directly via 
cross-coupling reactions were unsuccessful. However, an alternative approach was adopted that 
allowed access to biaryl structures. 
For the first time, enone-functionalised amino acids were deprotected to give the parent α-amino 
acids. This was an important element of the research as future applications of the compounds 
may necessitate either orthogonal protection or the free amino acid. 
A potential application of the novel enones has also been illustrated. Development of a highly 
conjugated α-amino acid fluorophore was carried out and the excitation and fluorescent emission 
of the compound was measured in a range of common organic solvents. 
Alongside the possible modifications and uses that have been presented, there are several 
avenues yet to be explored in relation to the enone-functionalised α-amino acids. Investigations 
to use the novel compounds as synthetic scaffolds to produce alternative structures is desirable.   
P a g e  | 84 
 
3 Chiral 6-Substituted-4-Oxygenated Pipecolic Acid 
Derivatives 
3.1 Introduction 
Chiral N-heterocycles are one of the most important structural motifs in chemical, biological and 
medicinal research. Piperidine has been the focus of extensive investigations due to the wealth of 
properties and functional roles possessed by molecules containing the heterocycle. Modifications 
to the piperidine scaffold have also provoked interest with synthetic chemists. As exemplified 
previously, 4-oxygenated pipecolic acid derivatives have emerged as significant bioactive 
molecules and valuable synthetic scaffolds. 
4-Oxo- and 4-hydroxypipecolic acid have been identified in several naturally occurring secondary 
metabolites which possess potent therapeutic properties. 4-Oxygenated pipecolic acid derivatives 
are also components of many active pharmaceutical products and therefore are highly sought 
after targets in organic synthesis. In particular, chiral pipecolic acid scaffolds are required in the 
pharmaceutical industry for specificity within the body. Natural products and medicinal agents 
can display a range of substitution patterns around the saturated N-heterocyclic core depending 
on the function of the molecule. A screen of the literature reveals the 2,4,6-substitution pattern 
of pipecolic acid as significant and abundant. Substituted pipecolic acid derivatives can include a 
wide variety of functional groups and side-chains on the heterocycle suited to their purpose.  
Substantial effort has been invested in the synthesis of chiral 4-oxygenated pipecolic acid 
derivatives. Reports of general synthetic strategies, as well as specific syntheses towards the 
heterocyclic core continue to advance the field. A successful synthesis is fast, efficient and 
stereocontrolled. The ability to incorporate diversity at a late stage in the route is also desirable. 
Many different strategies exist for construction of the N-heterocyclic product, however an 
approach that satisfies all the specifications remains a challenge. Despite the numerous synthetic 
strategies developed to date, a great deal of interest in these molecules remains and therefore 
the challenge to provide an efficient and varied route to these important compounds is still active.  
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3.2 Synthesis of 4-Oxopipecolic Acid Derivatives via an 
Intramolecular Conjugate Addition 
The functional significance of enantiopure 4-oxopipecolic acids makes them attractive synthetic 
targets. At present, there are many methods to obtain 4-oxopipecolic acid, however most 
strategies suffer from disadvantages. An efficient synthetic strategy would be highly beneficial 
and therefore the second objective of the research programme was to devise a rapid and 
sterocontrolled approach to obtain these important molecular scaffolds. 
 Following the development of an efficient methodology to synthesise novel enone-containing α-
amino acids, the aim was to convert the linear α-amino acids into the corresponding cycloadduct 
possessing the desired pipecolic acid motif. The strategy proposed was to take advantage of the 
electrophilic nature of α,β-unsaturated ketone 352 and initiate an intramolecular conjugate 
addition reaction using the α-amine as the internal nucleophile (Scheme 3.1). A diastereoselective 
cyclisation will generate highly functionalised 6-substituted-4-oxopipecolic acid analogues 354. 
The cyclisation reaction is formally classified as a 6-endo-trig cyclisation and is favoured according 
to Baldwin’s guidelines.133 The prospective route allows variation to the pipecolic acid template 
because the R1 substituent can include a range of alkyl or aryl groups.  
 
Scheme 3.1 Proposed intramolecular conjugate addition reaction to form 4-oxopipecolic acid 
derivatives 
A small selection of novel enone-containing α-amino acids were utilised during the research in an 
attempt to attain the desired 4-oxopipecolic acids. Various reaction conditions were explored to 
promote the diastereoselective intramolecular conjugate addition. 
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3.2.1 Model Substrate 1 – Phenyl Derivative 
Novel E-configured enone-containing α-amino acid with a phenyl side-chain was used for the 
preliminary investigation into a diastereoselective 6-endo-trig cyclisation to yield the 4-
oxopipecolic acid motif (Scheme 3.2). The initial research employed the model substrate in the N-
trityl protected form 294, as well as the free base 355. A variety of acids, Lewis acids and bases 
were investigated to facilitate the conjugate addition.  
 
Scheme 3.2 6-Endo-trig cyclisation using phenyl derivatives 294 and 355 
Literature precedent existed for simultaneous protecting group cleavage and cyclisation of a 
terminal enone-functionalised α-amino acid under acidic conditions.108,134 Using the previously 
reported conditions, trityl protected enone 294 was exposed to anhydrous ethereal hydrochloric 
acid (Table 3.1, entry 1), which resulted in removal of the protecting group, however the cyclised 
product was not observed. The HCl salt of the linear α-amino acid was produced and therefore 
there is no nucleophilic reacting centre to carry out the intramolecular cyclisation.  
Basic conditions were then explored to deprotonate the amine, which would increase 
nucleophilicity and therefore induce the intramolecular cyclisation. Although it was anticipated 
that a bulky protecting group would hinder the cyclisation reaction, trityl protected enone 294 
was treated with sodium hydride in an attempt to promote cyclisation (entry 2). A complex 
mixture resulted and no product was identified. The reaction was then attempted in the absence 
of the protecting group. The 6-endo-trig cyclisation was investigated using free amine 355 with 
strong bases (entries 3–5). Highly polar, complex mixtures resulted and no traces of the 
cycloadduct were observed by 1H NMR spectroscopy. It is possible that following deprotonation, 
polymerisation may occur resulting in the complex spectra. Formation of diketopiperazines is also 
feasible from the α-amino acids and may account for the complicated reaction composition. Weak 
base also did not instigate the reaction (entry 6).  
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An alternative approach was explored using a Lewis acid to activate the enone by increasing the 
electrophilicity of the system and therefore facilitate 1,4-conjugate addition. Oxophilic Lewis 
acids; boron trifluoride and cerium(III) chloride135 were employed (entries 7–9), however at room 
temperature and under reflux, complex mixtures were obtained and no product was identified.  
Entry R Reagent Solvent Conditions Outcome 
1 Tr HCl.Et2O - r.t., 48 h Tr removed 
2 Tr NaH THF r.t., 72 h complex mixture 
3 H nBuLi THF −78 °C → r.t., 24 h complex mixture 
4 H LiHMDS THF reflux, 24 h complex mixture 
5 H DBU MeOH r.t., 24 h complex mixture 
6 H Na2CO3 CH2Cl2 r.t., 48 h S.M. 
7 H BF3.Et2O CH2Cl2 r.t., 24 h complex mixture 
8 H BF3.Et2O toluene reflux, 24 h complex mixture 
9 H CeCl3.7H2O MeCN r.t., 48 h complex mixture 
Table 3.1 Conditions for the attempted intramolecular cyclisation 
The initial research proved unsuccessful as the trityl protected enone generated no product when 
exposed to acidic or basic conditions. Similarly, 4-oxopipecolic acid was not formed in the absence 
of the protecting group. When the free amine of the enone-containing α-amino acid was 
employed, complex, highly polar mixtures resulted. This made isolation and identification of side-
products difficult and therefore the postulated problems associated with the reaction were 
unconfirmed. To gain an insight into the reaction pathway, it was proposed that the nitrogen 
should be protected to decrease the polarity of the resultant mixtures. It was also suggested that 
the close proximity of the aromatic ring may hinder the intramolecular nucleophilic addition and 
therefore the enone-containing α-amino acid with a phenethyl side-chain 343 was used as the 
model substrate. 
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3.2.2 Model Substrate 2 – Phenethyl derivative 
Boc-protected enone-functionalised α-amino acid 343 was investigated for the diastereoselective 
conjugate addition reaction (Scheme 3.3). It was anticipated that the phenethyl derivative, with 
the aromatic ring further from the reacting centre, would enable a facile reaction. A Boc group 
was selected to protect the nitrogen and decrease the polarity of the compound to enable the 
reaction progress to be monitored. An array of bases and Lewis acids were explored to initiate the 
cyclisation. 
 
Scheme 3.3 Intramolecular cyclisation of Boc-protected phenethyl derivative 343 
Basic reaction conditions were investigated with Boc-protected enone 343 (Table 3.2, entries 1–
5). Precedent existed for an exocyclic aza-Michael ring closure of a linear N-Boc protected α,β-
unsaturated ketone using sodium hydride.136 Using the reported conditions at room temperature 
returned starting material, however increasing the temperature gave complex mixtures of 
compounds. An alternative strong base, lithium bis(trimethylsilyl)amide, was used, however a 
complex mixture resulted. The reaction was also explored using a weak base, potassium 
carbonate, heated under reflux and heated under microwave irradiation, however no product was 
formed.  
There is literature precedent for intermolecular 1,4-addition of carbamates to simple α,β-
unsaturated ketones using Lewis acids.137,138 Carbamates are weakly nucleophilic and only certain 
Lewis acids have proven suitable for the conjugate addition. Bismuth nitrate and gold(I) chloride 
have been employed for conjugate addition of carbamates to simple enone systems, however  did 
not promote the intramolecular reaction with the Boc-protected enone-functionalised α-amino 
acid 343 (entries 6 and 7).  
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Entry Reagent Solvent Conditions Outcome 
1 NaH THF r.t., 24 h S.M. 
2 NaH THF reflux, 3 h complex mixture 
3 LiHMDS THF reflux, 1 h complex mixture 
4 K2CO3 MeCN reflux, 48 h S.M. 
5 K2CO3 MeCN MW, 100 °C, 30 min S.M. 
6 Bi(NO3)3 CH2Cl2 r.t., 72 h S.M. 
7 AuCl THF 60 °C, 48 h S.M. 
Table 3.2 Attempted intramolecular conjugate addition reaction conditions 
Aside from the reaction of enone 343 with strong bases at high temperatures, basic conditions 
and Lewis acid catalysis returned starting material and there was no evidence of cyclisation.  We 
concluded that the N-carbamate was not sufficiently nucleophilic to attack the enone system of 
the unnatural amino acid. The lone pair of the carbamate is delocalised, which makes it weakly 
basic. It was evident that an alternative strategy was required to tune the amine nucleophilicity to 
make it suitable for a controlled conjugate addition. The proposed approach involved 
incorporation of a protecting group that would increase the nucleophilicity of the nitrogen to 
allow the 6-endo-trig reaction to take place, yet enable the reaction mixtures to be easily handled.  
3.3 One-Pot Reductive Amination/Intramolecular Cyclisation for 
the Synthesis of 4-Oxopipecolic Acid Derivatives 
An alternative strategy was devised to incorporate a protecting group that would increase the 
nucleophilicity of the amine of the amino acid and therefore facilitate the intramolecular 
conjugate addition. An N-benzyl protecting group was selected due to the inductive electron 
donating capability of the benzyl group towards the nitrogen. This increases the electron density 
on the nitrogen and increases the energy of the lone pair, which makes the nitrogen more basic. 
Selective mono-alkylation of the nitrogen atom was required to enable the conjugate addition to 
occur. A reductive amination reaction was proposed to avoid common issues with over alkylation 
of nitrogen using standard alkyl halides. 
Phenethyl derivative 359 was used as the test substrate for the investigation. The strategy devised 
was to generate an imine using the TFA salt of enone 359 followed by reduction to yield the 
desired N-benzyl protecting group (Scheme 3.4). Benzaldehyde was reacted with enone 359 in the 
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presence of 4Å molecular sieves to remove the resultant water and drive the equilibrium in favour 
of formation of imine 360. It was anticipated that reduction of imine 360 would give linear benzyl 
protected α-amino acid 361 and subsequent cyclisation would yield the desired cycloadduct 362. 
The caveat with this route is that a chemoselective reduction of the imine is required in the 
presence of the enone moiety. Exploration of mild reductive conditions to allow a selective 
reaction was carried out. 
 
Scheme 3.4 Reductive amination/6-endo-trig cyclisation strategy for the synthesis of 4-
oxopipecolic acid derivatives 
Following imine formation, reductive conditions were explored in an attempt to obtain a 
chemoselective process (Table 3.3). Preliminary investigations employed the mild reducing agent, 
triethylsilane, in the presence of acid or a Lewis acid to increase the electrophilicity of imine 360 
and allow reduction to take place (entries 1 and 2). These reductive conditions returned the 
starting imine with no trace of product. Reduction of the imine using trichlorosilane139 and DMF as 
a Lewis base gave rise to interesting results (entry 3).  Following aqueous work-up, the linear N-
benzyl-N-silyl-protected α-amino acid was observed by 1H NMR spectroscopy. Subsequent column 
chromatography on silica resulted in the desired 4-oxopipecolic acid 362 in 25% yield with a 2:1 
ratio of diastereomers. The anti-diastereomer is obtained as the major product (vide infra). 
Reduction using trichlorosilane occurs with simultaneous formation of a trichlorosilane–nitrogen 
bond. Cleavage of the N–Si bond with the slightly acidic silica gel initiated the intramolecular 6-
endo-trig cyclisation. As the yield of 4-oxopipecolic acid 362 was low, alternative reducing agents 
were explored in an attempt to optimise the reaction.  
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Conventional reductive amination conditions using borohydride reducing agents were then 
investigated (entries 4–7). After 48 hours at room temperature, reduction of imine 360 with 
sodium triacetoxyborohydride led directly to formation of cyclic pipecolic acid 362 in 45% yield. 
There was no evidence of the linear N-benzyl-protected α-amino acid 361. Changing the reducing 
agent to sodium cyanoborohydride resulted in a dramatic increase in the reaction rate. The yield 
of product also increased to 53%, however the same diastereoselectivity was achieved with both 
hydride reducing agents at room temperature (entries 4 and 5). In an attempt to improve the 
stereoselectivity, the reaction was carried out at lower temperatures with sodium 
cyanoborohydride, however the diastereomeric ratio remained the same but reaction rate 
decreased and the yields declined (entries 6 and 7).  
 
Scheme 3.5 Reductive amination/cyclisation strategy to generate 4-oxopipecolic acid derivatives 
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Entry Reductant Conditions Temp. (°C) Time (h) Yield (%)a d.r. (anti:syn)b 
1 Et3SiH TFA, CH2Cl2 r.t. 24 S.M. - 
2 Et3SiH Zn, CH2Cl2 r.t. 24 S.M. - 
3 Cl3SiH DMF, CH2Cl2 0 24 25 2:1 
4 NaB(OAc)3H THF r.t. 48 45 2:1 
5 NaBH3CN MeOH r.t. 1 53 2:1 
6 NaBH3CN MeOH 0 15 47 2:1 
7 NaBH3CN MeOH −20 24 30 2:1 
aRepresents overall isolated yield for both diastereomers. bDetermined by 1H NMR spectroscopy. 
Table 3.3 Reductive amination conditions 
The reductive amination/cyclisation sequence has three reactions occurring in a one-pot process 
and therefore a yield of 53% is acceptable, yet several factors limit the reaction yield. Imine 
formation is not quantitative, however the major problem is the issue of chemoselectivity. A 
search of the literature did not uncover a reducing agent that would selectively reduce the imine 
without a degree of 1,4-reduction of the enone system. The sodium cyanoborohydride conditions 
were therefore deemed optimal for this approach. 
The one-pot reductive amination/cyclisation strategy developed allows rapid access to the highly 
desirable 6-substituted-4-oxopipecolic acids. Despite the moderate diastereoselective 
discrimination with the phenethyl analogue, the reaction was attempted with a variety of enone-
containing α-amino acids to probe the scope of the reaction. A small library of functionalised 4-
oxopipecolic acids were synthesised using this one-pot approach (Figure 3.1).  
Enone-functionalised α-amino acids with an aromatic ring directly attached to the enone moiety 
were investigated to form the corresponding pipecolic acid cycloadducts. It was postulated that 
the direct attachment of the side-chain to the reacting centre of the enone may lead to an 
improvement in diastereoselectivity. Enone-functionalised phenyl derivative was cyclised 
according to the one-pot reductive amination/cyclisation strategy to give 4-oxopipecolic acid 364 
in a modest 37% yield. Also, electron rich para-methoxyphenyl 365 and electron deficient para-
bromophenyl 366 derivatives were produced in moderate yield with improved stereoselectivity in 
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comparison to phenethyl analogue 362. The para-bromophenyl 366 analogue is interesting 
because it could be further functionalised via cross-coupling reactions to yield a diverse array of 
structures containing the pipecolic acid core. 
 Alkyl substituted enone-containing α-amino acids were subjected to the cyclisation conditions to  
generate iso-butyl 367 and methyl 368 substituted derivatives in good yields and with good 
stereoselectivity. Significantly sterically hindered examples of enone-containing α-amino acids 
could also be cyclised using this approach, as naphthyl 369 and biphenyl 370 derivatives were 
synthesised in modest yields and with reasonable stereoselectivity. 
 
Figure 3.1 Small library of 4-oxopipecolic acid derivatives aRepresents overall isolated yield for 
both diastereomers 
Analysis of the results indicates that the cyclisation does not appear to follow a definite pattern of 
reactivity. Within the small library of 4-oxopipecolic acid derivatives, the alkyl analogues 362, 367 
and 368 are produced in the highest yields. Possibly the lack of conjugation is beneficial for the 
cyclisation reaction. In relation to stereocontrol, the iso-butyl 367 and methyl 368 derivatives are 
generated with good diastereoselective discrimination, however phenethyl derivative 362 is 
formed with the lowest diastereomeric ratio. It was expected that a bulkier side-chain would give 
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rise to high stereocontrol, yet the methyl analogue exhibits one of the highest 
diastereoselectivities.  
Aromatic analogues 364-366 appear to exhibit a trend in reactivity in terms of electronics. 
Bromophenyl derivative 366 was anticipated to be the most reactive because the electron-
withdrawing effect of the halide would increase the electrophilicity of the enone system and 
therefore lead to a high yielding reaction. The electron-donating methoxy substituent was 
expected to be the least reactive in the series, with the phenyl derivative inbetween the two 
extremes. This is observed experimentally, however the difference in yield is minor. Methoxy 
derivative 365 is formed with the highest diastereomeric ratio in the series of aromatic analogues. 
The reason for this outcome is unclear at present, however, the stereoelectronic subtleties of this 
reductive amination/cyclisation reaction mechanism have yet to be investigated.  
With the sterically demanding naphthyl 369 and biphenyl 370 analogues, lower yields were 
expected as the cyclic transition state would be more strained. As a consequence of the steric 
hindrance, it was postulated that these substrates would be highly diastereoselective, however 
they were no more selective than the previously described examples.  
Comparison of the most sterically hindered analogues, 369 and 370, with the least sterically 
hindered 4-oxopipecolic acid methyl derivative 368, reveals that atypical results are obtained.  
Complex stereoelectronic factors govern the cyclisation reaction to give rise to the observed 
outcome in terms of reactivity and steric bias and therefore further investigation is required.  
To summarise, eight examples of 6-substituted-4-oxopipecolic acids were synthesised rapidly via 
the one-pot reductive amination/cyclisation strategy. The analogues were produced in moderate 
yields over the three step process and moderate diastereoselectivity. The diastereomers can be 
readily separated by column chromatography to yield diastereomerically pure samples of the 
major anti-4-oxopipecolic acid products. 
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3.3.1 Rationale for the Observed Stereochemical Outcome of the 
Intramolecular Cyclisation 
Following compilation of the results from the 4-oxopipecolic acid synthesis, we aimed to provide 
an explanation for the observed stereochemical outcome. Analysis of the table of results for the 
cyclisation of imine 360 via reduction either during the one-pot process or the multistage 
approach, always yields the anti-diastereomer as the major pipecolic acid product. Comparison 
with previously reported cases of diastereoselective cyclisations gave insights into the possible 
mechanism and therefore the rationalisation of the stereochemical outcome for the reductive 
amination/cylisation reaction. 
Several examples of diastereoselective 6-endo-trig cyclisations to produce 2,6-disubstituted 
piperidines can be found in the literature. In almost all cases, a 6-membered chair-like transition 
state is adopted. This is a highly favoured transition state conformation as it is intrinsically strain-
free. Substituents tend to occupy equatorial positions where possible because of the severe strain 
associated with 1,3-diaxial interactions.140  
Research conducted by Krishna and Sreeshailam demonstrated that a conjugate addition reaction 
can give rise to an anti-diastereomeric piperidone as the major product via a 6-membered chair-
like transition state.141 The hypothesised transition state 372 depicts the energetically favourable 
equatorial positioning of the N-benzyl group to minimise 1,2-allylic strain via eclipsing interactions 
with the endocyclic alkene (Scheme 3.6). The geometry of the enone enables the R group to 
adopt a favourable equatorial position and the stereogenic centre is positioned axial. 6-Endo-trig 
cyclisation therefore produces the anti-diastereomer of piperidone 374 as the major product with 
a 3:1 anti:syn diastereomeric ratio.  
 
Scheme 3.6 Krishna and Sreeshailam’s anti-diastereoselective 6-endo-trig cyclisation 
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Interpretation of the results for the previous example of a diastereoselective 6-endo-trig 
cyclisation enables parellels to be made with the one-pot reductive amination/cyclisation 
strategy. A similar argument as Krishna’s hypothesis is presented, as the substrate under 
investigation is N-substituted and yields the anti-diastereomer. Following imine formation, a 
postulated 6-membered chair-like conformation 376 is adopted by the molecule (Scheme 3.7). To 
avoid 1,2-allylic strain with the endocyclic alkene, the imine will adopt an energetically favourable 
equatorial position. The E-configured enone enables the R group to be equatorial and the methyl 
ester is positioned axial. Reduction of the imine initiates the cyclisation, which results in the ester 
and R group having an anti-relationship to one another in the 4-oxopipecolic acid product 377. 
 
Scheme 3.7 Possible explanation for the stereochemical outcome of the one-pot reductive 
amination/6-endo-trig cyclisation 
The reductive amination/cyclisation reaction gives rise to a diastereomeric ratio that ranges from 
2:1 to 5:1 anti:syn depending on the substrate employed. Stereochemical preference for the anti-
diastereomer is not highly biased. The reversibility of the reaction was questioned as a possible 
explanation for the moderate diastereocontrol. An experiment to determine this would require 
separation of the diastereomers and then the minor syn-product should be resubmitted to the 
reaction conditions. If the reaction is reversible, the same 2:1 d.r. should be obtained. 
To summarise, the anti-diastereomer is formed as the major 4-oxopipecolic acid product as a 
result of the one-pot reductive amination/cyclisation reaction. Stereoelectronic factors control 
the process whereby the postulated 6-membered chair-like transition state strives to adopt a low 
energy conformation to minimise repulsive steric interactions. 
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3.4 Reduction of 4-Oxo- to 4-Hydroxypipecolic Acid Derivatives 
A diastereoselective one-pot reductive amination/cyclisation stategy was developed to synthesise 
highly desirable 4-oxopipecolic acid derivatives. This approach enabled rapid access from novel 
enone-functionalised α-amino acids. The 4-hydroxy permutation of the pipecolic acid scaffold is 
also a sought after motif. The importance of 4-hydroxypipecolic acid has been made apparent by 
the numerous biological and synthetic applications of the molecule. Reduction of the 6-
substituted-4-oxopipecolic acid derivatives would enable fast and efficient access to the hydroxyl 
analogues.  
The reduction of 4-oxo- to 4-hydroxypipecolic acid was initially investigated using phenethyl 
derivative 362 (Scheme 3.8). L-Selectride® was chosen as the reducing agent because it is bulky 
and known to prefer equatorial attack on cyclic ketones and therefore will generally provide good 
stereocontrol.142 Phenethyl derivative 362 was subjected to the reducing conditions, however 
anticipated axial 4-hydroxypipecolic acid 378 was not formed. An unusual result was obtained as 
equatorial 4-hydroxypipecolic acid 379 was produced in a low 25% yield which implied axial L-
Selectride® attack had occurred. The poor yield of 4-hydroxypipecolic acid resulted from a lack of 
chemoselectivity as the methy ester was also reduced to generate a 30% yield of diol 380.  
 
Scheme 3.8 Reduction of 4-oxopipecolic acid derivative 362 with L-Selectride® 
To overcome the chemoselectivity issue, the milder reducing agent, sodium borohydride, was 
selected for the reduction to produce 4-hydroxypipecolic acids. Small reducing agents such as 
sodium borohydride commonly attack cyclic ketones with an axial trajectory to produce 
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equatorial hydroxyl products. Reduction of phenethyl derivative 362 was readily achieved using 
sodium borohydride in methanol at 0 °C to produce the corresponding 4-hydroxypipecolic acids 
(Scheme 3.9). Unfortunately, the sodium borohydride reduction did not produce a single 
diastereomer, however a good 7:1 diastereomeric ratio of (4S)- to (4R)-4-hydroxypipecolic acid 
379 and 378 was observed in a 67% combined yield. 
 
Scheme 3.9 Reduction of 4-oxopipecolic acid derivative 362 with sodium borohydride 
A small library of 4-hydroxylated pipecolic acid analogues were synthesised using the sodium 
borohydride reduction (Figure 3.2). All analogues produced equatorial 4-hydroxypipecolic acid as 
the major diastereomer, however the diastereomeric ratio varied with different derivatives. 
Quantitative yields were observed for the reduction of 4-oxopipecolic acids with aromatic rings in 
the 6-position as exemplified with phenyl 381 and para-methoxy 382 analogues. The 
diastereomeric ratio was moderate for the aromatic derivatives. Alkyl analogues 383 and 384 
were also formed in excellent yields. Moderate stereocontrol was observed with the iso-butyl 
analogue 383, however the small methyl-substituted 4-hydroxypipecolic acid 384 provided the 
lowest diastereomeric ratio. Phenethyl analogue 379 gave the highest diasteroselective bias.  
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Figure 3.2 Small library of 4-hydroxypipecolic acid analogues aRepresents overall isolated yield for 
both diastereomers 
Overall, five examples of 4-hydroxypipecolic acid derivatives were synthesised in good to 
excellent yield. (4S)-4-Hydroxypipecolic acid was produced as the major diastereomer in 
moderate to good diastereomeric ratio. The diastereomers can be readily separated using column 
chromatography to yield diastereomerically pure samples of 4-hydroxypipecolic acid. 
3.4.1 Rationale for the Observed Stereochemical Outcome of the 
Reduction 
Nucleophilic attack on cyclohexanes and cyclohexanones are important organic reactions and 
therefore extensive research has been carried out in order to elucidate the mechanism and 
postulate viable transition states. Similar theories and reasoning can be applied to nucleophilic 
attack on saturated heterocyclic compounds. Taking into account previous findings, a hypothesis 
is presented for the observed stereochemical outcome for the reduction of 4-oxopipecolic acid to 
(4S)-4-hydroxypipecolic acid.  
 As mentioned previously, (4S)-4-hydroxypipecolic acid is formed as the major product from the 
sodium borohydride reduction. There are several contributing factors that may determine the 
stereochemical outcome of the reaction.  Nucleophilic attack on a carbonyl group will occur via 
the Bürgi-Dunitz trajectory to maximise orbital overlap with the nucleophile HOMO and the 
carbonyl anti-bonding orbital and minimise repulsive interactions with the filled bonding orbital of 
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the carbonyl.143 The combination of these factors results in the direction of nucleophilic attack on 
the carbonyl at an obtuse, 109° angle.144 Obscuring the favourable Bürgi-Dunitz angle of attack by 
means of steric hindrance can reduce the rate of addition and potentially alter the stereochemical 
outcome. 
In cyclic systems, the Bürgi-Dunitz angle restricts the direction of attack of the incoming 
nucleophile. The nucleophile can approach a cyclic ketone in an axial manner, despite strain 
caused by 1,3-diaxial interactions (Figure 3.3). Alternatively, the nucleophile can approach 
equatorial, parallel to adjacent 1,3-diaxial hydrogens. Several features such as the size of 
nucleophile and ring substituents impact the direction of attack.  
 
Figure 3.3 Angle of attack on an N-heterocyclic ketone (certain hydrogen atoms have been 
omitted for clarity) 
Small reducing agents such as sodium borohydride are known to reduce piperidones with an axial 
trajectory.65,93,142,145 A combination of postulated stereoelectronic factors influence the 
borohydride attack.146 Small nucleophiles have an inherent preference for axial attack, however as 
mentioned previously, this approach encounters unfavourable 1,3-diaxial steric hindrance.  
Preferential axial attack occurs because the transition state is more stable with the small hydride 
axial and the larger hydroxyl group equatorial. The energetically favourable transition state leads 
to the more stable product. 
The results from the diastereoselective reduction of 4-oxopipecolic acid demonstrate that axial 
hydride attack occurs to give the anticipated equatorial 4-hydroxypipecolic acid as the major 
product. It is postulated that anti-4-oxopipecolic acid 385 will mainly exist with methyl ester axial 
and the larger R group equatorial (Scheme 3.10). Axial hydride attack will give rise to 
hypothesised transition state 387 to yield the equatorially hydroxylated product 391 equivalent to 
(4S)-4-hydroxypipecolic acid 395. Analysis of the results from the small library of 4-
hydroxypipecolic acids reveals that a large 6-substituent as in phenethyl 4-oxopipecolic acid 
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derivative 362 will provide high levels of stereocontrol (7:1 d.r.), presumably due to the 
preference for the large R group to reside equatorial. Medium-sized substituents as with phenyl 
364, para-methoxyphenyl 365 and iso-butyl 367 analogues allow moderate diastereocontrol. The 
small methyl derivative 368 produced the poorest diastereoselective discrimination. This can be 
rationalised as the conformation of methyl derivative 368 can presumably easily alternate 
between conformations 385 and 386 due to the similar size of C-2 and C-6 substituents. 
Consequently, axial hydride attack on conformation 386 will generate equatorial hydroxyl product 
393 via transition state 389. Coupled with axial attack on conformation 385 results in a low 2:1 
diastereomeric ratio obtained with methyl analogue 368 to give (4S)- and (4R)-4-hydroxypipecolic 
acids. 
 
Scheme 3.10 Postulated mechanism and transition states for a diastereoselective reduction of 4-
oxopipecolic acid derivatives (certain hydrogen atoms have been omitted for clarity) 
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To explain the anomaly observed with the L-Selectride® reduction of phenethyl derivative 362, 
examination of the postulated transition states was carried out. In contrast with small reducing 
agents, bulky reductants tend to prefer an equatorial line of attack on cyclic ketones. The less 
sterically hindered equatorial approach parallel to axial hydrogens avoids the disfavoured 1,3-
diaxial strain associated with axial attack. It was postulated that equatorial attack of L-Selectride® 
on conformation 385 via transition state 388 would yield axial hydroxyl product 396. Instead, 
equatorial product 395 was observed. There is literature precedent for L-Selectride® reduction of 
pipecolic acid derivatives to yield the products of axial reduction.58,147 The reasons for this 
anomaly however are not known for certain. 
Using previous examples of cyclic ketone reductions, a hypothesis is presented to rationalise the 
experimentally observed results. Further investigation and computational analysis would be 
required to confirm the postulated mechanism, which gives rise to the relative stereochemical 
outcome. 
3.4.2 Relative Stereochemistry 
The diastereoselective one-pot reductive amination/cyclisation strategy, then subsequent 
reduction of the ketone establishes three stereogenic centres on the piperidine ring system. 
Elucidation of the relative stereochemistry was required for the major diastereomeric product. To 
confirm the relative stereochemistry of the pipecolic acid derivatives, nuclear Overhauser 
experiments (nOe) were carried out to determine the spacial relationships within the 4-
hydroxypipecolic acid analogues.  
Determination of the relative 2,6-configuration of 4-oxopipecolic acid derivatives 362, 364-370 
was not possible directly using nOe spectroscopy because enhancements through quadrupolar 
nuclei such as nitrogen atoms are not easily observed. If no enhancement was detected, the anti-
configuration could not be confirmed as quadrupolar relaxation may have affected the result. An 
unambiguous result could be obtained by irradiation of the three stereogenic centres of 4-
hydroxypipecolic acid derivatives 379, 381, 383 and 384 to establish their relationship to one 
another.  
Phenethyl derivative 379 was irradiated at stereogenic centre Ha to determine the spacial 
orientation relative to Hc and He. No enhancement was observed with either of the other 
stereogenic centres which implies they have an anti-relationship to one another (Figure 3.4). This 
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was confirmed using 1H NMR spectroscopic coupling constants (vide infra). Stereocentre Hc was 
then irradiated and an enhancement was identified with He indicating that Hc and He are on the 
same side of the pipecolic acid core. No enhancement was detected for signal Ha. The relative 
stereochemistry was confirmed by irradiating He to demonstrate the syn-relationship with Hc and 
anti-relationship to Ha. 
 
 
Figure 3.4 Key nOe enhancement of phenethyl derivative 379 and percentage enhancements 
Similar nOe spectroscopic experiments were carried out on phenyl 381, iso-butyl 383 and methyl 
384 derivatives to demonstrate the Ha/He anti-relationship and Hc/He syn-relationship (Figure 3.5 
– Figure 3.7). 
 
 
Figure 3.5 Key nOe enhancement of phenyl derivative 381 and percentage enhancements 
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Figure 3.6 Key nOe enhancement of iso-butyl derivative 383 and percentage enhancements 
 
 
 
 
Figure 3.7 Key nOe enhancement of methyl derivative 384 and percentage enhancements 
The nOe spectroscopy and 1H NMR spectroscopic coupling constants clearly demonstrate the 
relative Ha/He anti-configuration and the Hc/He syn-arrangement of 4-hydroxypipecolic acid 
analogues 379, 381, 383 and 384. 
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3.5 Deprotection of 4-Hydroxypipecolic Acid 
With the relative stereochemistry of the 4-hydroxypipecolic acid derivatives established via nOe 
spectroscopy, the subsequent goal was to fully deprotect the scaffold to give the parent pipecolic 
acid motif.  Deprotection to yield the cyclic amino acid is desirable to reveal the biological 
potential of the N-heterocycle. Liberating the amino acid would also allow subsequent synthetic 
modifications to the molecule.  
6-Methyl-4-hydroxypipecolic acid derivative 384 was employed as the model substrate. The 
proposed strategy was to remove the N-benzyl protecting group prior to ester hydrolysis. 
Conditions for removal of the N-benzyl protecting group were investigated. Standard conditions 
involve heterogeneous hydrogenation over palladium on carbon at high pressures. It was 
however desirable to avoid reactions at high pressures and avoid the use of highly flammable 
hydrogen gas. Consequently, transfer hydrogenation conditions were explored, which negated 
the need for hydrogen gas or high pressures. Initial conditions employed a mixture of formic acid 
and palladium on carbon (Scheme 3.11).148 Starting material was recovered from the reaction and 
there was no evidence of product.  
 
Scheme 3.11 Formic acid transfer hydrogenation for N-benzyl deprotection of 4-hydroxypipecolic 
acid derivative 384 
Alternative transfer hydrogenation conditions were explored using ammonium formate and 
palladium on carbon (Scheme 3.12). The free amine 397 was produced in a moderate 48% yield. 
Finally, acid-catalysed hydrolysis of the methyl ester in hydrochloric acid under reflux generated 
the hydrochloride salt of 6-methyl-4-hydroxypipecolic acid 398 as a white solid in quantitative 
yield.  
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Scheme 3.12 Deprotection of 6-methyl-4-hydroxypipecolic acid derivative 384 
Deprotection of 6-methyl-4-hydroxypipecolic acid derivative 384 has been demonstrated 
successfully using a simple transfer hydrogenation to remove the N-benzyl group followed by 
hydrolysis of the ester to yield the parent N-heterocyclic amino acid as a crystalline solid. 
3.5.1 X-Ray Crystal Structure of 6-Methyl-4-Hydroxypipecolic Acid 
The relative stereochemistry of 4-hydroxypipecolic acid analogues had been ascertained using 
nOe spectroscopy. It was however desirable to confirm the absolute stereochemistry of the 
pipecolic acid derivatives via X-ray crystallography. Deprotected 6-methyl-4-hydroxypipecolic acid 
398 was obtained as a crystalline salt and therefore an X-ray crystal structure of this product was 
desirable. 
Following recrystallisation to give appropriately sized crystals, X-ray crystallography was carried 
out to determine the absolute stereochemistry of the two new stereogenic centres.  Absolute 
stereochemical information can be obtained as enantiomerically pure L-aspartic acid was 
employed as the starting material and was proven to be unaltered by chemical transformations 
using chiral HPLC prior to cyclisation (vide supra). Therefore the carboxylic acid stereogenic centre 
at C-2 is already defined. 4-Hydroxypipecolic acid 398 crystallises in the orthorhombic space group 
P212121. An ORTEP representation of the X-ray crystal structure obtained shows the N-
heterocyclic core resides in a chair conformation (Figure 3.8). The C-2 carboxylic acid stereocentre 
is axial, the C-4 hydroxyl group is equatorial and the C-6 methyl stereogenic centre is also 
equatorial. The X-ray crystal structure has proven the stereochemistry as (2S,4S,6R)-6-methyl-4-
hydroxypipecolic acid 398.  
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Figure 3.8 ORTEP representation of X-ray crystal structure of the hydrochloride salt of (2S,4S,6R)-
6-methyl-4-hydroxypipecolic acid 398 
Confirmation of the relative and absolute stereochemistry of the deprotected pipecolic acid 
product has been demonstrated with the aid of X-ray crystallography. 
3.6 Alternative Approach to 4-Oxopipecolic Acid Derivatives 
A rapid approach for the synthesis of 6-substituted-4-oxopipecolic acid derivatives has been 
developed using a reductive amination/cyclisation strategy. The specifications for a new method 
to 4-oxopipecolic acid required a fast and efficient synthesis. The strategy devised is rapid, yet the 
yields are moderate and therefore the synthetic route is not highly efficient. Attempts to optimise 
the reductive amination did not improve the yield above approximately 50%. The approach is 
compromised because the chemoselectivity is low for reduction of the imine over the enone and 
therefore it was proposed to develop an alternative strategy to achieve higher yields of the 
cyclised product. Avoidance of reductive conditions in the presence of the enone may improve 
yields and therefore a strategy where the N-benzyl group is incorporated prior to enone 
formation is desirable. 
The initial strategy to probe if this hypothesis would be feasible was to alkylate Boc-protected 
enone derivative 343 to give orthogonally protected amine 399, then remove the Boc group 
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(Scheme 3.13). It was anticipated that the N-benzyl enone 400 should cyclise with an improved 
yield of cycloadduct 362. Alkylation of Boc-protected phenethyl analogue 343 was not possible 
with benzyl bromide. No product was obtained and starting material was returned, presumably 
due to the low nucleophilicity of the carbamate nitrogen. No further investigation of this method 
was carried out. 
 
Scheme 3.13 Attempted incorporation of an N-benzyl group onto Boc-protected enone 343 
Attempts to incorporate the N-benzyl group at an earlier stage of the synthesis were also 
explored. Mono-N-benzyl protection of the phosphonate ester was investigated. Alkylation of 
nitrogen with benzyl bromide is prone to over-alkylation, however the reaction was explored 
using a limited range of conditions. Phosphonate ester 293 was deprotected with TFA to remove 
the trityl protecting group to give phosphonate ester 401 quantitatively (Scheme 3.14). Alkylation 
with benzyl bromide and mild bases was investigated, however complex, polar mixtures were 
obtained and no product was identified (Table 3.4). 
 
Scheme 3.14 Attempted N-Benzyl protection of phosphonate ester 401 
  
P a g e  | 109 
 
Entry Base Solvent Outcome 
1 K2CO3 MeCN complex mixture 
2 DBU MeCN complex mixture 
3 Et3N CH2Cl2 complex mixture 
Table 3.4 Conditions for attempted N-benzyl protection of phosphonate ester 401 
N-Benzyl protection of the densely functionalised enone derivative 343 or phosphonate ester 401 
proved unsuccessful. It was therefore proposed to install the N-benzyl group as the first step in 
the synthetic sequence. An alternative scheme was devised to fully protect L-aspartic acid 266 
with benzyl groups. The approach involved reaction of excess benzyl bromide with L-aspartic acid 
266 to give per-benzylated intermediate 403 in good yield (Scheme 3.15).149 Removal of one of 
the N-benzyl groups was achieved using oxidative conditions with cerium ammonium nitrate to 
afford N-benzyl derivative 404 in excellent yield.150 In order to achieve high regioselectivity for the 
subsequent phosphonate ester formation, steric bulk is required on the nitrogen, and therefore a 
Boc-protecting group was deemed necessary. Unfortunately, Boc-protection of intermediate 404 
was not possible under standard conditions and therefore the route was terminated. 
 
Scheme 3.15 Alternative route to 4-oxopipecolic acid derivatives 
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Alternatively, it was postulated that di-N-benzyl compound 403 would be sufficiently hindered to 
control the regioselectivity of phosphonate ester synthesis. Following formation of the HWE 
substrate 409, removal of an N-benzyl group could potentially be achieved via the CAN oxidative 
conditions. N,N-Dibenzyl protected L-aspartic acid derivative 403 was subjected to the previously 
developed conditions for phosphonate ester synthesis, however the reaction gave inseparable 
complex, polar mixtures (Scheme 3.16). Possibly benzyl alcohol is not as effective a leaving group 
as methanol.  
 
Scheme 3.16 Attempted synthesis of N,N-dibenzyl phosphonate ester 409 
The final attempt to arrive at a suitable N-benzyl protected intermediate was investigated. O-
Benzyl L-aspartic acid derivative 403 appeared to be unsuitable for the phosphonate ester 
synthesis and therefore, an attempt to synthesise mono-N-benzyl protected bis-methyl ester 
aspartic acid 410 was explored. The methyl ester was anticipated to allow the phosphonate ester 
synthesis to occur, yet the question was whether the N-benzyl protecting group would induce 
sufficient regioselective discrimination. Previously synthesised dimethyl ester hydrochloride salt 
291 was reacted with benzyl bromide in the presence of base (Scheme 3.17).151 Both mono-N- and 
N,N-dibenzyl products were formed, however separation was feasible to give the desired mono-
N-benzyl product 410 in a moderate 55% yield. N-Benzyl protected aspartic acid 410 was 
subjected to conditions for phosphonate ester synthesis. A complex, polar mixture resulted from 
the reaction, however trace quantities of a mixture of phosphonate ester regioisomers were 
observed by 1H NMR spectroscopy. This indicated that the N-benzyl group did not provide 
adequate regioselectivity and therefore this method was no longer explored. 
 
Scheme 3.17 Attempted alternative route to N-benzyl protected phosphonate ester 402 
P a g e  | 111 
 
Initial investigation into an alternative route to 6-substituted-4-oxopipecolic acids was 
unsuccessful. The goal was to incorporate the nucleophilic N-benzyl group in advance of the 
cyclisation in order to optimise the yield of pipecolic acid products. Alkylation of advanced 
intermediates from the synthetic scheme proved unsuccessful. Whereas, alkylation of early, 
simple intermediates was possible, however subsequent transformations were compromised, 
which prevented further progress of the synthetic route.  
3.7 Future Work 
Further research into this project will focus on the development of a more efficient route to 4-
oxopipecolic acids. The general principle of an intramolecular conjugate addition reaction of an 
enone-functionalised α-amino acid will be retained, however a different route to arrive at the 
unsaturated amino acids will be explored.  
The proposed method will involve esterification of commercially available protected L-aspartic 
acid 411 to give tert-butyl ester 412 (Scheme 3.18). Hydrogenation of the benzyl ester and Cbz-
protecting group will provide β-amino acid 413. β-Lactam 414 will be formed via a dehydration 
reaction using tris(2-oxo-3-oxazolinyl)phosphine oxide.152 The crucial N-benzyl group will then be 
incorporated to generate protected β-lactam 415. Chemoselective ring-opening of the β-lactam 
with the anion of dimethyl methylphosphonate will be attempted. The bulky tert-butyl ester 
should allow for a selective, high yielding reaction for the formation of the HWE precursor 416.153 
HWE reaction under the previously established conditions with a range of aldehydes, followed by 
base-mediated cyclisation should allow generation of 4-oxopipecolic acids in improved yields. It is 
feasible that the bulky tert-butyl ester may also enhance the diastereoselectivity of the reaction.   
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Scheme 3.18 Proposed improved route to 4-oxopipecolic acid analogues using an E-enone 
If the proposed route is successful, a further modification could be made to enable access to syn-
pipecolic acid analogues via the Z-enones. It is possible that β-lactam 415 could be 
chemoselectively opened with the anion of bis(2,2,2-trifluoroethyl) methylphosphonate to give 
phosphonate ester 419 (Scheme 3.19). Still-Gennari conditions as previously described would 
enable the formation of N-benzyl protected Z-enone 420. The necessary functionality for the 
cyclisation reaction would already be in place and therefore cyclisation could be initiated with a 
mild base to potentially give rise to the syn-4-oxopipecolic acid diastereomer 421. This approach 
would negate the need for the acidic or Lewis acid conditions for protecting group cleavage, 
which previously resulted in geometric isomerisation of the Z-enones. 
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Scheme 3.19 Proposed improved route to 4-oxopipecolic acid analogues using a Z-enone 
Further work in this area would be beneficial to develop a robust and reliable method for the 
synthesis of both anti- and syn-substituted 4-oxopipecolic acid derivatives in high diastereomeric 
excess. If a complimentary, divergent route to both diastereomers was achievable, access to 
multiple natural products and therapeutic agents would be possible quickly and efficiently. 
3.8 Summary 
A fast synthetic strategy has been devised which utilises novel enone-containing α-amino acid 
derivatives as substrates for a one-pot reductive amination/6-endo-trig cyclisation reaction to 
afford highly sought after 6-substituted-4-oxopipecolic acid scaffolds. 
Using the one-pot strategy, eight examples of 4-oxopipecolic acid analogues were synthesised in 
moderate yields and diastereoselectivity. The 4-oxopipecolic acid derivatives differed at the 6-
position depending on the R group of the enone employed. This enables variation at a late stage 
in the synthetic route and therefore access to a range of analogues is possible as illustrated by the 
small, diverse library synthesised. 
Further modifications to the 4-oxopipecolic acid motif have been demonstrated. 
Diastereoselective reduction of the ketone moiety led to five examples of 4-hydroxypipecolic acid 
analogues in excellent yields and with good diastereoselective discrimination. These are also 
highly desirable synthetic scaffolds within organic synthesis and medicinal chemistry. 
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Deprotection of the pipecolic acid scaffold was exemplified with 6-methyl-4-hydroxypipecolic acid 
384. The N-benzyl group was readily removed via transfer hydrogenation, followed by acidic ester 
cleavage to produce the parent N-heterocyclic α-amino acid 398. 
The relative and absolute stereochemistry of the analogues was proven using nOe spectroscopic 
analysis and X-ray crystallography of the deprotected 4-hydroxypipecolic acid salt 398 to 
demonstrate the relationship of the substituents around the N-heterocyclic core. 
Following scrutiny of the devised approach, it was apparent that the objective for a highly 
efficient route had not been met. The route was fast, however the moderate yields could be 
improved. Several attempts were made to develop a route where reductive conditions were 
avoided. The aim was to incorporate the N-benzyl group, necessary for the 6-endo-trig cyclisation, 
at an earlier stage in the synthetic scheme. Unfortunately, an efficient, alternative method was 
not developed, therefore further investigation is required. 
Future goals of the research include development of a more efficient strategy to 4-oxopipecolic 
acid. Exploration of the cyclisation of Z-enones is also of interest to investigate whether the 
opposite diastereomeric 4-oxopipecolic acid products are formed and if stereoselectively is 
improved. Examination of Z-enone cyclisation was not possible using the current route as 
deprotection of the Z-enones was previously unsuccessful.  
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4 Conclusions 
To reiterate, the two primary objectives of the research programme were to develop a fast and 
efficient route to novel enone-containing α-amino acids and then to employ the enones as 
substrates for an intramolecular conjugate addition reaction to generate 4-oxopipecolic acid 
scaffolds.   
There are a limited number of examples of enone-containing α-amino acids in the literature, as 
illustrated previously. Consideration of the positive and negative features of these synthetic 
routes aided the development of an optimal strategy. Utilising a naturally occurring α-amino acid 
as the starting material was favourable because it provided >99% enantiomeric excess. Selection 
of the trityl protecting group for the synthetic scheme gave superior results in terms of 
regioselectivity and yield for phosphonate ester formation in comparison to previously reported 
cases. Overall, the phenyl-substituted E-enone derivative 294 was synthesised in an excellent 80% 
yield over 4 synthetic steps making the route fast and highly efficient. The connective double 
bong forming strategy also enabled variation at a late stage, which was a desirable feature and 
allowed the production of numerous enone-functionalised α-amino acid analogues.  
Conversely, there are innumerable approaches for the synthesis of pipecolic acid derivatives in 
the current literature. This is due to the significance of these N-heterocyclic compounds, and 
therefore extensive research has been carried out to develop efficient synthetic routes. This has 
proved challenging and is a contemporary problem with plenty of scope for improvement. In an 
attempt to provide an alternative strategy to 4-oxopipecolic acid, the novel enone-containing α-
amino acids were subjected to a one-pot reductive amination/cyclisation strategy. The desired 4-
oxopipecolic acid analogues were obtained in moderate yields over the one-pot, 3 step process to 
give the anti-diastereomer as the major product. Phenethyl derivative 362 was the highest 
yielding cycloadduct, which provided an overall 41% yield from L-aspartic over 5 synthetic steps. 
The one-pot cyclisation of enone-functionalised α-amino acids allows generation of these 
important targets in fewer steps and with higher overall yields, in comparison with several 
previously reported literature strategies. The diastereomeric selectivity of the reaction is not as 
high as other literature examples. One advantage of the route in contrast to other approaches is 
the ability to easily functionalise the 6-substituent of 4-oxopipecolic acid derivatives. Diversity is 
easily attained by variation of the R group of the enones employed in the intramolecular 
cyclisation. 
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To conclude, a facile and general approach has been developed for the synthesis of novel enone-
containing α-amino acids, which have several potential applications within organic, biological and 
medicinal research. These compounds have also been employed as substrates for an 
intramolecular conjugate addition reaction to give rise to 4-oxopipecolic acid derivatives, which 
may serve as useful synthetic scaffolds for organic chemists or for the synthesis of novel 
therapeutic agents. 
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5 Experimental 
5.1 General Considerations 
Reactions were carried out in flame-dried glassware under a positive atmosphere of argon. Dry 
solvents were purified using a PureSolv 500 MD solvent purification system. Unless otherwise 
noted, reagents were commercially available and used without further purification. Brine refers to 
a saturated solution of sodium chloride in distilled water. Flash column chromatography was 
carried out using Fisher matrix silica 60. Macherey-Nagel aluminium-backed plates pre-coated 
with silica gel 60 (UV254) were used for thin layer chromatography and were visualised by staining 
with KMnO4. 
1H NMR and 13C NMR spectra were recorded on a Bruker DPX 400 spectrometer with 
chemical shift values in ppm relative to TMS (δH 0.00 and δC 0.0) or residual chloroform (δH 7.28 
and δC 77.2) as standard. Proton and carbon assignments are based on two-dimensional COSY and 
DEPT experiments, respectively. Mass spectra were obtained using a JEOL JMS-700 spectrometer. 
Infrared spectra were obtained neat using a Shimadzu IRPrestige-21 spectrometer. Optical 
rotations were determined as solutions irradiating with the sodium D line (λ = 589 nm) using an 
Autopol V polarimeter. *α+D values are given in units 10
−1 deg cm2 g−1. Chiral HPLC was performed 
on a Hewlett Packard Agilent 1100 Series instrument and was calibrated with the appropriate 
racemic mixture. 
5.2 General Experimental 
General Procedure 1: Horner-Wadsworth-Emmons reaction 
Methyl (2S)-5-(dimethoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate 293 (0.20 g, 0.40 mmol) 
was dissolved in acetonitrile (4.0 mL) at room temperature under argon. Anhydrous potassium 
carbonate (0.058 g, 0.42 mmol) was added to the solution, and then an aldehyde (0.80 mmol) was 
added to the suspension and heated at 50 °C until the reaction was complete by TLC. The reaction 
mixture was allowed to cool to room temperature and then concentrated in vacuo. The resultant 
residue was dissolved in ethyl acetate (30 mL), washed with water (30 mL), brine (30 mL), dried 
(MgSO4), and then concentrated in vacuo. The crude products were purified by column 
chromatography on silica eluting with 20–40% diethyl ether in petroleum ether. 
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General Procedure 2: Still-Gennari reaction 
A suspension of finely ground anhydrous potassium carbonate (0.27 g, 1.9 mmol) and 18-crown-6 
(1.0 g, 3.8 mmol, recrystallised from acetonitrile) in toluene (3.0 mL) at room temperature under 
argon was stirred for 1 h. The suspension was cooled to −20 °C and then a solution of methyl (2S)-
5-[bis(2,2,2-trifluoroethylphosphoryl)]-4-oxo-2-(tritylamino)pentanoate 321 (0.20 g, 0.32 mmol) in 
toluene (2.0 mL) was added followed by an aldehyde (0.32 mmol). The reaction mixture was 
allowed to warm to 0 °C and stirred for 2.5 h. The reaction was quenched with a saturated 
solution of ammonium chloride (20 mL), and then extracted with diethyl ether (3 × 20 mL). The 
combined organic layers were dried (MgSO4), and then concentrated in vacuo. The crude products 
were purified by column chromatography on silica eluting with 10–20% diethyl ether in petroleum 
ether. 
General Procedure 3: Suzuki-Miyaura cross-coupling reaction 
To a solution of the aldehyde (1.6 mmol) in 95:5 DMF–water (10 mL) was added a boronic acid 
(2.4 mmol), tetrakis(triphenylphosphine)palladium (0.94 g, 0.081 mmol) and potassium carbonate 
(0.56 g, 4.1 mmol). The reaction mixture was heated to 110 °C and stirred for 4 h. The solution 
was allowed to cool to room temperature, and then concentrated in vacuo. The residue was 
dissolved in chloroform, filtered through Celite®, and then the filtrate was concentrated in vacuo. 
The resultant residue was dissolved in diethyl ether (100 mL), washed with water (6  100 mL), a 
saturated solution of copper sulphate (3 × 100 mL), brine (2  100 mL), dried (MgSO4), and then 
concentrated in vacuo. The crude products were purified by flash column chromatography on 
silica eluting with 10–15% ethyl acetate in petroleum ether. 
General Procedure 4: Synthesis of Boc-protected enones 
To a solution of the trityl protected amino acid (1.8 mmol) in dichloromethane (20 mL) at room 
temperature under argon was added trifluoroacetic acid (1.3 mL, 18 mmol) and the reaction 
mixture was stirred for 2 h. The reaction mixture was concentrated in vacuo, and then the residue 
was dissolved in water (40 mL) and washed with diethyl ether (2 × 40 mL). The aqueous layer was 
concentrated in vacuo, azeotroping with ethyl acetate–chloroform to give the TFA salts. These 
were dissolved in dichloromethane (18 mL) under argon and cooled to 0 °C. To the solution was 
added triethylamine (0.50 mL, 3.6 mmol) and di-tert-butyl dicarbonate (0.59 g, 2.7 mmol), and the 
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reaction mixture was allowed to warm to room temperature and stirred for 3 h. The reaction 
mixture was diluted with dichloromethane (10 mL), washed with water (2 × 30 mL), brine (30 mL), 
dried (MgSO4), and then concentrated in vacuo. The crude products were purified by column 
chromatography on silica eluting with 20–40% diethyl ether in petroleum ether. 
General Procedure 5: Deprotection of Boc-protected enones 
To a solution of Boc-protected amino methyl ester (0.25 mmol) in 1:1 methanol–water (8.0 mL) 
was added cesium carbonate (0.11 g, 0.33 mmol). The resultant suspension was stirred at room 
temperature for 48 h. The reaction mixture was concentrated in vacuo, the residue was dissolved 
in water (20 mL) and acidified to pH 1 with hydrochloric acid (1.0 M). The aqueous layer was 
washed with dichloromethane (3 × 20 mL) and the combined organic layers were concentrated in 
vacuo. To a solution of the resulting residue in dichloromethane (5.0 mL) was added 
trifluoroacetic acid (0.068 mL, 0.92 mmol) and the reaction mixture was stirred at room 
temperature under argon for 2 h. The reaction mixture was concentrated in vacuo to give the TFA 
salts, which were purified by recrystallisation from chloroform and methanol. 
General Procedure 6: Synthesis of 6-substituted-4-oxopipecolic acid derivatives 
To a solution of the trityl protected enone (2.5 mmol) in dichloromethane (25 mL) at room 
temperature under argon was added trifluoroacetic acid (1.9 mL, 25 mmol), and the reaction 
mixture was stirred for 2 h, and then concentrated in vacuo. The residue was dissolved in water 
(50 mL) and washed with diethyl ether (2 × 50 mL). The aqueous layer was concentrated in vacuo, 
azeotroping with ethyl acetate–chloroform to give the TFA salts. These were dissolved in 
tetrahydrofuran (25 mL) at room temperature under argon. To the solution was added 4Å 
molecular sieves, triethylamine (0.34 mL, 2.5 mmol) and benzaldehyde (0.25 mL, 2.5 mmol) and 
the mixture was stirred for 2 h. The reaction mixture was filtered and then concentrated in vacuo. 
The residue was dissolved in methanol (30 mL) at room temperature under argon and sodium 
cyanoborohydride (0.15 g, 2.5 mmol) was added to the solution and allowed to stir for 1 h. The 
reaction mixture was quenched with a saturated sodium hydrogen carbonate solution (1.0 mL), 
and then concentrated in vacuo. The residue was dissolved in dichloromethane (100 mL), then 
washed with a saturated sodium hydrogen carbonate solution (100 mL), brine (100 mL), dried 
(MgSO4), and concentrated in vacuo.  The crude products were purified by column 
chromatography on silica eluting with 20%–25% diethyl ether in petroleum ether. 
P a g e  | 120 
 
General Procedure 7: Synthesis of 6-substituted-4-hydroxypipecolic acid derivatives 
 To a solution of 6-substituted-4-oxopipecolic acid (0.44 mmol) in methanol (5.0 mL) under argon 
at 0 °C was added sodium borohydride (0.017 g, 0.44 mmol). The reaction mixture was allowed to 
warm gradually to room temperature and stirred for 16 h. The reaction mixture was quenched 
with hydrochloric acid (1.0 M, 0.1 mL), and then concentrated in vacuo. The residue was dissolved 
in dichloromethane (20 mL), washed with a saturated sodium hydrogen carbonate solution (20 
mL), brine (20 mL), dried (MgSO4), and then concentrated in vacuo. The crude products were 
purified by column chromatography on silica eluting with 40–50% diethyl ether in petroleum 
ether. 
5.3 Experimental Procedures 
Dimethyl (2S)-2-aminobutandioate hydrochloride 291111 
 
To a suspension of L-aspartic acid 266 (5.0 g, 38 mmol) in methanol (100 mL) at 0 °C under argon 
was added dropwise thionyl chloride (3.8 mL, 53 mmol). The reaction mixture was allowed to 
warm to room temperature and then heated under reflux for 3 h. The solution was allowed to 
cool to room temperature and then concentrated in vacuo, azeotroping with toluene–
dichloromethane to give 291 as a white solid (7.4 g, 100%). Mp 115–116 °C (lit.,111 mp 114–115 
°C); *α+D
24 +22.0 (c 1.0, MeOH); δH (400 MHz, (CD3)2SO) 2.99 (1H, dd, J 18.0, 5.5 Hz, 3-HH), 3.05 
(1H, dd, J 18.0, 5.5 Hz, 3-HH), 3.66 (3H, s, OMe), 3.74 (3H, s, OMe), 4.35 (1H, t, J 5.5 Hz, 2-H), 8.72 
(3H, br s, CHNH3
+); δC (100 MHz, (CD3)2SO) 34.0 (CH2), 48.4 (CH), 52.2 (CH3), 53.0 (CH3), 168.7 (C), 
169.6 (C); m/z (CI) 162 (MH+, 100%), 148 (5), 102 (20). 
Dimethyl (2S)-2-(tritylamino)butandioate 292107  
 
 To a solution of dimethyl (2S)-2-aminobutandioate hydrochloride 291 (7.4 g, 38 mmol) in 
dichloromethane (300 mL) at 0 °C under argon was added dropwise triethylamine (11 mL, 76 
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mmol) followed by triphenylmethyl chloride (13 g, 45 mmol). The reaction mixture was allowed to 
warm to room temperature and stirred for 6 h. The mixture was diluted with dichloromethane (50 
mL), washed with citric acid (2.0 M, 300 mL), water (300 mL), brine (300 mL), dried (MgSO4), and 
then concentrated in vacuo to give a colourless oil. The crude product was purified by column 
chromatography on silica eluting with 20% diethyl ether in petroleum ether to give 292 as a white 
solid (15 g, 100%). Mp 71–72 °C (lit.,107 mp 70–71 °C); *α+D
24 +36.6 (c 1.0, CHCl3); δH (400 MHz, 
CDCl3) 2.51 (1H, dd, J 14.7, 7.0 Hz, 3-HH), 2.66 (1H, dd, J 14.7, 5.4 Hz, 3-HH), 2.93 (1H, d, J 10.1 Hz, 
NH), 3.25 (3H, s, OMe), 3.65–3.74 (4H, m, 2-H and OMe), 7.15–7.20 (3H, m, ArH), 7.23–7.28 (6H, 
m, ArH), 7.46–7.51 (6H, m, ArH); δC (100 MHz, CDCl3) 39.0 (CH2), 50.5 (CH3), 50.7 (CH3), 52.4 (CH), 
69.9 (C), 125.2 (CH), 126.6 (CH), 127.5 (CH), 144.4 (C), 169.7 (C), 172.6 (C); m/z (EI) 403 (M+, 1%), 
326 (35), 258 (14), 243 (100), 228 (4), 192 (6), 165 (30), 160 (4), 83 (70). 
Methyl (2S)-5-(dimethoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate 293107  
 
A solution of dimethyl methylphosphonate (3.5 mL, 33 mmol) in THF (40 mL) was cooled to −78 °C 
under argon. nButyl lithium (2.5 M in hexane, 14 mL, 34 mmol) was added dropwise and the 
reaction mixture was stirred for 0.75 h. In a separate reaction vessel, a solution of dimethyl (2S)-2-
(tritylamino)butandioate 292 (6.0 g, 15 mmol) in THF (100 mL) was cooled to −78 °C under argon 
and the dimethyl methylphosphonate/nbutyl lithium solution was transferred via cannula into the 
flask, and the reaction mixture stirred at −78 °C for 3 h to give a yellow solution. The reaction was 
quenched with a saturated solution of ammonium chloride (2.0 mL) and allowed to warm to room 
temperature. The mixture was concentrated in vacuo. The resulting residue was diluted with ethyl 
acetate (250 mL), washed with water (250 mL), brine (250 mL), dried (MgSO4), and then 
concentrated in vacuo. The crude product was purified by column chromatography on silica 
eluting with 80% ethyl acetate in petroleum ether to give 293 as a white solid (6.2 g, 84%). Mp 
117–118 °C (lit.,107 mp 117–119 °C); [α]D
24 +31.1 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.78 (1H, dd, J 
16.7, 6.9 Hz, 3-HH), 2.85–2.95 (2H, m, 3-HH and NH), 3.06 (2H, d, JH–C–P 22.7 Hz, 5-H2), 3.29 (3H, s, 
OMe), 3.65–3.73 (1H, m, 2-H), 3.76 (3H, s, OMe), 3.79 (3H, s, OMe), 7.15–7.30 (9H, m, ArH), 7.44–
7.51 (6H, m, ArH); δC (100 MHz, CDCl3) 41.8 (d, JC–P 128 Hz, CH2), 48.7 (CH2), 52.0 (CH3), 52.9 (CH3), 
53.0 (CH3), 53.1 (CH), 71.2 (C), 126.5 (CH), 127.9 (CH), 128.7 (CH), 145.6 (C), 174.0 (C), 199.2 (C); δP 
(160 MHz, CDCl3) 22.3; m/z (CI) 496 (MH
+, 1%), 301 (5), 292 (5), 254 (90), 243 (100), 237 (55), 182 
(8), 167 (45). 
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Methyl (2S,5E)-4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate 294 
 
Method A: To a solution of methyl (2S)-5-(dimethoxyphosphoryl)-4-oxo-2-
(tritylamino)pentanoate 293 (0.10 g, 0.20 mmol) in acetonitrile (5.0 mL) at room temperature 
under argon was added anhydrous lithium chloride (0.010 g, 0.24 mmol) and DBU (0.040 mL, 0.24 
mmol). Benzaldehyde (0.040 g, 0.24 mmol) was added to the solution and stirred for 48 h. The 
reaction mixture was concentrated in vacuo, and then the resulting residue was dissolved in ethyl 
acetate (20 mL), washed with water (20 mL), brine (20 mL), dried (MgSO4), and then concentrated 
in vacuo. The crude product was purified by column chromatography on silica eluting with 20% 
diethyl ether in petroleum ether to give 294 as a yellow oil (0.039 g, 42%). νmax/cm
−1 (NaCl) 3320 
(NH), 3068, 3023 (ArH), 2950 (CH), 1737 (CO), 1687 (CO), 1657,  1608 (C=C), 1492, 1448, 1205, 
1174; *α+D
25 +111.0 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.80 (1H, dd, J 15.2, 7.0 Hz, 3-HH), 2.88–
2.97 (2H, m, 3-HH and NH), 3.28 (3H, s, OMe), 3.79–3.89 (1H, m, 2-H), 6.69 (1H, d, J 16.2 Hz, 5-H), 
7.10–7.31 (9H, m, ArH), 7.35–7.61 (12H, m, ArH and 6-H); δC (100 MHz, CDCl3) 45.7 (CH2), 48.7 
(CH), 52.0 (CH3), 71.3 (C), 126.4 (CH), 126.6 (CH), 128.0 (CH), 128.4 (CH), 128.9 (CH), 129.0 (CH), 
130.7 (CH), 134.4 (C), 143.4 (CH), 145.8 (C), 174.5 (C), 197.6 (C); m/z (FAB) 476.2231 (MH+. 
C32H30NO3 requires 476.2226), 398 (15%), 259 (6), 243 (100), 232 (25), 166 (23), 132 (24). 
Method B: Using general procedure 1 above with benzaldehyde (0.50 g, 1.0 mmol) gave 294 after 
36 h as a yellow oil (0.46 g, 95%). Spectroscopic data as reported above. 
Methyl (2S,5E)-6-(4’-fluorophenyl)-4-oxo-2-(tritylamino)hex-5-enoate 303 
 
Using general procedure 1 above with 4-fluorobenzaldehyde (0.086 mL, 0.80 mmol) gave 303 
after 3 days as a yellow oil (0.14 g, 69%). νmax/cm
−1 (NaCl) 3320 (NH), 3057, 3021 (ArH), 2950 (CH), 
2922, 1738 (CO), 1686 (CO), 1658, 1612 (C=C), 1598, 1508, 1490, 1447, 1233; *α+D
25 +128.8 (c 1.0, 
CHCl3); δH (400 MHz, CDCl3) 2.78 (1H, dd, J 15.2, 7.0 Hz, 3-HH), 2.87–2.95 (2H, m, 3-HH and NH), 
3.28 (3H, s, OMe), 3.78–3.85 (1H, m, 2-H), 6.61 (1H, d, J 16.3 Hz, 5-H), 6.96–7.35 (11H, m, ArH), 
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7.44 (1H, d, J 16.3 Hz, 6-H), 7.47–7.59 (8H, m, ArH); δC (100 MHz, CDCl3) 44.9 (CH2), 51.1 (CH3), 
52.9 (CH), 70.4 (C), 115.3 (d, JC–C–F 22.1 Hz, CH), 125.1 (CH), 127.0 (CH), 127.2 (CH), 128.2 (CH), 
129.4 (CH), 129.7 (C), 141.1 (CH), 144.8 (C), 163.2 (d, JC–F 251.5 Hz, C), 173.6 (C), 196.4 (C); m/z 
(FAB) 494.2128 (MH+. C32H29FNO3 requires 494.2131), 416 (31%), 258 (6), 243 (100), 166 (34), 150 
(35). 
Methyl (2S,5E)-6-(4’-chlorophenyl)-4-oxo-2-(tritylamino)hex-5-enoate 304 
 
Using general procedure 1 above with 4-chlorobenzaldehyde (0.11 g, 0.40 mmol) gave 304 after 2 
days as a white solid (0.16 g, 77%). Mp 121–122 °C; νmax/cm
−1 (NaCl) 3320 (NH), 3056, 3021 (ArH), 
2950 (CH), 1737 (CO), 1687, 1658 (CO), 1608 (C=C), 1592, 1490, 1447, 1205, 1174, 1090; *α+D
25 
+144.8 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.77 (1H, dd, J 15.2, 6.9 Hz, 3-HH), 2.86–2.93 (2H, m, 3-
HH and NH), 3.29 (3H, s, OMe), 3.75–3.82 (1H, m, 2-H), 6.65 (1H, d, J 16.2 Hz, 5-H), 7.11–7.30 
(10H, m, ArH and 6-H), 7.33–7.57 (10H, m, ArH); δC (100 MHz, CDCl3) 44.7 (CH2), 50.9 (CH3), 52.6 
(CH), 70.2 (C), 125.4 (CH), 125.6 (CH), 127.0 (CH), 128.0 (CH), 128.4 (CH), 128.7 (CH), 132.2 (C), 
135.4 (C), 140.6 (C), 144.9 (CH), 173.3 (C), 196.2 (C); m/z (FAB) 510.1847 (MH+. C32H29
35ClNO3 
requires 510.1836), 432 (11%), 267 (17), 243 (100), 166 (19). 
Methyl (2S,5E)-6-(4’-bromophenyl)-4-oxo-2-(tritylamino)hex-5-enoate 305 
 
Using general procedure 1 above with 4-bromobenzaldehyde (0.37 g, 2.0 mmol) gave 305 after 2 
days as a white solid (0.54 g, 96%). Mp 134–135 °C; νmax/cm
−1 (NaCl) 3320 (NH), 3084, 3057, 3021 
(ArH), 2950 (CH), 1737 (CO), 1687, 1659 (CO), 1608 (C=C), 1586, 1488, 1447, 1215, 1173, 1071; 
*α+D
27 +64.6 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.77 (1H, dd, J 15.2, 7.0 Hz, 3-HH), 2.86–2.95 (2H, 
m, 3-HH and NH), 3.29 (3H, s, OMe), 3.75–3.83 (1H, m, 2-H), 6.66 (1H, d, J 16.2 Hz, 5-H), 7.10–7.20 
(10H, m, ArH and 6-H), 7.35–7.57 (10H, m, ArH); δC (100 MHz, CDCl3) 45.8 (CH2), 51.9 (CH3), 53.7 
(CH), 71.2 (C), 124.9 (C), 126.2 (CH), 126.5 (CH), 127.9 (CH), 129.0 (CH), 129.7 (CH), 132.2 (CH), 
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133.3 (C), 141.7 (C), 145.7 (CH), 174.3 (C), 197.2 (C); m/z (FAB) 554.1332 (MH+. C32H29
79BrNO3 
requires 554.1331), 478 (16%), 476 (16), 378 (3), 312 (13), 310 (12), 243 (100), 209 (16), 166 (43). 
Methyl (2S,5E)-6-(2’-bromophenyl)-4-oxo-2-(tritylamino)hex-5-enoate 306 
 
Using general procedure 1 above with 2-bromobenzaldehyde (0.093 mL, 0.80 mmol) gave 306 
after 24 h as a yellow oil (0.16 g, 70%). νmax/cm
−1 (NaCl) 3321 (NH), 3058, 3021 (ArH), 2950 (CH), 
1737 (CO), 1691 (CO), 1662 (C=C), 1605, 1490, 1465, 1447, 1437, 1204, 1173, 1027; *α+D
25 +48.6 (c 
1.0, CHCl3); δH  (400 MHz, CDCl3) 2.82 (1H, dd, J 15.4, 6.8 Hz, 3-HH), 2.88–2.97 (2H, m, NH and 3-
HH), 3.30 (3H, s, OMe), 3.78–3.83 (1H, m, 2-H), 6.60 (1H, d, J 16.2 Hz, 5-H), 7.13–7.33 (11H, m, 
ArH), 7.48–7.53 (6H, m, ArH), 7.59 (2H, td, J 8.0, 1.1 Hz, ArH), 7.85 (1H, d, J 16.2 Hz, 6-H); δC (100 
MHz, CDCl3) 45.3 (CH2), 52.1 (CH3), 53.8 (CH), 71.3 (C), 125.9 (C), 126.6 (CH), 127.8 (CH), 127.9 
(CH), 128.0 (CH), 128.9 (CH), 129.1 (CH), 131.6 (CH), 133.6 (CH), 134.4 (C), 141.7 (CH), 145.8 (C), 
174.4 (C), 197.5 (C); m/z (FAB) 554.1322 (MH+. C32H29
79BrNO3 requires 554.1331), 478 (7%), 476 
(7), 312 (13), 310 (13), 243 (100), 209 (7), 165 (19).  
Methyl (2S,5E)-4-oxo-2-(tritylamino)-6-(3’-vinylphenyl)hex-5-enoate 307 
 
Using general procedure 1 above with 3-vinylbenzaldehyde (0.10 g, 0.80 mmol) gave 307 after 4 
days as a yellow oil (0.11 g, 56%). νmax/cm
−1 (NaCl) 3320 (NH), 3086, 3057, 3020 (ArH), 2950 (CH), 
2922, 1737 (CO), 1658 (CO), 1609 (C=C), 1490, 1447, 1215, 1172; *α+D
27 +52.0 (c 1.0, CHCl3); δH 
(400 MHz, CDCl3) 2.79 (1H, dd, J 15.1, 7.0 Hz, 3-HH), 2.89–2.96 (2H, m, 3-HH and NH), 3.27 (3H, s, 
OMe), 3.76–3.85 (1H, m, 2-H), 5.31 (1H, d, J 10.9 Hz, 8’-HH), 5.79 (1H, d, J 17.6 Hz, 8’-HH), 6.66–
6.76 (2H, m, 7’-H and 5-H), 7.13–7.28 (9H, m, ArH), 7.31–7.55 (11H, m, Ar and 6-H); δC (100 MHz, 
CDCl3) 45.8 (CH2), 52.0 (CH3), 53.9 (CH), 71.3 (C), 115.1 (CH2), 126.3 (CH), 126.7 (CH), 126.8 (CH), 
127.8 (CH), 128.2 (CH), 128.4 (CH), 129.1 (CH), 129.2 (CH), 134.7 (C), 136.1 (CH), 138.4 (C), 143.2 
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(CH), 145.8 (C), 174.5 (C), 197.5 (C); m/z (FAB) 502.2388 (MH+. C34H32NO3 requires 502.2382), 424 
(45%), 258 (72), 243 (100), 166 (83), 158 (77). 
Methyl (2S,5E)-6-(3’-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate 308 
 
Using general procedure 1 above with 3-nitrobenzaldehyde (0.12 g, 0.80 mmol) gave 308 after 5 
days as a yellow solid (0.12 g, 56%). Mp 61–62 °C; νmax/cm
−1 (NaCl) 3322 (NH), 3058, 3022 (ArH), 
2951 (CH), 1737 (CO), 1663 (CO), 1613 (C=C), 1530 (NO2), 1447, 1352 (NO2); *α+D
27 +49.3 (c 1.0, 
CHCl3); δH (400 MHz, CDCl3) 2.79 (1H, dd, J 15.4, 7.0 Hz, 3-HH), 2.88–2.98 (2H, m, 3-HH and NH), 
3.32 (3H, s, OMe), 3.77–3.85 (1H, m, 2-H), 6.79 (1H, d, J 16.2 Hz, 5-H), 7.10–7.31 (9H, m, ArH), 
7.41–7.62 (8H, m, ArH and 6-H), 7.81 (1H, d, J 8.0 Hz, ArH), 8.24 (1H, d, J 8.0 Hz, ArH), 8.37 (1H, s, 
ArH); δC (100 MHz, CDCl3) 46.2 (CH2), 52.1 (CH3), 53.8 (CH), 71.3 (C), 122.6 (CH), 124.8 (CH), 126.9 
(CH), 127.8 (CH), 128.6 (CH), 128.8 (CH), 130.1 (CH), 133.9 (CH), 136.2 (C), 140.1 (CH), 145.7 (C), 
148.8 (C), 174.3 (C), 196.9 (C); m/z (FAB) 521.2074 (MH+. C32H29N2O5 requires 521.2076), 443 
(63%), 277 (31), 243 (100), 184 (44), 166 (79). 
Methyl (2S,5E)-6-(4’-methoxyphenyl)-4-oxo-2-(tritylamino)hex-5-enoate 309 
 
Using general procedure 1 above with 4-methoxybenzaldehyde (0.25 g, 2.0 mmol) gave 309 as a 
colourless oil (0.32 g, 66%). νmax/cm
−1 (neat) 3320 (NH), 3057, 3021 (ArH), 2951 (CH), 2839, 1736 
(CO), 1682 (CO), 1653, 1595 (C=C), 1510, 1447, 1252, 1171, 1028; *α+D
23 +54.1 (c 1.0, CHCl3); δH 
(400 MHz, CDCl3) 2.78 (1H, dd, J 15.0, 7.0 Hz, 3-HH), 2.84–2.99 (2H, m, 3-HH and NH), 3.27 (3H, s, 
OMe), 3.71–3.93 (4H, m, 2-H and OMe), 6.59 (1H, d, J 16.1 Hz, 5-H), 6.92 (2H, d, J 8.7 Hz, ArH), 
7.11–7.35 (9H, m, ArH), 7.39–7.59 (9H, m, 6-H and ArH); δC (100 MHz, CDCl3) 45.7 (CH2), 52.0 
(CH3), 54.0 (CH), 55.4 (CH3), 71.3 (C), 114.5 (CH), 124.3 (CH), 126.6 (CH), 127.1 (C), 128.0 (CH), 
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128.9 (CH), 130.2 (CH), 143.2 (CH), 145.9 (C), 161.8 (C), 174.6 (C), 197.5 (C); m/z (FAB) 506.2329 
(MH+. C33H32NO4 requires 506.2331), 428 (5%), 262 (11), 243 (100), 162 (18), 86 (5). 
Methyl (2S,5E)-6-(3’,4’-dimethoxyphenyl)-4-oxo-2-(tritylamino)hex-5-enoate 310 
 
Using general procedure 1 above with 3,4-dimethoxybenzaldehyde (0.13 g, 0.80 mmol) gave 310 
after 10 days as a yellow solid (0.081 g, 38%). Mp 55–56 °C; νmax (NaCl)/cm
−1 3320 (NH), 3057, 
3020 (ArH), 2951 (CH), 2839, 1736 (CO), 1652 (CO), 1595 (C=C), 1513, 1464, 1448, 1265, 1161, 
1140, 1025; *α+D
24 +64.7 (c 0.5, CHCl3); δH (400 MHz, CDCl3) 2.79 (1H, dd, J 15.1, 7.1 Hz, 3-HH), 
2.88–2.97 (2H, m, 3-HH and NH), 3.26 (3H, s, OMe), 3.77–3.83 (1H, m, 2-H), 3.91–3.95 (6H, m, 2 × 
OMe), 6.58 (1H, d, J 16.2 Hz, 5-H), 6.88 (1H, d, J 8.3 Hz, ArH), 6.98–7.35 (10H, m, ArH), 7.39–7.54 
(8H, m, ArH and 6-H); δC (100 MHz, CDCl3) 44.5 (CH2), 50.8 (CH), 52.8 (CH3), 54.8 (CH3), 54.9 (CH3), 
70.2 (C), 108.6 (CH), 110.0 (CH), 122.2 (CH), 123.4 (CH), 125.4 (CH), 126.2 (C), 126.8 (CH), 127.7 
(CH), 142.4 (C), 144.7 (CH), 148.2 (C), 150.4 (C), 173.4 (C), 196.3 (C); m/z (FAB) 558.2260 (MNa+. 
C34H33NO5 requires 558.2256), 537 (2%), 459 (9), 292 (19), 243 (100), 192 (35), 166 (19). 
Methyl (2S,5E)-4-oxo-2-(tritylamino)hept-5-enoate 311 
 
To a solution of methyl (2S)-5-(dimethoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate 293 (1.0 g, 
2.0 mmol) in acetonitrile (20 mL) at room temperature under argon in a Schlenk tube, was added 
anhydrous potassium carbonate (0.29 g, 2.1 mmol) and acetaldehyde (0.34 mL, 6.1 mmol). The 
sealed tube was heated to 40 °C and stirred for 4 days. The reaction mixture was allowed to cool 
to room temperature and then concentrated in vacuo. The resulting residue was dissolved in ethyl 
acetate (60 mL), washed with water (60 mL), brine (60 mL), dried (MgSO4), and then concentrated 
in vacuo. The crude product was purified by column chromatography on silica eluting with 15% 
diethyl ether in petroleum ether to give 311 as a colourless oil (0.65 g, 78%). νmax/cm
−1 (neat) 3320 
(NH), 3058, 3022 (ArH), 2360, 1735 (CO), 1668 (CO), 1629 (C=C), 1490, 1448, 1435, 1215, 1172; 
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*α+D
25 +17.1 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.89 (3H, dd, J 6.8, 1.6 Hz, CH3), 2.66 (1H, dd, J 
15.4, 6.1 Hz, 3-HH), 2.79 (1H, dd, J 15.4, 6.1 Hz, 3-HH), 2.85 (1H, d, J 10.0 Hz, NH), 3.26 (3H, s, 
OMe), 3.63–3.79 (1H, m, 2-H), 6.07 (1H, dq, J 15.8, 1.6 Hz, 5-H), 6.77 (1H, dq, J 15.8, 6.8 Hz, 6-H), 
7.10–7.34 (9H, m, ArH), 7.40–7.54 (6H, m, ArH); δC (100 MHz, CDCl3) 18.4 (CH3), 45.0 (CH2), 52.0 
(CH3), 53.6 (CH), 71.2 (C), 126.5 (CH), 128.1 (CH), 128.8 (CH), 132.2 (CH), 143.7 (CH), 145.8 (C), 
174.6 (C), 197.5 (C); m/z (FAB) 414.2068 (MH+. C27H28NO3 requires 414.2069), 336 (22%), 243 
(100), 170 (32), 165 (14), 104 (1), 70 (10). 
Methyl (2S,5E)-8-methyl-4-oxo-2-(tritylamino)non-5-enoate 312 
 
Using general procedure 1 above with 3-methylbutyraldehyde (0.22 mL, 2.0 mmol) gave 312 as a 
colourless oil (0.26 g, 57%). νmax/cm
−1 (NaCl) 3320 (NH), 3058, 3021 (ArH), 2954 (CH), 2927, 1739 
(CO), 1692, 1669 (CO), 1626 (C=C), 1491, 1465, 1448, 1435, 1207, 1172; *α+D
18 +18.1 (c 1.0, CHCl3);  
δH (400 MHz, CDCl3) 0.91 (6H, d, J 6.7 Hz, 2 × CH3), 1.69–1.80 (1H, m, 8-H), 2.08 (2H, td, J 7.4, 1.3 
Hz, 7-H2), 2.63 (1H, dd, J 15.4, 7.1 Hz, 3-HH), 2.78 (1H, dd, J 15.4, 5.2 Hz, 3-HH), 2.84 (1H, d, J 10.0 
Hz, NH), 3.27 (3H, s, OMe), 3.62–3.78 (1H, m, 2-H), 6.02 (1H, dt, J 15.9, 1.3 Hz, 5-H), 6.71 (1H, dt, J 
15.9, 7.4 Hz, 6-H), 7.11–7.32 (9H, m, ArH), 7.40–7.55 (6H, m, ArH); δC (100 MHz, CDCl3) 22.5 (CH3), 
27.9 (CH), 41.8 (CH2), 44.9 (CH2), 52.0 (CH), 53.7 (CH3), 71.3 (C), 126.6 (CH), 128.0 (CH), 128.9 (CH), 
131.7 (CH), 145.9 (C), 147.5 (CH), 174.6 (C), 197.8 (C); m/z (FAB) 478.2359 (MNa+. C30H33NO3Na 
requires 478.2358), 378 (12%), 243 (100), 213 (8), 166 (17), 134 (1), 113 (4), 75 (11). 
Methyl (2S,5E)-6-tert-butyl-4-oxo-2-(tritylamino)oct-5-enoate 313 
 
To a solution of methyl (2S)-5-(dimethoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate 293 (1.0 g, 
2.0 mmol) in acetonitrile (20 mL) at room temperature under argon was added anhydrous 
potassium carbonate (0.29 g, 2.1 mmol) and trimethylacetaldehyde (0.66 mL, 6.1 mmol). The 
reaction mixture was heated under reflux for 5 days. The mixture was allowed to cool to room 
temperature and then concentrated in vacuo. The resultant residue was dissolved in ethyl acetate 
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(60 mL), washed with water (60 mL), brine (60 mL), dried (MgSO4), and then concentrated in 
vacuo. The crude product was purified by column chromatography on silica eluting with 20% 
diethyl ether in petroleum ether to give 313 as a yellow oil (0.10 g, 11%). νmax (neat)/cm
−1 3320 
(NH), 3021 (ArH), 2963, 2361, 1736 (CO), 1665 (CO), 1622 (C=C), 1490, 1448, 1215, 1203, 1171; 
*α+D
26 +10.8 (c 0.5 CHCl3); δH (400 MHz, CDCl3) 1.07 (9H, s, 
tBu), 2.66 (1H, dd, J 15.4, 7.0 Hz, 3-HH), 
2.73–3.01 (2H, m, 3-HH and NH), 3.27 (3H, s, OMe), 3.59–3.82 (1H, m, 2-H), 5.96 (1H, d, J 16.2 Hz, 
5-H), 6.73 (1H, d, J 16.2 Hz, 6-H), 7.11–7.34 (9H, m, ArH), 7.41–7.59 (6H, m, ArH); δC (100 MHz, 
CDCl3) 28.7 (CH3), 33.9 (C), 45.0 (CH2), 51.9 (CH3), 53.7 (CH), 71.3 (C), 125.8 (CH), 126.5 (CH), 127.9 
(CH), 128.8 (CH), 145.8 (C), 158.0 (CH), 174.6 (C), 198.4 (C); m/z (FAB) 456.2384 (MH+. C26H34NO6 
requires 456.2386), 378 (79%), 243 (100), 212 (71), 165 (47), 111 (66), 56 (55), 29 (56). 
Methyl (2S,5E)-4-oxo-8-phenyl-2-(tritylamino)oct-5-enoate 314 
 
Using general procedure 1 above with 3-phenylpropionaldehyde (0.16 mL, 1.2 mmol) gave 314 
after 2 days as a colourless oil (0.29 g, 93%). νmax/cm
−1 (NaCl) 3320 (NH), 3084, 3059, 3027 (ArH), 
2948 (CH), 2924, 1738 (CO), 1667 (CO), 1626, 1597 (C=C), 1492, 1448, 1205, 1173; *α+D
27 +26.6 (c 
1.0, CHCl3); δH (400 MHz, CDCl3) 2.39–3.01 (7H, m, 3-H2, 7-H2, 8-H2 and NH), 3.25 (3H, s, OMe), 
3.58–3.83 (1H, m, 2-H), 6.06 (1H, d, J 15.9 Hz, 5-H), 6.76 (1H, dt, J 15.9, 7.1 Hz, 6-H), 7.06–7.34 
(12H, m, ArH), 7.40–7.54 (8H, m, ArH); δC (100 MHz, CDCl3) 32.4 (CH2), 32.6 (CH2), 43.2 (CH2), 50.1 
(CH3), 51.9 (CH), 69.5 (C), 124.5 (CH), 125.0 (CH), 126.1 (CH), 126.6 (CH), 126.7 (CH), 127.0 (CH), 
129.2 (CH), 138.9 (C), 144.0 (C), 145.3 (CH), 172.7 (C), 195.8 (C); m/z (FAB) 504.2534 (MH+. 
C34H34NO3 requires 504.2539), 426 (69%), 378 (2), 366 (1), 266 (6), 252 (78), 243 (100), 241 (27), 
166 (78), 160 (38), 93 (31).  
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Methyl (2S,5E)-6-furan-2-yl-4-oxo-2-(tritylamino)hex-5-enoate 315 
 
Using general procedure 1 above with 2-furaldehyde (0.10 mL, 1.2 mmol) gave 315 after 2 days as 
a yellow oil (0.23 g, 81%). νmax/cm
−1 (NaCl) 3320 (NH), 3058 (NH), 2951 (ArH), 1737 (CO), 1607 
(C=C), 1552, 1491, 1447, 1267, 1203, 1018; [α]D
23 +42.9 (c 0.3, CHCl3); δH (400 MHz, CDCl3) 2.72 
(1H, dd, J 15.1, 7.0 Hz, 3-HH), 2.82–2.94 (2H, m, 3-HH and NH), 3.27 (3H, s, OMe), 3.68–3.84 (1H, 
m, 2-H), 6.40–6.75 (3H, m, 5-H and ArH), 7.10–7.54 (17H, m, 6-H and ArH); δC (100 MHz, CDCl3) 
46.2 (CH2), 52.0 (CH3), 53.9 (CH), 71.3 (C), 112.7 (CH), 116.2 (CH), 123.6 (CH), 126.6 (CH), 128.0 
(CH), 128.6 (CH), 129.8 (CH), 145.2 (CH), 145.8 (C), 151.0 (C), 174.5 (C), 197.1 (C); m/z (FAB) 
488.1833 (MNa+. C30H27NO4 requires 488.1838), 388 (7%), 352 (3), 243 (100), 241 (5), 166 (18), 
123 (7). 
Methyl (2S,5E)-6-(5-bromofuran-2-yl)-4-oxo-2-(tritylamino)hex-5-enoate 316 
 
Using general procedure 1 above with 5-bromo-2-furaldehyde (0.14 g, 0.80 mmol) gave 316 after 
5 days as a brown oil (0.15 g, 67%). νmax/cm
−1 (NaCl) 3320 (NH), 3058, 2952 (CH), 1739 (CO), 1606 
(C=C), 1552, 1492, 1469, 1447, 1358, 1208, 1017, 970; *α+D
24 +91.3 (c 0.1, CHCl3); δH (400 MHz, 
CDCl3) 2.71 (1H, dd, J 15.0, 6.8 Hz, 3-HH), 2.87–3.04 (2H, m, 3-HH and NH), 3.27 (3H, s, OMe), 
3.65–3.86 (1H, m, 2-H), 6.41 (1H, d, J 3.2 Hz, ArH), 6.52–6.66 (2H, m, ArH and 5-H), 7.08–7.32 
(10H, m, ArH and 6-H), 7.43–7.54 (6H, m, ArH); δC (100 MHz, CDCl3) 45.4 (CH2), 50.8 (CH3), 52.7 
(CH), 70.1 (C), 113.4 (CH), 116.9 (CH), 122.5 (CH), 124.8 (C), 125.4 (CH), 126.8 (CH), 126.9 (CH), 
127.6 (CH), 144.6 (C), 151.7 (C), 173.2 (C), 195.6 (C); m/z (FAB) 544.1118 (MH+. C30H27
79BrNO4 
requires 544.1123), 468 (4%), 466 (4), 413 (1), 378 (1), 302 (11), 243 (100), 241 (9), 198 (13), 166 
(32), 107 (2), 85 (2). 
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Methyl (2S,5E)-4-oxo-6-thiophen-2-yl-2-(tritylamino)hex-5-enoate 317 
 
Using general procedure 1 above with 2-thiophenecarboxaldehyde (0.075 mL, 0.80 mmol) gave 
317 after 7 days as a light brown oil (0.14 g, 71%). νmax/cm
−1 (NaCl) 3320 (NH), 3058, 2949 (ArH), 
1737 (CO), 1653 (CO), 1595 (C=C), 1490, 1447, 1263, 1200, 1030; [α]D
25 +52.6 (c 1.0, CHCl3); δH 
(400 MHz, CDCl3) 2.65 (1H, dd, J 15.0, 6.9 Hz, 3-HH), 2.71–2.91 (2H, m, 3-HH and NH), 3.19 (3H, s, 
OMe), 3.60–3.78 (1H, m, 2-H), 6.42 (1H, d, J 15.8 Hz, 5-H), 6.96 (1H, dd, J 5.1, 3.7 Hz, 4’-H), 7.04–
7.21 (10H, m, ArH and 3’-H), 7.29 (1H, d, J 5.1 Hz, 5’-H), 7.36–7.49 (6H, m, ArH), 7.51 (1H, d, J 15.8 
Hz, 6-H); δC (100 MHz, CDCl3) 44.7 (CH2), 50.8 (CH3), 52.7 (CH), 70.1 (C), 123.9 (CH), 125.5 (CH), 
127.0 (CH), 127.2 (CH), 127.6 (CH), 127.9 (CH), 130.7 (CH), 134.5 (CH), 138.6 (C), 144.6 (C), 173.2 
(C), 195.8 (C); m/z (FAB) 482.1793 (MH+. C30H28NO3S requires 482.1790), 404 (12%), 307 (8), 289 
(11), 258 (9), 243 (100), 228 (13), 193 (10), 165 (53), 155 (32), 107 (23), 77 (36), 51 (17). 
Methyl (2S,5E)-4-oxo-6-pyridin-3-yl-2-(tritylamino)hex-5-enoate 318 
 
Using general procedure 1 above with 3-pyridinecarboxaldehyde (0.075 mL, 0.80 mmol) gave 318 
after 24 hours as an orange oil (0.17 g, 87%). νmax/cm
−1 (NaCl) 3320 (NH), 3056, 2949 (CH), 1737 
(CO), 1691, 1662 (CO), 1612 (C=C), 1490, 1447, 1415, 1203, 1025; *α+D +54.3 (c 1.0, CHCl3);  δH (400 
MHz, CDCl3) 2.78 (1H, dd, J 15.4, 7.0 Hz, 3-HH), 2.84–2.30 (2H, m, 3-HH and NH), 3.31 (3H, s, 
OMe), 3.69–3.88 (1H, m, 2-H), 6.73 (1H, d, J 16.1 Hz, 5-H), 7.10–7.3 (9H, m, ArH), 7.34 (1H, dd, J 
7.9, 4.7 Hz, ArH), 7.44 (1H, d, J 16.1 Hz, 6-H), 7.46–7.59 (6H, m, ArH), 7.83 (1H, d, J 7.9 Hz, ArH), 
8.63 (1H, d, J 4.7 Hz, ArH), 8.74 (1H, s, ArH); δC (100 MHz, CDCl3) 45.9 (CH2), 52.1 (CH3), 53.7 (CH), 
71.3 (C), 123.9 (CH), 126.6 (CH), 127.8 (CH), 128.8 (CH), 130.2 (C), 134.4 (CH), 139.4 (CH), 145.8 
(C), 151.2 (CH), 151.7 (CH), 174.4 (C), 197.0 (C); m/z (FAB) 477.2180 (MH+. C31H29N2O3 requires 
477.2178), 399 (12%), 243 (100), 233 (14), 215 (5), 165 (21), 132 (11), 104 (4), 83 (20). 
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Methyl (2S,5E)-6-naphthalen-2-yl-4-oxo-2-(tritylamino)hex-5-enoate 319 
 
Using general procedure 1 above with 2-naphthaldehyde (0.13 g, 0.80 mmol) gave 319 after 2 
days as a yellow solid (0.16 g, 78%). Mp 62–63 °C; νmax/cm
−1 (NaCl) 3321 (NH), 3055, 3021 (ArH), 
2982 (CH), 1734 (CO), 1655 (CO), 1604 (C=C), 1593, 1489, 1447, 1198, 1172, 1159; [α]D
24 +64.1 (c 
1.0, CHCl3); δH (400 MHz, CDCl3) 2.84 (1H, dd, J 15.1, 7.0 Hz, 3-HH), 2.89–3.02 (2H, m, 3-HH and 
NH), 3.29 (3H, s, OMe), 3.78–3.87 (1H, m, 2-H), 6.80 (1H, d, J 16.2 Hz, 5-H), 7.12–7.33 (9H, m, 
ArH), 7.48–7.70 (10H, m, ArH and 6-H), 7.78–7.98 (4H, m, ArH); δC (100 MHz, CDCl3) 45.9 (CH2), 
52.1 (CH3), 54.0 (CH), 71.4 (C), 123.6 (CH), 126.6 (CH), 126.6 (CH), 126.9 (CH), 127.6 (CH), 128.0 
(CH), 128.0 (CH), 128.2 (CH), 128.7 (CH), 128.9 (CH), 130.7 (CH), 132.0 (C), 133.4 (C), 134.5 (C), 
143.5 (CH), 145.9 (C), 174.6 (C), 197.6 (C); m/z (FAB) 526.2388 (MH+. C36H32NO3 requires 
526.2382), 448 (7%), 289 (7), 273 (11), 243 (100), 242 (14), 181 (19), 165 (24), 152 (17), 107 (12), 
77 (19). 
Methyl (2S,5E,7E)-4-oxo-8-phenyl-2-(tritylamino)octa-5,7-dienoate 320 
 
Using general procedure 1 above with trans-cinnamaldehyde (0.10 mL, 0.80 mmol) gave 320 after 
5 days as a yellow solid (0.084 g, 42%). Mp 66–67 °C; νmax/cm
−1 (NaCl) 3322 (NH), 3083, 3058, 
3024 (ArH), 2950 (CH), 2925, 1737 (CO), 1655 (CO), 1619 (C=C), 1586, 1491, 1448, 1215, 1173; 
[α]D
27 +64.2 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.72 (1H, dd, J 15.0, 7.0 Hz, 3-HH), 2.83–2.93 (2H, 
m, 3-HH and NH), 3.26 (3H, s, OMe), 3.64–3.84 (1H, m, 2-H), 6.22 (1H, d, J 15.5 Hz, 5-H), 6.86 (1H, 
dd, J 15.5, 10.2 Hz, 7-H), 6.94 (1H, d, J 15.5 Hz, 8-H) 7.09–7.40 (13H, m, ArH), 7.42–7.59 (8H, m, 
ArH and 6-H); δC (100 MHz, CDCl3) 45.6 (CH2), 52.0 (CH3), 53.9 (CH), 71.3 (C), 126.5 (CH), 126.7 
(CH), 127.3 (CH), 127.9 (CH), 128.8 (CH), 128.9 (CH), 129.4 (CH), 129.8 (CH), 136.0 (C), 141.8 (CH), 
143.5 (CH), 145.8 (C), 174.5 (C), 197.6 (C); m/z (FAB) 502.2387 (MH+. C34H32NO3 requires 
502.2382), 424 (21%), 258 (22), 243 (100), 194 (17), 166 (91), 158 (55), 129 (13), 106 (9). 
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Methyl (2S)-5-[bis(2,2,2-trifluoroethyl)phosphoryl]-4-oxo-2-(tritylamino)pentanoate 321 
 
A solution of bis(2,2,2-trifluoroethyl) methylphosphonate (0.92 mL, 5.5 mmol) in tetrahydrofuran 
(15 mL) under argon was cooled to −100 °C. To the solution was added lithium 
bis(trimethylsilyl)amide solution (1.0 M in tetrahydrofuran, 6.0 mL, 6.0 mmol) and stirred for 0.5 
h. A solution of dimethyl (2S)-2-(tritylamino)butandioate 292 (1.0 g, 2.5 mmol) in tetrahydrofuran 
(10 mL) was added to the bis(2,2,2-trifluoroethyl) methylphosphonate/lithium 
bis(trimethylsilyl)amide solution and stirred for 2 h. The reaction mixture was quenched with a 
saturated solution of ammonium chloride (0.5 mL) and allowed to warm to room temperature. 
The mixture was diluted with brine (50 mL) and extracted with dichloromethane (3 × 50 mL). The 
combined organic layers were dried (MgSO4), and then concentrated in vacuo. The crude product 
was purified by column chromatography on silica eluting with 50% diethyl ether in petroleum 
ether to give 321 as a colourless oil (1.3 g, 81%). νmax/cm
−1 (neat) 3320 (NH), 3020 (ArH), 2360, 
2342, 2333, 1720 (CO), 1491, 1449, 1294 (P=O), 1261, 1169, 1069, 1029 (P–O); [α]D
26 +15.6 (c 1.0, 
CHCl3); δH (400 MHz, CDCl3) 2.59 (1H, dd, J 16.4, 7.0 Hz, 3-HH), 2.71 (1H, dd, J 16.4, 4.4 Hz, 3-HH), 
2.98 (1H, br s, NH), 3.17 (2H, d, JH-C-P 16.4 Hz, 5-H2), 3.36 (3H, s, OMe), 3.59–3.85 (1H, m, 2H), 
4.29–4.53 (4H, m, 2 × OCH2CF3), 7.12–7.33 (9H, m, ArH), 7.38–7.57 (6H, m, ArH); δC (100 MHz, 
CDCl3) 41.8 (d, JC-P 138.9 Hz, CH2), 48.7 (CH2), 52.2 (CH3), 52.9 (CH), 62.4 (q, JC-C-F 6.0 Hz, CH2), 71.3 
(C), 122.5 (q, JC-F 277.3 Hz, C), 126.7 (CH), 128.0 (CH), 128.7 (CH), 145.5 (C), 173.8 (C), 198.8 (C); δP 
(160 MHz, CDCl3) 23.2. 
Methyl (2S,5Z)-4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate 322 
 
Method A: A solution of methyl (2S)-5-[bis(2,2,2-trifluoroethyl)phosphoryl]-4-oxo-2-
(tritylamino)pentanoate 321 (0.20 g, 0.32 mmol) in tetrahydrofuran (6.0 mL) under argon was 
cooled to −78 °C. To the solution was added 18-crown-6 (0.42 g, 1.6 mmol, recrystallised from 
acetonitrile), potassium bis(trimethylsilyl)amide solution (0.5 M in toluene, 0.64 mL, 0.32 mmol) 
and benzaldehyde (0.032 mL, 0.32 mmol). The reaction mixture was stirred at −78 °C for 48 h. The 
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mixture was diluted with a saturated solution of ammonium chloride (20 mL), extracted with 
diethyl ether (3 × 20 mL), dried (MgSO4), and then concentrated in vacuo. The crude product was 
purified by column chromatography on silica eluting with 15% diethyl ether in petroleum ether to 
give 322 as a yellow oil (0.12 g, 76%). νmax/cm
−1 (neat) 3320 (NH), 3021 (ArH), 1735 (CO), 1686 
(CO), 1596 (C=C), 1492, 1448, 1216, 1173; [α]D
25 +54.0 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.63 (1H, 
dd, J 15.6, 7.0 Hz, 3-HH), 2.73 (1H, dd, J 15.6, 4.8 Hz, 3-HH), 2.89 (1H, br s, NH), 3.24 (3H, s, OMe), 
3.56–3.88 (1H, m, 2-H), 6.10 (1H, d, J 12.8 Hz, 5-H), 6.80 (1H, d, J 12.8 Hz, 6-H), 7.09–7.68 (20H, m, 
ArH); δC (100 MHz, CDCl3) 48.7 (CH2), 51.9 (CH), 53.5 (CH3), 71.3 (C), 126.5 (CH), 127.9 (CH), 128.3 
(CH), 128.8 (CH), 129.5 (CH), 129.8 (CH), 130.7 (CH), 135.1 (C), 140.6 (CH), 145.8 (C), 174.4 (C), 
199.7 (C); m/z (CI) 234.1131 (MH+−Tr. C13H15NO3 requires 234.1130), 318 (1%), 301 (4), 285 (3), 
257 (3), 243 (98), 219 (12), 182 (8), 167 (48), 147 (13), 133 (2), 113 (5), 85 (15). 
Method B: Using general procedure 2 above with benzaldehyde (0.20 g, 0.32 mmol) gave 322 as a 
yellow oil (0.14 g, 91%). Spectroscopic data as reported above. 
Methyl (2S,5Z)-6-(4’-bromophenyl)-4-oxo-2-(tritylamino)hex-5-enoate 323 
 
Using general procedure 2 above with 4-bromobenzaldehyde (0.089 g, 0.48 mmol) gave 323 as a 
yellow oil (0.21 g, 78%). νmax/cm
−1 (neat) 3320 (NH), 3057, 3020 (ArH), 2360, 2343, 2331, 1733 
(CO), 1690, 1663 (CO), 1597 (C=C), 1486, 1448, 1213, 1172; [α]D
25 +52.4 (c 1.1, CHCl3); δH (400 
MHz, CDCl3) 2.61 (1H, dd, J 15.8, 7.0 Hz, 3-HH), 2.73 (1H, dd, J 15.8, 4.8 Hz, 3-HH), 2.90 (1H, br d, J 
9.6 Hz, NH), 3.26 (3H, s, OMe), 3.58–3.86 (1H, m, 2-H), 6.13 (1H, d, J 12.8 Hz, 5-H), 6.68 (1H, d, J 
12.8 Hz, 6-H), 7.10–7.31 (9H, m, ArH), 7.35–7.58 (10H, m, ArH); δC (100 MHz, CDCl3) 48.8 (CH2), 
52.0 (CH3), 53.5 (CH), 71.3 (C), 123.8 (C), 126.6 (CH), 127.9 (CH), 128.2 (CH), 128.8 (CH), 131.5 
(CH), 131.6 (CH), 133.8 (C), 139.6 (CH), 145.7 (C), 174.3 (C), 199.0 (C); m/z (CI) 312.0227 (MH+−Tr. 
C13H15
79BrNO3 requires 312.0235), 299 (7%), 297 (7), 285 (3), 258 (2), 243 (98), 219 (7), 167 (67), 
147 (6), 113 (8), 85 (33). 
  
P a g e  | 134 
 
Methyl (2S,5Z)-6-(4’-methoxyphenyl)-4-oxo-2-(tritylamino)hex-5-enoate 324 
 
Using general procedure 2 above with 4-methoxybenzaldehyde (0.058 mL, 0.48 mmol) gave 324 
as a yellow oil (0.17 g, 70%). νmax/cm
−1 (neat) 3320 (NH), 3057, 3020 (ArH), 1732 (CO), 1681, 1649 
(CO), 1588 (C=C), 1560, 1510, 1490, 1448, 1256, 1214, 1172; [α]D
25 +69.6 (c 1.1, CHCl3); δH (400 
MHz, CDCl3) 2.65 (1H, dd, J 15.4, 6.8 Hz, 3-HH), 2.77 (1H, dd, J 15.4, 5.0 Hz, 3-HH), 2.88 (1H, br d, J 
10.0 Hz, NH), 3.25 (3H, s, OMe), 3.65–3.91 (4H, m, 2-H and OMe), 6.02 (1H, d, J 12.8 Hz, 5-H), 6.70 
(1H, d, J 12.8 Hz, 6-H), 6.86 (2H, d, J 8.7 Hz, ArH), 7.07–7.33 (9H, m, ArH), 7.38–7.59 (6H, m, ArH), 
7.72 (2H, d, J 8.7 Hz, ArH); δC (100 MHz, CDCl3) 49.0 (CH2), 51.9 (CH), 53.7 (CH3), 55.3 (CH3), 71.3 
(C), 113.6 (CH), 125.1 (CH), 126.5 (CH), 127.7 (CH), 127.9 (C), 128.8 (CH), 132.5 (CH), 141.6 (CH), 
145.8 (C), 160.9 (C), 174.6 (C), 198.8 (C); m/z (CI) 264.1237 (MH+−Tr. C14H18NO4 requires 
264.1236), 243 (99%), 214 (2), 177 (16), 167 (69), 137 (3), 121 (5), 97 (17). 
Methyl (2S,5Z)-8-methyl-4-oxo-2-(tritylamino)non-5-enoate 325 
 
Using general procedure 2 above with 3-methylbutyraldehyde (0.085 mL, 0.79 mmol) gave 325 as 
a colourless oil (0.30 g, 83%). νmax/cm
−1 (neat) 3320 (NH), 3057, 3021 (ArH), 2956, 2927 (CH), 
2870, 2360, 2341, 2333, 1734 (CO), 1689 (CO), 1613, 1597 (C=C), 1490, 1447, 1216, 1172; [α]D
25 
+40.5 (c 1.1, CHCl3); δH (400 MHz, CDCl3) 0.91 (3H, d, J 3.0 Hz, 9-H3), 0.92 (3H, d, J 3.0 Hz, 8-CH3), 
1.64–1.77 (1H, m, 8-H), 2.43–2.63 (3H, m, 3-HH and 7-H2), 2.71 (1H, dd, J 15.6, 5.0 Hz, 3-HH), 2.87 
(1H, d, J 7.3 Hz, NH), 3.28 (3H, s, OMe), 3.62–3.79 (1H, m, 2-H), 6.04–6.15 (2H, m, 5-H and 6-H), 
7.11–7.36 (9H, m, ArH), 7.40–7.57 (6H, m, ArH); δC (100 MHz, CDCl3) 22.4 (CH3), 28.7 (CH), 38.3 
(CH2), 49.1 (CH2), 51.9 (CH), 53.4 (CH3), 71.3 (C), 126.6 (CH), 127.3 (CH), 128.0 (CH), 128.6 (CH), 
145.8 (C), 148.6 (CH), 174.6 (C), 198.5 (C); m/z (CI) 214.1447 (MH+−Tr. C11H20NO3 requires 
214.1443), 344 (1%), 312 (3), 301 (5), 285 (3), 270 (5), 243 (98), 197 (8), 167 (61), 154 (3), 127 (3), 
97 (5), 81 (15). 
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Methyl (2S,5Z)-4-oxo-8-phenyl-2-(tritylamino)oct-5-enoate 326 
 
Using general procedure 2 above with 3-phenylpropionaldehyde (0.11 g, 0.79 mmol) gave 326 as 
a colourless oil (0.38 g, 74%). νmax/cm
−1 (neat) 3320 (NH), 3086, 3061, 3024 (ArH), 2950, 2926 
(CH), 2920, 2360, 2331, 1735 (CO), 1686 (CO), 1604, 1491, 1449, 1216, 1174; [α]D
25 +36.1 (c 1.0, 
CHCl3); δH (400 MHz, CDCl3) 2.52 (1H, dd, J 15.5, 7.0 Hz, 3-HH), 2.61–3.01 (6H, m, 3-HH, 7-H2, 8-H2 
and NH), 3.26 (3H, s, OMe), 3.62–3.77 (1H, m, 2-H), 6.01–6.15 (2H, m, 5-H and 6-H), 7.04–7.35 
(14H, m, ArH), 7.41–7.54 (6H, m, ArH); δC (100 MHz, CDCl3) 31.1 (CH2), 34.6 (CH2), 49.1 (CH2), 52.0 
(CH3), 53.5 (CH), 71.3 (C), 126.1 (CH), 126.5 (CH), 127.1 (CH), 127.9 (CH), 128.4 (CH), 128.5 (CH), 
128.8 (CH), 140.3 (C), 146.1 (C), 148.2 (CH), 174.6 (C), 198.4 (C); m/z (CI) 262.1445 (MH+−Tr. 
C15H20NO3 requires 262.1443), 357 (1%), 343 (1), 318 (3), 301 (5), 243 (98), 230 (5), 202 (4), 167 
(63), 165 (2), 133 (3), 117 (4), 88 (11). 
Methyl (2S,5E)-6-biphen-4-yl-4-oxo-2-(tritylamino)hex-5-enoate 328 
 
To a solution of methyl (2S,5E)-6-(4’-bromophenyl)-4-oxo-2-(tritylamino)hex-5-enoate 305 (0.10 g, 
0.18 mmol) in 5:1 toluene/methanol (12 mL) under argon at room temperature was added 
phenylboronic acid (0.044 g, 0.36 mmol), tetrakis(triphenylphosphine)palladium (0.010 g, 0.0090 
mmol) and potassium phosphate tribasic (0.076 g, 0.36 mmol). The reaction mixture was heated 
to 80 °C and stirred for 24 h. The mixture was allowed to cool to room temperature and then 
concentrated in vacuo. The residue was dissolved in ethyl acetate (20 mL), washed with water (20 
mL), brine (20 mL), dried (MgSO4), and then concentrated in vacuo. The crude product was 
purified by column chromatography on silica eluting with 20% diethyl ether in petroleum ether to 
give 328 as a colourless oil (0.014 g, 14%). νmax/cm
−1 (NaCl) 3313 (NH), 3083, 3057, 3029 (ArH), 
2949 (CH), 1737 (CO), 1687 (CO), 1599 (C=C), 1489, 1446, 1211; *α+D
25 +27.3 (c 1.9, CHCl3); δH (400 
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MHz, CDCl3) 2.81 (1H, dd, J 15.1, 7.0 Hz, 3-HH), 2.87–2.30 (2H, m, 3-HH and NH), 3.75–3.87 (1H, m, 
2-H), 6.73 (1H, d, J 16.2 Hz, 5-H), 7.13–7.72 (25H, m, ArH and 6-H); δC (100 MHz, CDCl3) 45.8 (CH2), 
52.0 (CH3), 53.9 (CH), 71.3 (C), 126.6 (CH), 126.6 (CH), 127.1 (CH), 127.7 (CH), 127.9 (CH), 128.2 
(CH), 128.8 (CH), 128.9 (CH), 129.0 (CH), 133.4 (C), 140.1 (C), 142.9 (CH), 145.8 (C), 148.6 (C) 174.5 
(C), 197.5 (C); m/z (FAB) 552.2542 (MH+. C38H34NO3 requires 552.2539), 474 (11%), 414 (3), 378 
(2), 325 (1), 266 (4), 243 (100), 207 (38), 182 (92), 166 (73), 106 (22). 
4-(3’-Nitrophenyl)benzaldehyde 331154 
 
Using general procedure 3 above with 3-nitrophenylboronic acid (0.14 g, 0.81 mmol) and 4-
bromobenzaldehyde (0.10 g, 0.54 mmol) gave 331 as a yellow solid (0.13 g, 100%). 4-(3’-
Nitrophenyl)benzaldehyde 331 was used without further purification. δH (400 MHz, CDCl3) 7.67 
(1H, d, J 8.0 Hz, ArH), 7.82 (2H, d, J 8.0 Hz, ArH), 7.97 (1H, d, J 7.6 Hz, ArH), 8.04 (2H, d, J 8.4 Hz, 
ArH), 8.29 (1H, d, J 8.0 Hz, ArH), 8.51 (1H, s, ArH), 10.10 (1H, s, CHO). Spectroscopic data as 
previously reported.154 
4-(4’-Benzyloxycarbonylaminophenyl)benzaldehyde 334  
 
Using general procedure 3 above with (4-benzyloxycarbonylaminophenyl)boronic acid (0.66 g, 2.4 
mmol) and 4-bromobenzaldehyde (0.30 g, 1.6 mmol) gave 334 as a white solid (0.19 g, 36%). Mp 
132–133 °C; νmax/cm
−1 (neat) 3331 (NH), 3291, 3275, 1730 (CO), 1697, 1593, 1533, 1514, 1325, 
1219, 1188, 1169; δH (400 MHz, CDCl3) 5.23 (2H, s, PhCH2), 6.81 (1H, s, NH), 7.29–7.46 (5H, m, 
ArH), 7.51 (2H, d, J 8.2 Hz, ArH), 7.60 (2H, d, J 8.2 Hz, ArH), 7.72 (2H, d, J 8.0 Hz, ArH), 7.93 (2H, d, J  
8.0 Hz, ArH), 10.04 (1H, s, CHO); δC (100 MHz, CDCl3) 67.2 (CH2), 119.1 (CH), 127.2 (CH), 128.0 
(CH), 128.4 (CH), 128.5 (CH), 128.7 (CH), 130.4 (CH), 134.5 (C), 134.9 (C), 136.0 (C), 138.5 (C), 
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146.5 (C), 153.4 (C), 192.1 (CH); m/z (EI) 331.1207 (M+. C21H17NO3 requires 331.1208), 287 (33%), 
223 (92), 222 (60), 166 (23), 139 (20), 91 (98), 83 (78). 
5-(4’-Fluorophenyl)-2-furaldehyde 337155 
 
Using general procedure 3 above with 4-fluorophenylboronic acid (0.60 g, 4.3 mmol) and 5-
bromo-2-furaldehyde (0.50 g, 2.9 mmol) gave 337 as a white solid (0.54 g, 99%). 5-(4’-
Fluorophenyl)-2-furaldehyde 337 was used without further purification. δH (400 MHz, CDCl3) 6.79 
(1H, d, J 3.8 Hz, ArH), 7.13 (2H, d, J 8.8 Hz, ArH), 7.32 (1H, d, J 3.8 Hz, ArH), 7.83 (2H, d, J 8.8 Hz, 
ArH), 9.65 (1H, s, CHO). Spectroscopic data as previously reported.155 
Methyl (2S,5E)-6-(3’-nitrobiphen-4-yl)-4-oxo-2-(tritylamino)hex-5-enoate 332 
 
Using general procedure 1 above with 4-(3’-nitrophenyl)benzaldehyde 331 (0.37 g, 1.7 mmol) 
gave 332 after 3 days as an off-white foam (0.19 g, 59%). νmax/cm
−1 (neat) 3320 (NH), 3056, 3030 
(ArH), 1736 (CO), 1688, 1657 (CO), 1603 (C=C), 1530, 1514, 1348, 1171; *α+D
23 +61.7 (c 1.0, CHCl3); 
δH (400 MHz, CDCl3) 2.82 (1H, dd, J 15.2, 6.9 Hz, 3-HH), 2.88–3.07 (2H, m, 3-HH and NH), 3.30 (3H, 
s, OMe), 3.70–3.91 (1H, m, 2-H), 6.75 (1H, d, J 16.2 Hz, 5-H), 7.10–7.34 (9H, m, ArH), 7.42–7.79 
(12H, m, ArH and 6-H), 7.93 (1H, d, J 7.9 Hz, ArH), 8.23 (1H, d, J 7.9 Hz, ArH), 8.48 (1H, s, ArH); δC 
(100 MHz, CDCl3) 45.9 (CH2), 52.1 (CH3), 53.8 (CH), 71.3 (C), 121.9 (CH), 122.7 (CH), 126.6 (CH), 
127.0 (CH), 127.7 (CH), 128.0 (CH), 128.9 (CH), 129.2 (CH), 130.0 (CH), 132.9 (CH), 134.7 (C), 140.6 
(C), 141.7 (C), 142.2 (CH), 145.8 (C), 148.8 (C), 174.5 (C), 197.4 (C); m/z (FAB) 597.2384 (MH+. 
C38H33N2O5 requires 597.2389), 519 (23%), 503 (2), 419 (5), 353 (32), 266 (3), 243 (100), 194 (9), 
166 (54), 129 (2). 
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Methyl (2S,5E)-6-(4’-benzyloxycarbonylaminobiphen-4-yl)-4-oxo-2-(tritylamino)hex-5-enoate 
335 
 
Using general procedure 1 above with 4-(4’-benzyloxycarbonylaminophenyl)benzaldehyde 334 
(0.083 g, 0.25 mmol) gave 335 after 2 days as a yellow foam (0.057 g, 63%). νmax/cm
−1 (NaCl) 3333 
(NH), 3058, 3031, 2951 (ArH), 2850, 1734 (CO), 1654 (CO), 1595 (C=C), 1559, 1534, 1517, 1499, 
1318, 1217; *α+D
24 +62.3 (c 0.6, CHCl3); δH (400 MHz, CDCl3) 2.79 (1H, dd, J 15.2, 7.2 Hz, 3-HH), 
2.88–3.01 (2H, m, 3-HH and NH), 3.29 (3H, s, OMe), 3.69–3.90 (1H, m, 2-H), 5.23 (2H, s, PhCH2), 
6.65–6.81 (2H, m, 5-H and NH), 7.08–7.72 (29H, m, ArH and 6-H); δC (100 MHz, CDCl3) 45.7 (CH2), 
52.0 (CH3), 53.9 (CH), 67.2 (CH2), 71.3 (C), 119.0 (CH), 126.1 (CH), 126.6 (CH), 127.2 (CH), 127.7 
(CH), 128.0 (CH), 128.4 (CH), 128.5 (CH), 128.7 (CH), 128.8 (CH), 129.0 (CH), 133.1 (C), 135.1 (C), 
136.0 (C), 137.9 (C), 142.7 (C), 143.0 (CH), 145.8 (C), 153.3 (C), 174.6 (C), 197.6 (C); m/z (FAB) 
701.3018 (MH+. C46H41N2O5 requires 701.3015), 664 (1%), 623 (2), 530 (3), 457 (5), 419 (2), 356 (8), 
313 (3), 243 (100), 166 (9), 120 (3), 86 (94). 
Methyl (2S,5E)-6-[5-(4’-fluorophenyl)furan-2-yl]-4-oxo-2-(tritylamino)hex-5-enoate 338 
 
Using general procedure 1 above with 5-(4’-fluorophenyl)-2-furaldehyde 337 (0.23 g, 1.2 mmol) 
gave 338 after 19 h as a yellow foam (0.16 g, 73%). νmax/cm
−1 (NaCl) 3324 (NH), 3058, 3021, 2950 
(CH), 1737 (CO), 1681 (CO), 1652, 1601 (C=C), 1562, 1486, 1448, 1234, 1173, 1158, 1027; *α+D
23 
+63.6 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.77 (1H, dd, J 14.9, 7.0 Hz, 3-HH), 2.83–3.02 (2H, m, 3-
HH and NH), 3.27 (3H, s, OMe), 3.59–3.79 (1H, m, 2-H), 6.61–6.82 (3H, m, 5-H and ArH), 7.04–7.59 
(18H, m, ArH and 6-H), 7.67–7.79 (2H, m, ArH); δC (100 MHz, CDCl3) 46.3 (CH2), 52.0 (CH3), 54.0 
(CH), 71.3 (C), 107.9 (CH), 116.1 (d, JC-C-F 22.1 Hz, CH), 118.8 (CH), 123.1 (CH), 126.3 (C), 126.4 (CH), 
126.6 (CH), 128.0 (CH), 128.9 (CH), 129.0 (CH), 145.8 (C), 150.4 (C), 155.7 (C), 162.9 (d, JC-F  249.6 
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Hz, C), 174.5 (C), 196.9 (C); m/z (FAB) 560.2233 (MH+. C36H31FNO4 requires 560.2237), 498 (2%), 
482 (24), 419 (4), 378 (3), 349 (2), 316 (98), 243 (100), 216 (96), 166 (71), 124 (35). 
(2S,5E)-2-Amino-4-oxo-6-phenyl-hex-5-enoic acid hydrochloride 340 
 
To a solution of methyl (2S,5E)-4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate 294 (0.20 g, 0.42 
mmol) in methanol (3.0 mL) was added 6.0 M hydrochloric acid (15 mL), and the reaction mixture 
heated under reflux for 24 h. The mixture was allowed to cool to room temperature and then 
extracted with diethyl ether (2 × 20 mL). The aqueous layer was concentrated in vacuo to give a 
yellow solid. The crude product was purified by column chromatography on cellulose eluting with 
30:69:1 methanol/dichloromethane/acetic acid to give 340 as an off-white solid (0.034 g, 32%). 
Mp 151–153 °C (decomposition); *α+D
24 +35.8 (c 1.0, MeOH); δH (400 MHz, CD3OD) 3.38–3.58 (2H, 
m, 3-H2), 4.36 (1H, dd, J 6.6, 4.2 Hz, 2-H), 6.92 (1H, d, J 16.3 Hz, 5-H), 7.38–7.50 (3H, m, ArH), 
7.63–7.81 (3H, m, ArH and 6-H); δC (100 MHz, CD3OD) 40.7 (CH2), 49.3 (CH), 126.0 (CH), 129.8 
(CH), 130.2 (CH), 132.2 (CH), 135.6 (C), 146.2 (CH), 171.3 (C), 197.6 (C); m/z (CI) 220.0978 (MH+. 
C12H14NO3 requires 220.0974), 205 (98%), 203 (61), 159 (53), 147 (34), 113 (21), 97 (20), 81 (50), 
69 (61). 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-4-oxo-6-phenylhex-5-enoate 342 
 
Using general procedure 4 above gave 342 as a colourless oil (1.4 g, 84%). νmax/cm
−1 (NaCl) 3368 
(NH), 3005, 2979 (CH), 2953, 2931, 1747 (CO), 1713 (CO), 1663 (CO), 1610 (C=C), 1496, 1450, 
1367, 1340, 1289, 1250, 1218, 1168; *α+D
17 +56.9 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.44 (9H, s, 
OtBu), 3.33 (1H, dd, J 17.8, 4.2 Hz, 3-HH), 3.44 (1H, dd, J 17.8, 4.2 Hz, 3-HH), 3.75 (3H, s, OMe), 
4.46–4.76 (1H, m, 2-H), 5.60 (1H, d, J 8.5 Hz, NH), 6.71 (1H, d, J 16.1 Hz, 5-H), 7.31–7.67 (6H, m, 
ArH and 6-H); δC (100 MHz, CDCl3) 28.3 (CH3), 42.4 (CH2), 49.6 (CH), 52.6 (CH3), 79.9 (C), 125.6 
(CH), 128.4 (CH), 129.2 (CH), 130.9 (CH), 134.1 (C), 143.9 (CH), 155.6 (C), 172.0 (C), 197.6 (C); m/z 
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(CI) 334.1653 (MH+. C18H24NO5 requires 334.1654), 320 (4%), 279 (17), 278 (98), 234 (13), 233 (1), 
206 (1), 179 (1), 147 (3), 113 (8), 81 (15); Chiral HPLC (OD-H®) hexane/iso-propanol 90:10, flow 
rate 1.0 mL min-1: tR = 18.3 min (minor, R), tR = 21.6 min (major, S) showed >99% e.e.. 
Methyl (2S,5E)-6-(4’-bromophenyl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-enoate 327 
 
Using general procedure 4 above gave 327 as a white solid (0.33 g, 93%). Mp 78–79 °C; νmax/cm
−1 
(NaCl) 3437 (NH), 3370, 2978 (CH), 2953, 2929, 1747 (CO), 1712 (CO), 1666 (CO), 1611 (C=C), 
1586, 1488, 1436, 1403, 1392, 1367, 1217, 1168; *α+D
20 +42.4 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 
1.44 (9H, s, OtBu), 3.22 (1H, br d, J 17.8 Hz, 3-HH), 3.41 (1H, br d, J 17.8 Hz, 3-HH), 3.75 (3H, s, 
OMe), 4.30–4.80 (1H, m, 2-H), 5.56 (1H, br d, J 8.0 Hz, NH), 6.69 (1H, d, J 16.0 Hz, 5-H), 7.32–7.63 
(5H, m, ArH and 6-H); δC (100 MHz, CDCl3) 28.3 (CH3), 42.6 (CH2), 49.6 (CH), 52.7 (CH3), 80.0 (C), 
125.2 (C), 126.0 (CH), 129.8 (CH), 132.3 (CH), 133.0 (C), 142.5 (CH), 155.6 (C), 172.0 (C), 197.5 (C); 
m/z (FAB) 412.0755 (MH+. C18H23
79BrNO5 requires 412.0760), 358 (98%), 356 (84), 355 (8), 314 
(93), 312 (98), 296 (7), 254 (9), 252 (10), 227 (13), 225 (20), 212 (48), 210 (51), 183 (2), 147 (6), 
114 (2), 90 (55). 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-4-oxo-8-phenyloct-5-enoate 343 
 
Using general procedure 4 above gave 343 as a colourless oil (0.37 g, 78%). νmax/cm
−1 (NaCl) 3439 
(NH), 3371, 3027, 3004, 2978 (CH), 2952, 2930, 2859, 1749 (CO), 1714 (CO), 1672, 1630 (CO), 
1584 (C=C), 1497, 1367, 1167; *α+D
19 +47.4 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.44 (9H, s, O
tBu), 
2.46–2.63 (2H, m, 7-H2), 2.79 (2H, t, J 7.7 Hz, 8-H2), 3.06 (1H, dd, J 18.0, 4.0 Hz, 3-HH), 3.30 (1H, 
dd, J 18.0, 4.0 Hz, 3-HH), 3.73 (3H, s, OMe), 4.42–4.64 (1H, m, 2-H), 5.53 (1H, br d, J 8.8 Hz, NH), 
6.10 (1H, dt, J 16.0, 1.4 Hz, 5-H), 6.88 (1H, dt, J 16.0, 6.8 Hz, 6-H), 7.11–7.37 (5H, m, ArH); δC (100 
MHz, CDCl3) 28.3 (CH3), 34.2 (CH2), 34.3 (CH2), 41.8 (CH2), 49.5 (CH), 52.6 (CH3), 79.9 (C), 126.3 
(CH), 128.3 (CH), 128.6 (CH), 130.3 (CH), 140.5 (C), 147.8 (CH), 155.6 (C), 172.0 (C), 197.7 (C); m/z 
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(FAB) 362.1974 (MH+. C20H28NO5 requires 362.1967), 306 (94%), 262 (100), 203 (11), 176 (14), 160 
(34), 93 (35), 90 (32). 
(2S,5E)-2-Amino-4-oxo-6-phenylhex-5-enoic acid 339 
 
Using general procedure 5 above gave 339 as a white solid (0.13 g, 95%). Mp 112–114 °C 
(decomposition); νmax/cm
−1 (neat) 3028 (NH3
+), 3015 (ArH), 2915, 1738 (CO), 1655 (CO), 1626, 
1614, 1184, 1134; *α+D
19 +23.3 (c 1.0, MeOH); δH (400 MHz, CD3OD) 3.37–3.59 (2H, m, 3-H2), 4.24–
4.39 (1H, m, 2-H), 6.90 (1H, d, J 16.2 Hz, 5-H), 7.29–7.82 (6H, m, ArH and 6-H); δC (100 MHz, 
CD3OD) 40.9 (CH2), 50.2 (CH), 126.1 (CH), 129.7 (CH), 130.2 (CH), 132.1 (CH), 135.6 (C), 146.0 (CH), 
171.8 (C), 198.0 (C); m/z (FAB) 220.0973 (MH+. C12H14NO3 requires 220.0974), 220 (3%), 175 (7), 
148 (16), 132 (12), 104 (1), 76 (6). 
(2S,5E)-2-Amino-6-(4’-bromophenyl)-4-oxohex-5-enoic acid 344 
 
Using general procedure 5 above gave 344 as a white solid (0.14 g, 93%). Mp 151–152 °C 
(decomposition); νmax/cm
−1 (neat) 3094 (NH3
+), 3080, 3050, 3034 (ArH), 2955 (OH), 2930, 1684 
(CO), 1640, 1607 (C=C), 1545, 1487, 1397, 1337, 1055; *α+D
18 +55.0 (c 0.3, MeOH); δH (400 MHz, 
CD3OD) 3.23 (1H, dd, J 18.8, 9.3 Hz, 3-HH), 3.46 (1H, dd, J 18.8, 3.4 Hz, 3-HH), 3.95 (1H, dd, J 9.3, 
3.4 Hz, 2-H), 6.91 (1H, d, J 16.3 Hz, 5-H), 7.54–7.73 (5H, m, ArH and 6-H); δC (100 MHz, CD3OD) 
40.9 (CH2), 50.2 (CH), 126.2 (C), 126.7 (CH), 131.3 (CH), 133.4 (CH), 134.8 (C), 144.6 (CH), 171.5 (C), 
197.7 (C); m/z (FAB) 298.0067 (MH+. C12H13
79BrNO3 requires 298.0079), 292 (16%), 254 (12), 243 
(21), 211 (13), 209 (16), 155 (29), 138 (15), 137 (13), 92 (1), 75 (10). 
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(2S,5E)-2-Amino-4-oxo-8-phenyloct-5-enoic acid 345 
 
To a solution of methyl (2S,5E)-2-(tert-butoxycarbonylamino)-4-oxo-8-phenyloct-5-enoate 343 
(0.056 g, 0.15 mmol) in 1:1 acetonitrile–water (8.0 mL) was added cesium carbonate (0.065 g, 
0.20 mmol). The resultant suspension was stirred at room temperature for 48 h. The reaction 
mixture was concentrated in vacuo and the residue was dissolved in water (10 mL) and acidified 
to pH 1 with 1.0 M hydrochloric acid. The aqueous layer was washed with dichloromethane (3 × 
20 mL) and the combined organic layers were dried (MgSO4), and then concentrated in vacuo. To 
a solution of the resulting residue (0.052 g, 0.15 mmol) in dichloromethane (2.0 mL) was added 
trifluoroacetic acid (0.056 mL, 0.75 mmol) and the reaction mixture was stirred at room 
temperature under argon for 2 h. The reaction mixture was concentrated in vacuo to give the TFA 
salt, which was purified by recrystallisation from chloroform and methanol to give 345 as a white 
solid (0.10 g, 98%). Mp 94–96 °C (decomposition); νmax/cm
−1 (neat) 3161 (NH3
+), 3144, 3088, 3030 
(ArH), 3009, 2988, 2918 (CH), 1736 (CO), 1661 (CO), 1640, 1604 (C=C), 1180, 1136; *α+D
18 +10.2 (c 
0.3, MeOH); δH (400 MHz, CD3OD) 2.51–2.91 (4H, m, 7-H2 and 8-H2), 3.20 (1H, dd, J 18.8, 8.0 Hz, 3-
HH), 3.30–3.39 (1H, m, 3-HH), 4.11 (1H, dd, J 8.0, 3.6 Hz, 2-H), 6.17 (1H, dt, J 16.0, 1.4 Hz, 5-H), 
7.03 (1H, dt, J 16.0, 6.9 Hz, 6-H), 7.09–7.35 (5H, m, ArH); δC (100 MHz, CD3OD) 35.3 (CH2), 35.5 
(CH2), 40.4 (CH2), 50.5 (CH), 127.3 (CH), 129.5 (CH), 129.6 (CH), 130.8 (CH), 142.1 (C), 150.5 (CH), 
172.5 (C), 198.1 (C); m/z (FAB) 248.1289 (MH+. C14H18NO3 requires 248.1287), 247 (2%), 203 (8), 
176 (12), 160 (8), 132 (4), 100 (1), 90 (3), 76 (4). 
Methyl (2S,5E)-6-(4’-dimethylaminonaphthalen-1-yl)-4-oxo-2-(tritylamino)hex-5-enoate 349 
 
Using general procedure 1 above with 4-dimethylamino-1-naphthaldehyde (0.24 g, 1.2 mmol) 
gave 349 after 4 days as an orange oil (0.24 g, 72%). νmax/cm
−1 (NaCl) 3321 (NH), 3057, 3019 (ArH), 
2948, 2835, 2787, 1737 (CO), 1651 (CO), 1597 (C=C), 1569, 1449, 1390, 1337, 1202; *α]D
18 +73.7 (c 
0.4, CHCl3); δH (400 MHz, CDCl3) 2.84 (1H, dd, J 14.8, 6.8 Hz, 3-HH), 2.88–3.05 (8H, m, 3-HH, NH 
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and NMe2), 3.30 (3H, s, OMe), 3.76–3.90 (1H, m, 2-H), 6.71 (1H, d, J 15.7 Hz, 5-H), 7.04 (1H, d, J 
8.0 Hz, ArH), 7.11–7.33 (9H, m, ArH), 7.44–7.64 (8H, m, ArH), 7.74 (1H, d, J 8.0 Hz, ArH), 8.08–8.27 
(2H, m, ArH), 8.30 (1H, d, J 15.7 Hz, 6-H); δC (100 MHz, CDCl3) 44.9 (CH3), 45.8 (CH2), 52.0 (CH3), 
54.0 (CH), 71.3 (C), 113.4 (CH), 123.6 (CH), 125.2 (CH), 125.3 (CH), 125.4 (C), 125.8 (CH), 126.5 
(CH), 126.6 (CH), 126.9 (CH), 127.9 (CH), 128.4 (C), 128.9 (CH), 133.1 (C), 140.2 (CH), 145.9 (C), 
153.8 (C), 174.7 (C), 197.4 (C); m/z (FAB) 569.2799 (MH+. C38H37N2O3 requires 569.2804), 567 (3%), 
491 (3), 460 (4), 443 (1), 325 (52), 243 (100), 224 (19), 120 (2), 85 (56), 84 (5). 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4’-dimethylaminonaphthalen-1-yl)-4-oxohex-5-
enoate 350 
 
Using general procedure 4 above gave 350 as a yellow oil (0.091 g, 54%). νmax/cm
−1 (NaCl) 3438, 
3362 (NH), 2978 (CH), 2950, 1747 (CO), 1709 (CO), 1512, 1499, 1391, 1366, 1338, 1167; [α]D
23 
+49.3 (c 0.5, CHCl3); δH (400 MHz, CDCl3) 1.45 (9H, s, O
tBu), 2.96 (6H, s, NMe2), 3.29 (1H, dd, J 17.7, 
3.7 Hz, 3-HH), 3.53 (1H, dd, J 17.7, 3.7 Hz, 3-HH), 3.77 (3H, s, OMe), 4.53–4.73 (1H, m, 2-H), 5.64 
(1H, d, J 8.7 Hz, NH), 6.75 (1H, d, J 15.8 Hz, 5-H), 7.04 (1H, d, J 8.0 Hz, ArH), 7.43–7.65 (2H, m, 
ArH), 7.76 (1H, d, J 8.0 Hz, ArH), 8.17 (1H, d, J 8.2 Hz, ArH), 8.23 (1H, d, J 8.2 Hz, ArH), 8.41 (1H, d, J 
15.8 Hz, 6-H); δC (100 MHz, CDCl3) 28.4 (CH3), 42.7 (CH2), 44.9 (CH3), 49.7 (CH), 52.6 (CH3), 80.0 (C), 
113.3 (CH), 123.5 (CH), 125.0 (C), 125.2 (CH), 125.3 (CH), 125.4 (CH), 126.0 (CH), 126.9 (CH), 128.3 
(C), 133.1 (C), 140.8 (CH), 154.0 (C), 155.6 (C), 172.2 (C), 197.5 (C); m/z (CI) 427.2239 (MH+. 
C24H31N2O5 requires 427.2233), 426 (6%), 353 (6), 312 (6), 296 (2), 240 (12), 228 (5), 172 (12), 134 
(10), 113 (26), 71 (32). 
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(2S,5E)-2-Amino-6-(4’-dimethylaminonaphthalen-1-yl)-4-oxohex-5-enoic acid 351  
 
Using general procedure 5 above gave 351 as an orange solid (0.037 g, 46%). Mp 78–80 °C 
(decomposition); νmax/cm
−1 (neat) 3009, 2930, 1738 (CO), 1667 (CO), 1609 (C=C), 1566, 1393, 
1180, 1126; *α]D
17 +42.5 (c 0.8, MeOH); δH (400 MHz, CD3OD) 3.00 (6H, s, NMe2), 3.47–3.64 (2H, m, 
3-H2), 4.39 (1H, dd, J 6.0, 4.4 Hz, 2-H), 6.95 (1H, d, J 15.9 Hz, 5-H), 7.21 (1H, d, J 8.1 Hz, ArH), 7.49–
7.72 (2H, m, ArH), 7.94 (1H, d, J 8.1 Hz, ArH), 8.16–8.41 (2H, m, ArH), 8.57 (1H, d, J 15.9 Hz, 6-H); 
δC (100 MHz, CD3OD) 41.0 (CH2), 45.7 (CH3), 50.0 (CH), 115.5 (CH), 124.7 (CH), 125.4 (CH), 126.6 
(CH), 127.1 (CH), 127.2 (CH), 128.1 (C), 128.4 (CH), 129.0 (C), 134.5 (C), 142.3 (CH), 152.8 (C), 
171.3 (C), 197.5 (C); m/z (FAB) 313.1551 (MH+. C18H21N2O3 requires 313.1552), 312 (38%), 291 (4), 
268 (3), 241 (8), 224 (18), 198 (8), 185 (11), 172 (2), 158 (1). 
Methyl (2S,6R)-1-benzyl-4-oxo-6-phenethylpiperidine-2-carboxylate  362 
 
Method A: To a solution of methyl (2S,5E)-4-oxo-8-phenyl-2-(tritylamino)oct-5-enoate 314 (0.27 
g, 0.53 mmol) in dichloromethane (5.0 mL) at room temperature under argon was added 
trifluoroacetic acid (0.39 mL, 5.3 mmol). The reaction mixture was stirred for 2 h, and then 
concentrated in vacuo. The residue was dissolved in water (10 mL) and washed with diethyl ether 
(2 × 10 mL). The aqueous layer was concentrated in vacuo, azeotroping with ethyl acetate–
chloroform to give the TFA salt. The TFA salt was dissolved in tetrahydrofuran (5.0 mL) at room 
temperature under argon. To the solution was added 4 Å molecular sieves, triethylamine (0.074 
mL, 5.3 mmol) and benzaldehyde (0.054 mL, 0.53 mmol) and the mixture was stirred for 2 h. The 
mixture was filtered and then concentrated in vacuo. The residue was dissolved in 
tetrahydrofuran (3.0 mL) at room temperature under argon and sodium triacetoxyborohydride 
(0.12 g, 0.53 mmol) was added to the solution and stirred for 48 h. The reaction mixture was 
quenched with a saturated sodium hydrogen carbonate solution (1.0 mL), and then concentrated 
in vacuo. The residue was dissolved in dichloromethane (15 mL), washed with saturated sodium 
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hydrogen carbonate solution (15 mL), brine (15 mL), dried (MgSO4), and then concentrated in 
vacuo.  The product was purified by column chromatography on silica eluting with 25% diethyl 
ether in petroleum ether to give 362 as a colourless oil (0.084 g, 45%). νmax/cm
−1 (neat) 3026 
(ArH), 1731 (CO), 1714 (CO), 1496, 1453, 1437, 1216, 1171; *α+D
26 −31.5 (c 1.0, CHCl3); δH (400 
MHz, CDCl3) 1.68–1.86 (1H, m, 7-HH), 1.89–2.07 (1H, m, 7-HH), 2.37 (1H, dd, J 14.8, 7.4 Hz, 5-HH), 
2.48–2.79 (5H, m, 3-H2, 5-HH and 8-H2), 3.25–3.39 (1H, m, 6-H), 3.70 (3H, s, OMe), 3.82 (1H, d, J 
13.8 Hz, 1’-HH), 3.87 (1H, t, J 5.2 Hz, 2-H), 3.93 (1H, d, J 13.8 Hz, 1’-HH), 7.09–7.49 (10H, m, ArH); 
δC (100 MHz, CDCl3) 29.0 (CH2), 32.4 (CH2), 38.4 (CH2), 41.5 (CH2), 49.7 (CH), 49.9 (CH2), 53.6 (CH3), 
56.8 (CH), 123.7 (CH), 125.1 (CH), 126.0 (CH), 126.2 (CH), 126.3 (CH), 136.2 (C), 139.3 (C), 169.8 
(C), 205.0 (C); m/z (FAB) 352.1915 (MH+. C22H26NO3 requires 352.1913), 292 (77%), 260 (6), 246 
(40), 218 (1), 178 (3), 158(2), 132 (4), 117 (6), 91 (93), 69 (5), 55 (5), 43 (4), 41 (4). 
Method B: Using general procedure 6 above gave 362 as a colourless oil (0.050 g, 53%). 
Spectroscopic data as reported above. 
Methyl (2S,6S)-1-benzyl-4-oxo-6-phenylpiperidine-2-carboxylate  364 
 
Using general procedure 6 above gave 364 as a colourless oil (0.14 g, 37%). νmax/cm
−1 (NaCl) 3030 
(ArH), 2952, 2848 (CH), 1731 (CO), 1494, 1454, 1197, 1162; *α+D
22 −119.0 (c 0.1, CHCl3); δH (400 
MHz, CDCl3) 2.51 (1H, dt, J 14.8, 2.2 Hz, 3-HHeq), 2.61 (1H, dd, J 14.9, 9.8 Hz, 5-HaxH), 2.70 (1H, 
ddd, J 14.9, 4.8, 2.2 Hz, 5-HHeq), 2.76 (1H, dd, J 14.8, 6.5 Hz, 3-HaxH), 3.25 (1H, d, J 13.8 Hz, 1’-HH), 
3.74–3.80 (4H, m, OMe and 1’-HH), 3.92 (1H, dd, Jeq-ax,eq-eq 6.5, 2.2 Hz, 2-H), 4.40 (1H, dd, Jax-ax,ax-eq 
9.8, 4.8 Hz, 6-H), 7.17–7.54 (10H, m, ArH); δC (100 MHz, CDCl3) 42.9 (CH2), 49.2 (CH2), 51.6 (CH), 
54.2 (CH2), 58.6 (CH3), 62.7 (CH), 127.4 (CH), 127.4 (CH), 128.0 (CH), 128.4 (CH), 128.6 (CH), 129.1 
(CH), 138.3 (C), 142.9 (C), 172.0 (C), 206.0 (C); m/z (EI) 323.1519 (M+. C20H21NO3 requires 
323.1521), 294 (3%), 264 (100), 246 (1), 232 (5), 218 (3), 187 (5), 161 (6), 131 (85), 103 (18), 91 
(100), 83 (21), 65 (8), 44 (4). 
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Methyl (2S,6S)-1-benzyl-6-(4’-methoxyphenyl)-4-oxopiperidine-2-carboxylate  365 
 
Using general procedure 6 above gave 365 as a yellow oil (0.060 g, 34%). νmax/cm
−1 (NaCl) 3030 
(ArH), 2953, 2838, 1731 (CO), 1611, 1512, 1246, 1197, 1162; *α+D
22 −57.0 (c 0.5, CHCl3);  δH (400 
MHz, CDCl3) 2.42 (1H, dt, J 14.9, 2.2 Hz, 3-HHeq), 2.52 (1H, dd, J 15.2, 9.6 Hz, 5-HaxH), 2.60 (1H, 
ddd, J 15.2, 4.7, 2.1 Hz, 5-HHeq), 2.67 (1H, dd, J 14.9, 6.7 Hz, 3-HaxH), 3.17 (1H, d, J 13.8 Hz, 1’-HH), 
3.66–3.79 (7H, m, 2 × OMe and 1’-HH), 3.84 (1H, dd, Jeq-ax,eq-eq 6.7, 2.2 Hz, 2-H), 4.27 (1H, dd, Jax-
ax,ax-eq 9.6, 4.7 Hz, 6-H), 6.84 (2H, d, J 8.7 Hz, ArH), 7.12–7.28 (5H, m, ArH), 7.33 (2H, d, J 8.7 Hz, 
ArH); δC (100 MHz, CDCl3) 42.9 (CH2), 49.3 (CH2), 51.6 (CH), 54.0 (CH2), 55.3 (CH3), 58.6 (CH3), 62.0 
(CH), 114.4 (CH), 127.3 (CH), 128.4 (CH), 128.5 (CH), 128.6 (CH), 134.9 (C), 138.5 (C), 159.3 (C), 
172.0 (C), 206.3 (C); m/z (EI) 353.1629 (M+. C21H23NO4 requires 353.1627), 352 (4%), 294 (99), 262 
(35), 224 (16), 203 (6), 161 (99), 134 (72), 91 (99), 65 (27), 44 (5). 
Methyl (2S,6S)-1-benzyl-6-(4’-bromophenyl)-4-oxopiperidine-2-carboxylate  366 
 
Using general procedure 6 above gave 366 as a colourless oil (0.14 g, 40%). νmax/cm
−1 (NaCl) 3029 
(ArH), 2952, 2849, 1732 (CO), 1486, 1454, 1434, 1354, 1329, 1300, 1197, 1162; *α+D
23 −54.3 (c 1.1, 
CHCl3); δH (400 MHz, CDCl3) 2.37–2.54 (2H, m, 3-HHeq and 5-HaxH), 2.61 (1H, ddd, J 15.4, 4.7, 2.3 
Hz, 5-HHeq), 2.69 (1H, ddd, J 14.9, 6.6, 0.6 Hz, 3-HaxH), 3.20 (1H, d, J 13.8 Hz, 1’-HH), 3.67 (1H, d, J 
13.8 Hz, 1’-HH), 3.71 (3H, s, OMe), 3.85 (1H, dd, Jeq-ax,eq-eq 6.6, 2.2 Hz, 2-H), 4.34 (1H, dd, Jax-ax,ax-eq 
9.6, 4.7 Hz, 6-H), 7.14–7.52 (9H, m, ArH); δC (100 MHz, CDCl3) 42.9 (CH2), 48.9 (CH2), 51.7 (CH), 
54.3 (CH2), 58.5 (CH3), 62.1 (CH), 121.7 (C), 127.5 (CH), 128.5 (CH), 128.6 (CH), 129.1 (CH), 132.3 
(CH), 138.0 (C), 142.1 (C), 172.0 (C), 205.5 (C); m/z (CI) 402.0706 (MH+. C20H21
79BrNO3 requires 
402.0705), 404 (98%), 344 (16), 342 (17), 324 (12), 264 (1), 246 (1), 178 (2), 133 (1), 91 (5). 
  
P a g e  | 147 
 
Methyl (2S,6R)-1-benzyl-6-iso-butyl-4-oxopiperidine-2-carboxylate  367 
 
Using general procedure 6 above gave 367 as a colourless oil (0.072 g, 50%). νmax/cm
−1 (neat) 
2955, 2353, 1728 (CO), 1458, 1366, 1165, 1026; *α+D
23 −37.4 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 
0.84 (3H, d, J 6.6 Hz, 8-H3), 0.85 (3H, d, J 6.6 Hz, 9-CH3), 1.08–1.34 (1H, m, 8-H), 1.49–1.82 (2H, m, 
7-H2), 2.23 (1H, ddd, J 14.8, 7.5, 1.1 Hz, 5-HHeq), 2.46–2.58 (2H, m, 3-HHeq and 5-HaxH), 2.64 (1H, 
ddd, J  15.2, 5.4, 1.4 Hz, 3-HaxH), 3.22–3.33 (1H, m, 6-H), 3.69 (3H, s, OMe), 3.78 (1H, d, J 13.8 Hz, 
1’-HH), 3.82–3.90 (2H, m, 1’-HH and 2-H) 7.21–7.45 (5H, m, ArH); δC (100 MHz, CDCl3) 22.4 (CH3), 
22.7 (CH), 24.4 (CH3), 39.9 (CH2), 41.9 (CH2), 43.8 (CH2), 51.5 (CH2), 52.1 (CH), 54.7 (CH), 59.3 (CH3), 
127.4 (CH), 128.5 (CH), 128.5 (CH), 138.7 (C), 172.3 (C), 207.6 (C); m/z (FAB) 304.1914 (MH+. 
C18H26NO3 requires 304.1913), 326 (30%), 244 (90), 241 (2), 202 (2), 170 (3), 132 (3), 117 (3), 91 
(98), 70 (5). 
Methyl (2S,6R)-1-benzyl-6-methyl-4-oxopiperidine-2-carboxylate  368 
 
Using general procedure 6 above gave 368 as a colourless oil (0.22 g, 53%). νmax/cm
−1 (neat) 2966, 
2954 , 2357, 1726 (CO), 1195, 1165; *α+D
25 −107.4 (c 0.7, CHCl3); δH (400 MHz, CDCl3) 1.21 (3H, d, J 
6.3 Hz, 7-H3), 2.23 (1H, dd, J 15.0, 8.7 Hz, 5-HaxH), 2.45–2.59 (3H, m, 3-H2 and 5-HHeq), 3.25–3.43 
(1H, m, 6-H), 3.62 (1H, d, J 13.7 Hz, 1’-HH), 3.71 (3H, s, OMe), 3.79 (1H, t, J 4.9 Hz, 2-H), 4.08 (1H, 
d, J 13.7 Hz, 1’-HH), 7.17–7.50 (5H, m, ArH); δC (100 MHz, CDCl3) 20.3 (CH3), 42.7 (CH2), 48.3 (CH2), 
51.7 (CH), 51.8 (CH), 53.5 (CH2), 59.3 (CH3), 127.3 (CH), 128.5 (CH), 128.7 (CH), 138.9 (C), 172.0 (C), 
207.3 (C); m/z (FAB) 262.1447 (MH+. C15H20NO3 requires 262.1443), 260 (66%), 246 (8), 202 (100), 
184 (9), 170 (4), 160 (3), 114 (5), 92 (83), 70 (4). 
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Methyl (2S,6S)-1-benzyl-6-naphthalen-2-yl-4-oxopiperidine-2-carboxylate  369 
 
Using general procedure 6 above gave 369 as a colourless oil (0.062 g, 26%). νmax/cm
−1 (neat) 
3023, 2917, 2850, 2360, 1729 (CO), 1215, 1196, 1161; *α+D
26 −28.7 (c 0.7, CHCl3); δH (400 MHz, 
CDCl3) 2.45–2.89 (4H, m, 3-H2 and 5-H2), 3.58–3.89 (5H, m, 1’-H2 and OMe), 3.97 (1H, dd, Jeq-ax,eq-eq 
6.4, 2.0 Hz, 2-H), 4.59 (1H, dd, Jax-ax,ax-eq 8.0, 6.0 Hz, 6-H), 7.14–7.37 (4H, m, ArH), 7.39–7.57 (2H, m, 
ArH), 7.61–8.07 (6H, m, ArH); δC (100 MHz, CDCl3) 42.9 (CH2), 48.9 (CH2), 51.6 (CH), 54.4 (CH2), 
58.6 (CH3), 62.8 (CH), 124.5 (CH), 126.2 (CH), 126.4 (CH), 126.9 (CH), 127.4 (CH), 127.7 (CH), 127.8 
(CH), 128.4 (CH), 128.7 (CH), 129.3 (CH), 133.2 (C), 133.4 (C), 138.2 (C), 140.2 (C), 172.0 (C), 205.9 
(C); m/z (CI) 374.1757 (MH+. C24H24NO3 requires 374.1756), 372 (1%), 337 (3), 314 (5), 282 (6), 269 
(37), 253 (5), 237 (5), 217 (4), 181 (4), 147 (25), 123 (34), 107 (98), 91 (44), 71 (28). 
Methyl (2S,6S)-1-benzyl-6-(3’-nitrobiphen-4-yl)-4-oxopiperidine-2-carboxylate  370 
 
Using general procedure 6 above gave 370 as a colourless oil (0.033 g, 29%). νmax/cm
−1 (NaCl) 
3029, 2953, 2918, 2850, 1730 (CO), 1531, 1514, 1350, 1198, 1163; *α+D
22 −46.8 (c 1.3, CHCl3); δH 
(400 MHz, CDCl3) 2.48 (1H, dt, J 15.0, 2.2 Hz, 3-HHeq), 2.56 (1H, dd, J 15.2, 9.6 Hz, 5-HaxH), 2.68 
(1H, ddd, J 15.2, 4.7, 2.1 Hz, 5-HHeq), 2.74 (1H, dd, J 15.0, 6.6 Hz, 3-HaxH), 3.27 (1H, d, J 13.8 Hz, 1’-
HH), 3.66–3.79 (4H, m, 1’-HH and OMe), 3.89 (1H, dd, Jeq-ax,eq-eq 6.6, 2.2 Hz, 2-H), 4.45 (1H, dd, Jax-
ax,ax-eq 9.6, 4.7 Hz, 6-H), 7.11–7.34 (5H, m, ArH), 7.41–7.68 (5H, m, ArH), 7.93 (1H, d, J 7.6 Hz, ArH), 
8.12 (1H, dd, J 7.6, 1.4 Hz, ArH), 8.38 (1H, s, ArH); δC (100 MHz, CDCl3) 42.9 (CH2), 49.0 (CH2), 51.7 
(CH), 54.4 (CH2), 58.6 (CH3), 62.3 (CH), 121.9 (CH), 122.2 (CH), 127.5 (CH), 127.9 (CH), 128.2 (CH), 
128.5 (CH), 128.6 (CH), 129.8 (CH), 132.9 (CH), 138.1 (C), 138.4 (C), 142.3 (C), 143.5 (C), 148.7 (C), 
172.0 (C), 205.7 (C); m/z (CI) 445.1756 (MH+. C26H25N2O5 requires 445.1763), 415 (98%), 355 (15), 
325 (7), 322 (5), 246 (4), 223 (3), 178 (4), 151 (4), 108 (12), 69 (11). 
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Methyl (2S,4S,6R)-1-benzyl-4-hydroxy-6-phenethylpiperidine-2-carboxylate  379 
 
Method A: A solution of methyl (2S,6R)-1-benzyl-4-oxo-6-phenethylpiperidine-2-carboxylate  362 
(0.065 g, 0.18 mmol) in tetrahydrofuran (3.0 mL) under argon was cooled to −78 °C. L-Selectride® 
was added slowly dropwise to the solution and stirred for 40 min. The reaction mixture was 
quenched with methanol (0.20 mL) and allowed to warm to room temperature. The mixture was 
concentrated in vacuo. The resultant residue was dissolved in water (20 mL) and extracted with 
dichloromethane (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried 
(MgSO4), and then concentrated in vacuo. The crude product was purified by column 
chromatography on silica eluting with 20% diethyl ether in petroleum ether to give 379 as a 
colourless oil (0.016 g, 25%). νmax /cm
−1 (neat) 3399 (OH), 2949 (CH), 2360, 2343, 1730 (CO), 1496, 
1452, 1216, 1162; *α+D
23 −32.1 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.36 (1H, q, J 11.5 Hz, 5-HaxH), 
1.50 (1H, br s, OH), 1.58 (1H, ddd, J 12.6, 11.6, 5.6 Hz, 3-HaxH), 1.66–1.79 (1H, m, 7-HH), 1.81–1.92 
(2H, m, 5-HHeq and 7-HH), 2.08 (1H, ddt, J 12.6, 4.4, 2.4 3-HHeq), 2.54–2.72 (2H, m, 8-H2), 3.11–
3.32 (1H, m, 6-H), 3.52 (1H, dd, Jeq-ax,eq-eq 5.6, 2.4 Hz, 2-H), 3.57 (3H, s, OMe), 3.63 (1H, d, J 14.2 Hz, 
1’-HH), 3.68–3.83 (1H, m, 4-H), 3.89 (1H, d, J 14.2 Hz, 1’-HH), 6.99–7.33 (10H, m, ArH); δC (100 
MHz, CDCl3) 31.2 (CH2), 34.1 (CH2), 35.8 (CH2), 38.5 (CH2), 51.5 (CH), 51.5 (CH2), 54.2 (CH), 58.8 
(CH3), 66.5 (CH), 125.8 (CH), 127.1 (CH), 128.3 (CH), 128.4 (CH), 128.5 (CH), 139.7 (C), 142.5 (C), 
173.7 (C); m/z (FAB) 354.2070 (MH+. C22H28NO3 requires 354.2069), 352 (20%), 336 (12), 294 (46), 
248 (27), 246 (1), 207 (3), 193 (3), 172 (2), 147 (4), 117 (6), 91 (100), 73 (20). 
Method B: Using general procedure 7 above gave 379 as a colourless oil (0.13 g, 67%). 
Spectroscopic data as reported above. 
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Methyl (2S,4S,6S)-1-benzyl-4-hydroxy-6-phenylpiperidine-2-carboxylate  381 
 
Using general procedure 7 above gave 381 as a colourless oil (0.052 g, 100%). νmax/cm
−1 (neat) 
3383 (OH), 2951 (CH), 2359, 2334, 1729 (CO), 1493, 1454, 1216, 1200, 1166, 1119; *α+D
20 −5.8 (c 
0.2, CHCl3); δH (400 MHz, CDCl3) 1.42 (1H, d, J 5.2 Hz, OH), 1.63 (1H, q, J 11.6, 5-HaxH), 1.79 (1H, td, 
J 12.2, 6.0 Hz, 3-HaxH), 2.07–2.30 (2H, m, 3-HHeq and 5-HHeq), 3.34 (1H, d, J 14.1 Hz, 1’-HH), 3.63–
3.77 (5H, m, 2-H, 1’-HH and OMe), 3.84–4.01 (1H, m, 4-H), 4.51 (1H, dd, Jax-ax,ax-eq 11.6, 3.2 Hz, 6-
H), 7.14–7.39 (8H, m, ArH), 7.51 (2H, d, J 7.2 Hz, ArH); δC (100 MHz, CDCl3) 36.7 (CH2), 45.2 (CH2), 
51.2 (CH), 54.0 (CH2), 57.7 (CH3), 61.1 (CH), 65.8 (CH), 126.9 (CH), 127.4 (CH), 127.6 (CH), 128.3 
(CH), 128.3 (CH), 128.7 (CH), 139.2 (C), 144.2 (C), 173.8 (C); m/z (CI) 326.1748 (MH+. C20H24NO3 
requires 326.1756), 309 (59%), 266 (18), 248 (5), 218 (3), 186 (3), 161 (3), 137 (5), 97 (6), 69 (20). 
Methyl (2S,4S,6S)-1-benzyl-4-hydroxy-6-(4’-methoxyphenyl)piperidine-2-carboxylate  382 
 
Using general procedure 7 above gave 382 as a colourless oil (0.025 g, 100%). νmax/cm
−1 (neat) 
3387 (OH), 2923 (CH), 2363, 1735 (CO), 1730, 1719, 1511, 1244, 1170; *α+D
20 −5.0 (c 0.2, CHCl3); δH 
(400 MHz, CDCl3) 1.82–2.27 (4H, m, 3-H2 and 5-H2), 2.61 (1H, d, J 6.6 Hz, OH), 3.42 (1H, d, J 14.2 
Hz, 1’-HH), 3.53 (1H, dd, Jeq-ax,eq-eq 6.2, 2.1 Hz, 2-H), 3.63–3.85 (7H, m, 1’-HH and 2 × OMe), 4.05–
4.15 (1H, m, 4-H), 4.60 (1H, dd, Jax-ax,ax-eq 10.7, 4.2 Hz, 6-H), 6.87 (2H, d, J 8.8 Hz, ArH), 7.14–7.34 
(5H, m, ArH), 7.39 (2H, d, J 8.8 Hz, ArH); δC (100 MHz, CDCl3) 34.3 (CH2), 42.9 (CH2), 51.3 (CH), 54.1 
(CH2), 55.1 (CH), 55.3 (CH3), 55.8 (CH3), 65.0 (CH), 114.0 (CH), 126.8 (CH), 128.2 (CH), 128.3 (CH), 
128.7 (CH), 136.2 (C), 139.53 (C), 158.8 (C), 176.1 (C); m/z (CI) 356.1865 (MH+. C21H26NO4 requires 
356.1862), 324 (98%), 296 (12), 279 (20), 248 (3), 226 (6), 216 (4), 161 (10), 137 (4), 97 (3), 69 (9). 
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Methyl (2S,4S,6R)-1-benzyl-6-iso-butyl-4-hydroxypiperidine-2-carboxylate  383 
 
Using general procedure 7 above gave 383 as a colourless oil (0.022 g, 80%). νmax/cm
−1 (neat) 3373 
(OH), 2953 (CH), 2360, 2342, 1730 (CO), 1368, 1215, 1151; *α+D
23 −27.9 (c 0.9, CHCl3); δH (400 MHz, 
CDCl3) 0.82 (3H, d, J 6.6 Hz, 8-H3), 0.89 (3H, d, J 6.6 Hz, 9-CH3), 1.03–1.12 (1H, m, 7-HH), 1.22 (1H, 
q, J 11.6 Hz, 5-HaxH), 1.43 (1H, br s, OH), 1.49–1.62 (3H, m, 3-HaxH and 7-HH), 1.67–1.79 (2H, m, 5-
HHeq and 8-H), 2.08 (1H, ddt, J 12.8, 4.4, 2.2 Hz, 3-HHeq), 3.00–3.15 (1H, m, 6-H), 3.51 (1H, dd, Jeq-
ax,eq-eq 5.6, 2.2 Hz, 2-H), 3.61 (3H, s, OMe), 3.67 (1H, d, J 14.4 Hz, 1’-HH), 3.70–3.82 (2H, m, 1’-HH 
and 4-H), 7.10–7.35 (5H, m, ArH); δC (100 MHz, CDCl3) 22.6 (CH), 23.0 (CH3), 24.6 (CH3), 32.3 (CH2), 
38.0 (CH2), 43.4 (CH2), 50.4 (CH2), 51.5 (CH), 52.8 (CH), 59.0 (CH3), 66.8 (CH), 126.9 (CH), 128.2 
(CH), 128.4 (CH), 140 (C), 173.8 (C); m/z (CI) 306.2071 (MH+. C18H28NO3 requires 306.2069), 288 
(82%), 275 (4), 246 (13), 242 (2), 198 (3), 184 (2), 138 (2), 113 (4), 81 (12). 
Methyl (2S,4S,6R)-1-benzyl-4-hydroxy-6-methylpiperidine-2-carboxylate  384 
 
Using general procedure 7 above gave 384 as a colourless oil (0.096 g, 83%). νmax/cm
−1 (neat) 3380 
(OH), 2950 (CH), 2934, 1731 (CO), 1190, 1174, 1152, 1146; *α+D
25 −89.0 (c 0.3, CHCl3); δH (400 MHz, 
CDCl3) 1.16 (3H, d, J 6.2 Hz, 7-H3), 1.29 (1H, q, J 11.4 Hz, 5-HaxH), 1.53 (1H, br s, OH), 1.62 (1H, td, J 
12.2, 6.0 Hz, 3-HaxH), 1.94 (1H, dtd, J 11.4, 5.1, 2.0 Hz, 5-HHeq), 2.18 (1H, ddt, J 12.2, 4.4, 2.0 Hz, 3-
HHeq), 3.37–3.48 (1H, m, 6-H), 3.52–3.62 (2H, m, 2-H and 1’-HH), 3.67 (3H, s, OMe), 3.71–3.82 (1H, 
m, 4-H), 4.11 (1H, d, J 14.2 Hz, 1’-HH), 7.16–7.39 (5H, m, ArH); δC (100 MHz, CDCl3) 21.8 (CH3), 36.6 
(CH2), 43.9 (CH2), 51.2 (CH), 51.5 (CH), 53.5 (CH2), 59.1 (CH3), 66.1 (CH), 126.9 (CH), 128.3 (CH), 
128.3 (CH), 140.3 (C), 173.8 (C); m/z (CI) 264.1597 (MH+. C15H22NO3 requires 264.1600), 246 (62%), 
232 (5), 204 (10), 172 (3), 156 (1), 124 (2), 113 (4), 81 (11), 71 (12). 
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Methyl (2S,4S,6R)-4-hydroxy-6-methylpiperidine-2-carboxylate  397 
 
To a solution of methyl (2S,4S,6R)-1-benzyl-4-hydroxy-6-methylpiperidine-2-carboxylate 384 
(0.032 g, 0.18 mmol) in tert-butanol (3.0 mL) at room temperature under argon was added 
palladium (10% wt.) on activated carbon (0.077 g, 0.072 mmol) and ammonium formate (0.058 g, 
0.92 mmol). The reaction mixture was heated under reflux and stirred for 24 h. The mixture was 
allowed to cool to room temperature, then diluted with methanol (10 mL), filtered through 
Celite® and then concentrated in vacuo. The crude product was purified by column 
chromatography on silica eluting with 6% methanol in dichloromethane to give 397 as a 
colourless oil (0.015 g, 48%). νmax/cm
−1 (neat) 3438 (OH/NH), 3020, 2939 (CH), 1730 (CO), 1215; 
*α+D
28 +12.4 (c 0.5, CHCl3);  δH (400 MHz, CDCl3) 1.03–1.18 (4H, m, 5-HaxH and 7-H3), 1.62 (1H, td, J 
12.5, 5.8 Hz, 3-HaxH), 1.73 (2H, br s, OH and NH), 1.90 (1H, dtd, J 11.9, 4.5, 2.4, 5-HHeq), 2.44 (1H, 
ddt, J 12.5, 4.5, 2.4 Hz, 3-HHeq), 2.83–2.94 (1H, m, 6-H), 3.62–3.77 (4H, m, 4-H and OMe), 3.82 (1H, 
dd, Jeq-ax,eq-eq 5.6, 2.4 Hz, 2-H); δC (100 MHz, CDCl3) 22.7 (CH3), 35.1 (CH2), 43.1 (CH2), 46.6 (CH), 
52.0 (CH), 55.7 (CH3), 66.5 (CH), 174.4 (C); m/z (CI) 174.1131 (MH
+. C8H16NO3 requires 174.1130), 
156 (30%), 133 (10), 113 (13), 85 (65), 69 (98). 
(2S,4S,6R)-4-Hydroxy-6-methylpiperidine-2-carboxylic acid hydrochloride 398 
 
A solution of methyl (2S,4S,6R)-4-hydroxy-6-methylpiperidine-2-carboxylate 397 (0.012 g, 0.069 
mmol) in hydrochloric acid (6.0 M, 5.0 mL) was heated under reflux and stirred for 24 h. The 
reaction mixture was allowed to cool to room temperature and then concentrated in vacuo. The 
residual oil was triturated with acetone to give an off-white solid. The product was purified by 
recrystallisation from methanol to give 398 as a white solid (0.017 g, 100%). Mp 140–141 °C 
(decomposition); νmax/cm
−1 (neat) 3333 (OH/NH), 2945 (CH), 2835, 2360, 1653, 1448, 1260, 1118, 
1105; *α+D
24 +27.0 (c 0.7, MeOH); δH (400 MHz, CD3OD) 1.23–1.63 (4H, m, 5-HH and 7-H3), 1.98 
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(1H, ddd, J 15.9, 10.5, 5.4 Hz, 3-HaxH), 2.22–2.31 (1H, m, 5-HH), 2.59–2.71 (1H, m, 3-HHeq), 3.77–
3.85 (1H, m, 6-H), 3.91–3.99 (1H, m, 4-H), 4.60 (1H, dd, Jeq-ax,eq-eq 5.3, 3.9 Hz, 2-H); δC (100 MHz, 
CD3OD) 19.0 (CH3), 34.0 (CH2), 39.7 (CH2), 47.9 (CH), 50.4 (CH), 64.0 (CH), 170.6 (C); m/z (CI) 
160.0980 (MH+. C7H14NO3 requires 160.0974), 142 (29%), 123 (5), 114 (19), 85 (34), 69 (50). 
Methyl (2S)-2-amino-5-(dimethoxyphosphoryl)-4-oxopentanoate trifluoroacetate 401 
 
To a solution of methyl (2S)-5-(dimethoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate 293 (0.60 
g, 1.2 mmol) in dichloromethane (12 mL) under argon at room temperature was added 
trifluoroacetic acid (0.90 mL, 12 mmol). The reaction mixture was stirred for 2 h and then 
concentrated in vacuo. The resultant residue was dissolved in water (30 mL), washed with diethyl 
ether (2 × 30 mL), and then the aqueous layer was concentrated in vacuo to give 401 as a yellow 
oil (0.44 g, 100%). Methyl (2S)-2-amino-5-(dimethoxyphosphoryl)-4-oxopentanoate 
trifluoroacetate 401 was used without further purification. δH (400 MHz, CDCl3) 3.23 (2H, d, JH–C–P 
22.0 Hz, 5-H2), 3.42–3.51 (2H, m, 3-H2), 3.68–3.84 (9H, m, 3 × OMe), 4.31–4.39 (1H, m, 2-H), 8.38 
(3H, br s, NH3
+).  
Dibenzyl (2S)-2-(dibenzylamino)butandioate 403149 
 
To a solution of L-aspartic acid 266 (3.0 g, 23 mmol) in water (60 mL) was added potassium 
carbonate (16 g, 113 mmol), and the reaction mixture was heated to 100 °C. Benzyl bromide (16 
mL, 135 mmol) was added portion-wise to the solution over 0.25 h and the mixture was stirred for 
24 h. The reaction mixture was allowed to cool to room temperature and then diluted with water 
(100 mL) and extracted with dichloromethane (3 × 150 mL). The combined organic layers were 
washed with brine (150 mL), dried (MgSO4), and then concentrated in vacuo. The crude product 
was purified by column chromatography on silica eluting with 10% diethyl ether in petroleum 
ether to give 403 as a colourless oil (8.4 g, 76%). νmax/cm
−1 (neat) 3031 (ArH), 1728 (CO), 1495, 
1454, 1153; *α+D
24 −61.0 (c 1.0, CHCl3) (lit.,
149 *α+D
23 −63.0 (c 1.0, CHCl3)); δH (400 MHz, CDCl3) 2.75 
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(1H, dd, J 15.7, 7.2 Hz, 3-HH), 2.96 (1H, dd, J 15.7, 7.9 Hz, 3-HH), 3.56 (2H, d, J 13.7 Hz, NCH2Ph), 
3.81 (2H, d, J 13.7 Hz, NCH2Ph), 3.99 (1H, dd, J 7.9, 7.2 Hz, 2-H), 6.94 (1H, d, J 12.3 Hz, CO2CH2Ph), 
5.09–5.23 (2H, m, CO2CH2Ph), 5.29 (1H, d, J 12.3 Hz, CO2CH2Ph), 7.18–7.52 (20H, m, ArH); δC (100 
MHz, CDCl3) 35.2 (CH2), 54.8 (CH2), 58.1 (CH), 66.5 (CH2), 66.6 (CH2), 127.2 (CH), 128.3 (CH), 128.4 
(CH), 128.5 (CH), 128.6 (CH), 128.6 (CH), 128.7 (CH), 128.9 (CH), 135.7 (C), 135.8 (C), 138.9 (C), 
170.9 (C), 171.4 (C); m/z (EI) 492 (M+, 1%), 402 (30), 359 (98), 358 (98), 314 (2), 266 (5), 223 (14), 
181 (26), 132 (65), 91 (98), 65 (44), 51 (5). 
Dibenzyl (2S)-2-(benzylamino)butandioate 404156 
 
To a solution of dibenzyl (2S)-2,2-(dibenzylamino)butandioate 403 (0.20, 0.41 mmol) in 3:1 
acetonitrile–water (4.0 mL) at room temperature was added ammonium cerium(IV) nitrate (0.49 
g, 0.85 mmol), and the reaction mixture was stirred for 2.5 h. The mixture was quenched with a 
saturated sodium hydrogen carbonate solution (5.0 mL), and then extracted with diethyl ether (3 
× 20 mL). The combined organic layers were dried (MgSO4), and then concentrated in vacuo. The 
crude product was purified by column chromatography on silica eluting with 20% diethyl ether in 
petroleum ether to give 404 as a colourless oil (0.14 g, 87%). Spectroscopic data consistent with 
literature.156 νmax/cm
−1 (neat) 3343 (NH), 3063, 3031 (ArH), 1735 (CO), 1496, 1455, 1263, 1213, 
1162; *α+D
22 −14.9 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.02 (1H, br s, NH), 2.64 (1H, dd, J 15.8, 7.0 
Hz, 3-HH), 2.72 (1H, dd, J 15.8, 5.8 Hz, 3-HH), 3.53–3.71 (2H, m, 2-H and NCH2Ph), 3.76 (1H, d, J 
13.0 Hz, NCH2Ph), 4.92–5.11 (4H, m, 2 × CO2CH2Ph), 7.06–7.33 (15H, m, ArH); δC (100 MHz, CDCl3) 
38.3 (CH2), 52.0 (CH2), 57.2 (CH), 66.6 (CH2), 67.0 (CH2), 127.2 (CH), 128.3 (CH), 128.3 (CH), 128.4 
(CH), 128.4 (CH), 128.4 (CH), 128.5 (CH), 128.6 (CH), 128.7 (CH), 135.6 (C), 135.7 (C), 139.5 (C), 
170.6 (C), 173.4 (C); m/z (CI) 404 (MH+, 100%), 402 (4), 360 (2), 314 (7), 268 (14), 223 (1), 178 (3), 
147 (3), 107 (8), 69 (7). 
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Dimethyl (2S)-2-(benzylamino)butandioate 410157 
 
To a solution of dimethyl (2S)-2-aminobutandioate hydrochloride 291 (0.10 g, 0.51 mmol) in 
acetonitrile (5.0 mL) at room temperature under argon was added benzyl bromide (0.073 mL, 0.61 
mmol) and potassium carbonate (0.14 g, 1.0 mmol). The reaction mixture was stirred for 24 h and 
then concentrated in vacuo. The resultant residue was dissolved in ethyl acetate (20 mL), washed 
with water (20 mL), brine (20 mL), dried (MgSO4), and then concentrated in vacuo. The crude 
product was purified by column chromatography on silica eluting with 20% ethyl acetate in 
petroleum ether to give 410 as a colourless liquid (0.071 g, 55%). νmax/cm
−1 (neat) 3350 (NH), 3028 
(ArH), 2953, 1733 (CO), 1436, 1200, 1165; *α+D
26 −32.4 (c 1.2, CHCl3) (lit.,
157 *α+D
20 −33.0 (c 1.4, 
CHCl3)); δH (400 MHz, CDCl3) 2.68 (1H, dd, J 15.8, 7.0 Hz, 3-HH), 2.75 (1H, dd, J 15.8, 5.8 Hz, 3-HH), 
3.60–3.81 (8H, m, NCH2Ph, 2-H, 2 × OMe), 3.83 (1H, d, J 13.2 Hz, NCH2Ph), 7.19–7.38 (5H, m, ArH); 
δC (100 MHz, CDCl3) 38.0 (CH2), 51.8 (CH), 52.0 (CH2), 52.1 (CH3), 56.9 (CH3), 127.1 (CH), 128.2 
(CH), 128.4 (CH), 139.6 (C), 171.3 (C), 174.1 (C); m/z (CI) 252 (MH+, 69%), 250 (4), 207 (3), 192 (5), 
151 (4), 137 (10), 113 (13), 85 (60), 69 (100). 
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X-ray crystal structure of 398 
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Table 1.  Crystal data and structure refinement for lf01. 
 
Identification code   lf01 
Empirical formula   C7H16ClNO4 
Formula weight    213.66 
Temperature    100(2) K 
Wavelength    0.71073 Å 
Crystal system    Orthorhombic 
Space group    P212121 
Unit cell dimensions  a = 8.2209(2) Å α= 90°. 
    b = 8.9923(3) Å β= 90°. 
    c = 13.8130(4) Å γ = 90°. 
Volume    1021.12(5) Å3 
Z    4 
Density (calculated)  1.390 Mg/m3 
Absorption coefficient  0.360 mm-1 
F(000)    456 
Theta range for data collection 2.70 to 27.88°. 
Index ranges   -10<=h<=9, -11<=k<=10, -18<=l<=17 
Reflections collected  8583 
Independent reflections  2418 [R(int) = 0.0345] 
Completeness to theta = 27.88° 99.5 %  
Absorption correction  Semi-empirical from equivalents 
Max. and min. transmission 0.7455 and 0.5232 
Refinement method  Full-matrix least-squares on F2 
Data / restraints / parameters 2418 / 0 / 137 
Goodness-of-fit on F2  1.057 
Final R indices [I>2sigma(I)] R1 = 0.0283, wR2 = 0.0617 
R indices (all data)  R1 = 0.0352, wR2 = 0.0639 
Absolute structure parameter 0.10(5) 
Largest diff. peak and hole 0.231 and -0.161 e.Å-3  
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Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for lf01.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
N(1) 7380(2) 6829(2) 6285(1) 18(1) 
Cl(1) 1128(1) 4877(1) 4238(1) 21(1) 
O(2) 4211(1) 6592(1) 5718(1) 23(1) 
O(3) 4711(1) 4624(1) 4755(1) 25(1) 
O(4) 10668(1) 6949(1) 6143(1) 24(1) 
O(1) 7705(2) 2380(1) 7176(1) 24(1) 
C(6) 5132(2) 5695(2) 5365(1) 19(1) 
C(2) 7604(2) 4152(2) 5857(1) 18(1) 
C(4) 7556(2) 4945(2) 7593(1) 20(1) 
C(3) 7028(2) 3762(2) 6874(1) 20(1) 
C(1) 6961(2) 5675(2) 5545(1) 17(1) 
C(7) 7569(2) 7694(2) 7973(1) 26(1) 
C(5) 6911(2) 6471(2) 7317(1) 20(1) 
________________________________________________________________________________ 
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Table 3.   Bond lengths [Å] and angles [°] for  lf01. 
___________________________________________________  
N(1)-C(1)  1.4967(19) 
N(1)-C(5)  1.511(2) 
N(1)-H(1)  0.93(2) 
N(1)-H(2)  0.92(2) 
O(2)-C(6)  1.2095(19) 
O(3)-C(6)  1.3253(19) 
O(3)-H(3A)  0.8200 
O(4)-H(4)  0.82(2) 
O(4)-H(5)  0.86(2) 
O(1)-C(3)  1.4245(19) 
O(1)-H(1A)  0.8200 
C(6)-C(1)  1.5237(19) 
C(2)-C(3)  1.524(2) 
C(2)-C(1)  1.530(2) 
C(2)-H(2A)  0.9700 
C(2)-H(2B)  0.9700 
C(4)-C(3)  1.519(2) 
C(4)-C(5)  1.520(2) 
C(4)-H(4A)  0.9700 
C(4)-H(4B)  0.9700 
C(3)-H(3B)  0.9800 
C(1)-H(1B)  0.9800 
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C(7)-C(5)  1.524(2) 
C(7)-H(7A)  0.9600 
C(7)-H(7B)  0.9600 
C(7)-H(7C)  0.9600 
C(5)-H(5A)  0.9800 
C(1)-N(1)-C(5) 115.96(12) 
C(1)-N(1)-H(1) 106.8(12) 
C(5)-N(1)-H(1) 108.0(13) 
C(1)-N(1)-H(2) 109.4(13) 
C(5)-N(1)-H(2) 110.4(13) 
H(1)-N(1)-H(2) 105.6(17) 
C(6)-O(3)-H(3A) 109.5 
H(4)-O(4)-H(5) 105.9(19) 
C(3)-O(1)-H(1A) 109.5 
O(2)-C(6)-O(3) 125.27(14) 
O(2)-C(6)-C(1) 124.00(14) 
O(3)-C(6)-C(1) 110.71(13) 
C(3)-C(2)-C(1) 110.99(12) 
C(3)-C(2)-H(2A) 109.4 
C(1)-C(2)-H(2A) 109.4 
C(3)-C(2)-H(2B) 109.4 
C(1)-C(2)-H(2B) 109.4 
H(2A)-C(2)-H(2B) 108.0 
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C(3)-C(4)-C(5) 111.65(13) 
C(3)-C(4)-H(4A) 109.3 
C(5)-C(4)-H(4A) 109.3 
C(3)-C(4)-H(4B) 109.3 
C(5)-C(4)-H(4B) 109.3 
H(4A)-C(4)-H(4B) 108.0 
O(1)-C(3)-C(4) 107.91(13) 
O(1)-C(3)-C(2) 110.48(13) 
C(4)-C(3)-C(2) 110.65(13) 
O(1)-C(3)-H(3B) 109.3 
C(4)-C(3)-H(3B) 109.3 
C(2)-C(3)-H(3B) 109.3 
N(1)-C(1)-C(6) 109.33(13) 
N(1)-C(1)-C(2) 110.43(12) 
C(6)-C(1)-C(2) 113.41(13) 
N(1)-C(1)-H(1B) 107.8 
C(6)-C(1)-H(1B) 107.8 
C(2)-C(1)-H(1B) 107.8 
C(5)-C(7)-H(7A) 109.5 
C(5)-C(7)-H(7B) 109.5 
H(7A)-C(7)-H(7B) 109.5 
C(5)-C(7)-H(7C) 109.5 
H(7A)-C(7)-H(7C) 109.5 
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H(7B)-C(7)-H(7C) 109.5 
N(1)-C(5)-C(4) 109.86(13) 
N(1)-C(5)-C(7) 108.48(13) 
C(4)-C(5)-C(7) 112.26(14) 
N(1)-C(5)-H(5A) 108.7 
C(4)-C(5)-H(5A) 108.7 
C(7)-C(5)-H(5A) 108.7 
_____________________________________________________________  
 
Table 4.   Anisotropic displacement parameters  (Å2x 103) for lf01.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
N(1) 16(1)  18(1) 18(1)  -1(1) -1(1)  0(1) 
Cl(1) 19(1)  20(1) 22(1)  -3(1) -1(1)  -2(1) 
O(2) 19(1)  26(1) 25(1)  -4(1) 0(1)  1(1) 
O(3) 20(1)  27(1) 30(1)  -8(1) -7(1)  2(1) 
O(4) 20(1)  31(1) 21(1)  -5(1) -1(1)  1(1) 
O(1) 33(1)  19(1) 21(1)  0(1) -5(1)  0(1) 
C(6) 20(1)  21(1) 17(1)  2(1) -2(1)  -2(1) 
C(2) 19(1)  19(1) 16(1)  -1(1) -1(1)  -1(1) 
C(4) 22(1)  23(1) 16(1)  1(1) 0(1)  -1(1) 
C(3) 20(1)  19(1) 18(1)  1(1) -1(1)  1(1) 
C(1) 18(1)  20(1) 15(1)  0(1) 1(1)  -1(1) 
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C(7) 26(1)  27(1) 23(1)  -5(1) -3(1)  4(1) 
C(5) 19(1)  25(1) 16(1)  0(1) 0(1)  1(1) 
______________________________________________________________________________ 
 
Table 5.  Torsion angles [°] for lf01. 
________________________________________________________________  
C(5)-C(4)-C(3)-O(1) 178.98(13) 
C(5)-C(4)-C(3)-C(2) 58.00(17) 
C(1)-C(2)-C(3)-O(1) -176.85(12) 
C(1)-C(2)-C(3)-C(4) -57.40(17) 
C(5)-N(1)-C(1)-C(6) 73.61(17) 
C(5)-N(1)-C(1)-C(2) -51.84(17) 
O(2)-C(6)-C(1)-N(1) 5.2(2) 
O(3)-C(6)-C(1)-N(1) -176.29(12) 
O(2)-C(6)-C(1)-C(2) 128.87(16) 
O(3)-C(6)-C(1)-C(2) -52.59(18) 
C(3)-C(2)-C(1)-N(1) 53.26(16) 
C(3)-C(2)-C(1)-C(6) -69.84(16) 
C(1)-N(1)-C(5)-C(4) 51.76(17) 
C(1)-N(1)-C(5)-C(7) 174.81(13) 
C(3)-C(4)-C(5)-N(1) -53.49(17) 
C(3)-C(4)-C(5)-C(7) -174.29(13) 
